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Desomorphine is a semi-synthetic opioid that is ten times more potent than 
morphine, with a faster onset but shorter duration of action.  It is a major component of the 
drug referred to as “Krokodil”, which is used as a heroin substitute.  Its prevalence is 
difficult to estimate due to a lack of analytically confirmed cases, which may in part be due 
to the limited studies regarding its pharmacology or methodology to detect the drug in 
biological specimens.  This research seeks to further the understanding of both 
desomorphine’s metabolism and its detection in biological specimens, to facilitate its 
identification in clinical and forensic toxicology laboratories.    
Six commercially available enzyme-linked immunosorbent assays were evaluated 
to determine their effectiveness with respect to desomorphine detection.  Cross-reactivities 
were highly variable between assays, ranging from <2.5-77%. Recombinant human 
cytochrome P450 enzymes (rCYPs) and recombinant uridine 5'-diphospho-
glucuronosyltransferases (rUGTs) were used to investigate the biotransformational 
pathways involved in desomorphine metabolism.  Phase I metabolism could be attributed 
to seven rCYPs (rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C18, rCYP2C19, rCYP2D6 and 
rCYP3A4), producing a total of nine phase I metabolites (nordesomorphine, 
desomorphine-N-oxide, two norhydroxydesomorphine isomers, and five hydroxylated 
isomers). During phase II metabolism, desomorphine-glucuronide was produced by nine 
rUGTs (rUGT1A1, rUGT1A3, rUGT1A8, rUGT1A9, rUGT1A10, rUGT2B4, rUGT2B7, 
rUGT2B15, and rUGT2B17). 
v 
Chemical and enzymatic hydrolysis of conjugated metabolites were investigated 
using desomorphine-glucuronide generated in situ using rUGT enzyme. Acid hydrolysis 
and five β-glucuronidase sources (BGTurbo™, IMCSzyme™, Escherichia coli, Helix 
pomatia and Patella vulgata) were evaluated.  Acid hydrolysis produced complete 
hydrolysis of desomorphine-glucuronide, and under optimal conditions, each enzyme 
produced complete or near complete hydrolysis (≥96%), with BGTurbo™ and IMCSzyme™ 
offering the shortest incubation times.  Under simulated challenging conditions, P. vulgata 
was the most effective enzyme evaluated. 
Desomorphine was analyzed in blood and urine samples using gas 
chromatography-mass spectrometry (GC-MS), and urine samples were additionally 
analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid 
chromatography-quadrupole/time of flight-mass spectrometry (LC-Q/TOF-MS).  Each 
method was validated in accordance with published guidelines for forensic use.  
Additionally, LC-Q/TOF-MS was used to analyze desomorphine metabolites, which in the 
absence of commercially available reference material or authentic urine specimens, were 
generated in-vitro.   
 KEY WORDS: Desomorphine, Immunoassays, Metabolism, Gas Chromatography, 
Liquid Chromatography, High Resolution Mass Spectrometry  
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The recreational abuse of opioids has a long and vivid history, from the discovery 
of the medicinal properties of Papaver somniferum thousands of years ago to the present-
day opioid epidemic (1).  In recent years that abuse has skyrocketed, particularly in the 
United States where the widespread abuse of both illegal and prescription opioids has led 
to the declaration of an “opioid crisis”.  It is an unfortunate fact that while measures can be 
taken regarding prescribed opioids, such as compliance testing and incentives to prescribe 
alternative medications, curtailing the clandestine manufacture and consumption of opioids 
is more difficult, particularly with the rise in popularity of so called ‘designer drugs’, whose 
legality is variable between jurisdictions.  This challenge is compounded by the fact that 
the chemical modifications undertaken may render designer drugs undetectable by 
previously existing analytical methods.   
Much attention has been placed upon the designer opioids with high prevalence, 
such as the fentanyl analogs.  Considerably less attention has been given to more obscure 
opioids with unknown prevalence, such as desomorphine.  Arguments can be made that 
resources should not be dedicated to the research of drugs unless there is evidence of their 
abuse.  However, the number of analytically confirmed cases does not always represent 
actual prevalence.  When drug users continue to self-report lesser known drugs such as 
desomorphine, the absence of confirmed cases should instead increase attention.  Self-




and surveillance systems.  If a drug is being reported but not identified in casework, 
research should be initiated to resolve the discrepancy. 
History of desomorphine 
Therapeutic use 
Analgesia is defined as the inability to feel pain.  Analgesics are classified as either 
non-narcotic or narcotic, with non-narcotic analgesics acting upon the peripheral nervous 
system (PNS) while narcotic analgesics act upon the central nervous system (CNS).  The 
mechanism of action for non-narcotic analgesics is to suppress nociceptive signals in the 
PNS and prevent them from reaching the CNS.  Conversely, the mechanism of action for 
narcotic analgesics is to suppress incoming nociceptive signals in the CNS.  As a 
consequence, they typically suppress outgoing signals leading to side effects such as 
respiratory depression. 
Common therapeutic uses of opioids include post-operative analgesia, chronic pain 
management, and medical emergencies.  They can also be used as supplements for 
anesthesia and sedatives as well as antitussives and antidiarrheals.  Their purpose is to 
provide analgesia without an accompanying loss of consciousness.  Disadvantages 
associated with their use includes respiratory depression and addiction liability.   
While desomorphine was first synthesized in the United States (2), it was never 
sold commercially in the country due to concerns about its addiction liability.  In fact, its 
only recorded use as a therapeutic drug was in Switzerland, where it saw limited use as a 
post-operative analgesic.  Beginning in 1940, the pharmaceutical company Hoffman-
Roche produced desomorphine under the trade name Permonid, which was available in 




market twelve years later in 1952.  Despite no longer being sold, the production of 
Permonid continued until 1981.  This small-scale production was for the use of a single 
individual suffering from an unspecified disease that resulted in specialized analgesic 
needs.  After their death all production of desomorphine ceased permanently.  The 
individual was reported to have consumed 80 ampules of Permonid daily.  Each ampule 
contained 2 mg of desomorphine, making the total amount of desomorphine consumed per 
day 160 mg (3).  No information exists in the literature regarding whether this was typical 
for patients receiving desomorphine, or a result of the individual’s specific needs. 
Illicit use and epidemiology 
The lack of therapeutic applications for desomorphine can be attributed to its abuse 
potential, which is derived from its capacity to produce physical dependence, characterized 
by the emergence of classical opioid abstinence syndrome (4), including irritability, 
tremors, hypertension, nausea, vomiting and hyperthermia.  The sought-after effects of 
opioid misuse include euphoria and analgesia, while undesirable effects include sedation, 
dizziness, nausea, vomiting, constipation, respiratory depression and mental clouding.  
Tolerance to opioids can develop within three weeks of repeated use and physical 
symptoms of withdrawal can begin in as little as six hours after the last dose.  In addition 
to physical dependence, there is a psychological component to drug addiction, where the 
pleasurable memory of the experienced high creates a craving for a repeat of the 
experience.  Chronic drug abuse is characterized by the cycle of positive reinforcement 
from desirable effects, and negative reinforcement associated with the symptoms of 




The illicit use of desomorphine, in the form of the clandestine heroin replacement 
Krokodil, was first reported in the media in 2003 (3).  Krokodil use began in eastern Russia 
before expanding into neighboring countries, and later central Europe.  To date, 
approximately twenty case reports have been published in the scientific literature.   
The earliest report of desomorphine abuse was in 2008 (5).  Limited information 
included beyond its alleged abuse and its status as a controlled substance in Russia.  It was 
not until 2012 that additional information regarding estimated prevalence was published, 
along with the first mention of the term Krokodil, which has been attributed to both the 
discoloration and texture of the skin from associated side effects like gangrene (3), as well 
as an intermediate product of one of the synthesis pathways for desomorphine, α-
chlorocodide (6).  According to media reports, approximately sixty-five million doses of 
Krokodil were seized in 2011 in Russia and one hundred thousand individuals were using 
Krokodil, many claiming to have switched from heroin due to the lower cost.  The apparent 
spike in popularity coincided with a severe shortage in the heroin supply during the 
preceding year due to disease affecting poppy crops (7, 8).  In response to the rise in 
Krokodil use, the Russian government implemented stricter controls on desomorphine’s 
primary precursor codeine, which had previously been available without a prescription (9).  
During the same period, the Eurasian Harm Reduction Network conducted a survey of 
needle and syringe programs and pharmacies in seventeen countries regarding the 
preferences of intravenous drug users (10).  The results from four countries (Russia and 
the Republics of Armenia, Georgia and Kazakhstan) included reports of Krokodil use.  The 
first published case report linked to Krokodil, but not analytically confirmed, also appeared 




By 2013, Krokodil had apparently spread to Belgium, the Czech Republic, France, 
Norway, Poland, Sweden, Ukraine and the United Kingdom as well (6, 12-14).  This was 
attributed to the flow of immigrants from Russia, where Krokodil use was widespread.  In 
Ukraine, an estimated twenty thousand people were using Krokodil (6), with data from one 
published survey showing approximately 25% of interviewees (n=550) self-reported 
Krokodil use (15).  While no statistics are provided, the use of Krokodil is included by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCCDA) in overviews 
prepared for the Republics of Georgia and Kazakhstan (16, 17). 
In 2014, case reports involving Krokodil use were published from the United States 
(18) and the Republics of Armenia and Georgia (19, 20).  Clinical case reports have since 
been published from Italy (21), Poland (22), Russia (23, 24), Spain (25) and the United 
Kingdom (14), as well as additional case reports from the Republic of Armenia (26, 27) 
and the United States (28-31).  The first and only analytically confirmed case originated 
from Italy.  Table 1.1 summarizes the case reports in the literature, including the symptoms 
noted with each case.  Based on these reports Krokodil use has been associated with 
necrotic ulcers, osteonecrosis (death of bone tissue) and osteomyelitis (infection of bone 
tissue) in multiple patients.  In cases involving fatalities, respiratory distress, organ failure, 
paroxysmal hypoxia (reoccurring instances of low oxygen supply), dyspnea (shortness of 








Published case reports of Krokodil use. 
Origin Year 
Last Use of 
Krokodil 






2014 unknown heroin necrotic ulcer 1 no (18) 
Unites States 
(Ohio) 
2015 unknown heroin necrotic ulcers 2a no (28) 
United States 2016 1 year prev. heroin necrotic ulcers 1 no (29) 
United States 
(Colorado) 




1 yes (30) 
United States  
(New York) 
2018 4 days prev. 
heroin, alprazolam, 
cocaine 
necrotic ulcers 1 no (31) 
Republic of 
Armenia 
2014 unknown none jaw osteonecrosis 40 no (20) 
Republic of 
Armenia 
2017 unknown none jaw osteonecrosis 1 no (26) 
Republic of 
Armenia 














160 yesb (19) 
Germany 2012 unknown heroin 
paroxysmal 
hypoxia; coma 
1 yesc (11) 





1 yese (21) 
Poland 2018 unknown none necrotic lesions 1 no (22) 
Russia 2015 unknown none jaw osteonecrosis 165 no (23) 
Russia 2015 unknown none jaw osteomyelitis 52 no (24) 







1 no (25) 
United Kingdom 2013 3 months heroin, amphetamines hallucinations 1 no (14) 
aOnly 1 reported Krokodil use.  
bIn 1 patient out of 160.  
cNo desomorphine in blood or urine; femoral blood findings: morphine (40 ng/mL), morphine-3-glucuronide (100 ng/mL), methadone 
(400 ng/mL), trimipramine (200 ng/mL) and N-desmethyltrimipramine (200 ng/mL).  
dLast use was estimated to be 2-3 days based on the toxicology. 
eDesomorphine (270 ng/mL) in urine with caffeine, acetominophen and phosphoric acid also detected.
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As Krokodil is used as a clandestine heroin substitute, users also commonly report 
having used heroin, as can be seen in the case reports (Table 1.1) where it is the most 
frequent additional drug reported, though it is unclear whether these drugs are co-
administered.  Other drugs reported include: barbiturates and benzodiazepines, which are 
CNS depressants used clinically to treat anxiety and seizures; cannabis (marijuana), which 
is used medically for analgesia and appetite stimulation or illicitly for its hallucinogenic 
properties; cocaine, a CNS stimulant which also sees limited medical use as a topical 
anesthetic; and methamphetamine, which is used clinically both to treat attention deficit 
hyperactivity disorder under the brand name Desoxyn® and as a nasal decongestant (l-
methamphetamine), with d-methamphetamine being used illicitly for its psychoactive 
properties.  Additional drugs identified from toxicological testing in reported Krokodil 
cases are morphine, trimipramine (antidepressant), caffeine and acetaminophen (11, 21).  
In a study to detect desomorphine in authentic urine specimens, desomorphine’s precursor 
codeine was also detected (5).   
With a lack of analytically confirmed case reports, the available information 
regarding the prevalence of Krokodil use suggests that it is primarily used in Russia and 
bordering states.  In the United States in particular, there is contention over the validity of 
known reports of Krokodil use, with physicians arguing for and against the acceptance of 
reports of Krokodil use without analytical confirmation  (29, 32-34).  Desomorphine’s 
precursor, codeine, is a schedule V drug and is available only with prescription. While this 
might diminish its abuse, it is still possible to obtain codeine illicitly.  Of particular note, 
two exhibits submitted to forensic laboratories in 2004 were analytically identified as 
desomorphine, according to the National Forensic Laboratory Information System 
9 
 
(NIFLIS) (35).  While there is no further information regarding these two exhibits, the 
report raises interesting questions regarding Krokodil use in the United States. 
Legal Status  
 Today desomorphine is generally regarded as having no medical use and is 
controlled in multiple countries.  The United Nations Single Convention of Narcotic Drugs 
(1961) classified it as a schedule IV drug (36).  Russia included it on the List of Narcotics, 
Psychotropic Substances and Precursors Thereof, Subject to Control in the Russian 
Federation (5) and it is considered non-marketable in both Austria and Germany (3).  In 
Brazil, desomorphine is a class F1 drug (37) and in the United Kingdom it is a class A drug 
(38).  
In the United States desomorphine is a schedule I drug under the Federal Controlled 
Substances Act (CSA) (35), though its sale was prohibited even before the creation of the 
CSA.  In 1935, the Committee on Drug Addiction recommended desomorphine be 
prohibited in the United States due to its addiction liability (39).  This was largely based 
on early studies demonstrating that desomorphine produced respiratory depression and 
withdrawal symptoms similar to morphine (40).  This was the first instance of addiction 
liability being the decisive factor in narcotics control.  Indeed, the studies of desomorphine 
are regarded as being used to devise the first reliable test for addiction potential among the 
opioids (41). 
Chemistry of desomorphine 
Chemical properties 
Opioids can be divided into seven classifications, including phenanthrenes, 
morphinans, phenylheptylamines, phenylpiperidines, benzomorphinans, cyclohexanols 
10 
 
and phenols.  All have aromatic cores and many are considered amphoteric bases.  
Desomorphine belongs to the phenanthrene class, also called 4,5-epoxymorphinans, which 
includes the morphine-like opioid alkaloids found in P. somniferum.  Derivatization of 
these natural alkaloids, also referred to as opiates, to produce semi-synthetic opioids has 
led to the phenanthrenes becoming the largest class of opioids.  Morphine and codeine were 
the most commonly used starting materials for chemical alterations, each causing changes 
to the pharmacological action, which will be discussed in greater detail later.  Synthetic 
opioids, while having similar mechanism of action, do not structurally resemble natural 
and semi-synthetic opioids.  Figure 1.1 shows the structure of desomorphine and morphine 
for comparison.  Phenanthrene opioids are composed of five rings: the aromatic A ring, 
two six-membered carbon rings B and C, the nitrogen containing D ring and the oxygen 
containing five membered E ring.  Desomorphine differs from morphine in the absence of 
the hydroxyl group at C6 and the saturation of the C7-C8 double bond.  It is a solid at room 
temperature, with a molecular weight of 271.35 g/mol and a melting point of 189°C (2).  It 
is soluble in water as a salt and partially soluble as a free base.  It is also soluble in acetone 
and ethyl acetate (42).   
 
Figure 1.1. Structures of desomorphine and morphine. Carbon numbers are shown for 





Desomorphine’s absolute structural conformation is a T-shape, with the C ring in 
chair confirmation. This is in contrast to morphine, whose C ring is in boat confirmation.  
Desomorphine’s levorotary isomer has a specific optical rotation of [𝛼]𝐷
28 -77° (c 1.6, 
methanol) (42).  Research with morphine has shown that the structural conformation of 
opioids can play an important role in terms of their analgesic potency.  Levorotary isomers 
may have diminished activity relative to their dextrorotary counterparts (43). 
Desomorphine is an amphoteric base, with a tertiary amine and phenolic group, 
which have disassociation constants of 9.69 and 10.62, respectively (42, 44).  The 
isoelectric point (pI) of this zwitterionic drug is pH 10.16 (Figure 1.2).   Analytically, 
zwitterions like desomorphine can be challenging to isolate from biological specimens.  
During extraction, the charge on the drug is manipulated by changing the pH. Using liquid-
liquid extraction (LLE), drugs are preferentially partitioned into the organic phase in their 
uncharged state. For zwitterions, functional groups on the drug may be charged over a 
wider range of pH values. At the pI, although the net charge on the drug is zero, functional 
groups are still ionized. Although this can diminish extraction efficiency using LLE, it can 
be exploited using mixed-mode solid phase extraction if the stationary phase has anion or 









The structure of morphine was first published in 1925 by Gulland and Robinson 
(1).  Shortly after, research emerged regarding chemical modifications to morphine’s 
structure, in an effort to discover non-addictive analgesics that could be used in its place 
(40).  In 1933 the first synthesis for desomorphine was published as part of a series on the 
catalytic hydrogenation of halogenocodides and halogenomorphides (45, 46).  Figure 1.3 
depicts the structures of the different desoxymorphines and desoxycodeines produced by 




Figure 1.3. Desomorphine with examples of other desoxymorphines and desoxycodeines.  
 
Beginning with chloromorphide and bromomorphide, palladium-barium sulfate was used 
to catalyze the reaction and produce dihyrodesoxymorphine-D ((5α,6α)-17-methyl-7,8-
didehydro-4,5-epoxymorphinan-3-ol; desomorphine).  They found that the yield of 
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desomorphine varied, depending on which compound was used as the precursor and what 
the reaction solvent was.  Figure 1.4 depicts the different reactions investigated and the 
yield of desomorphine associated with each precursor and solvent used.  They noted that 
tetrahydrodesoxydesomorphine was also produced in smaller amounts from reactions 
starting with α-chloromorphide and an uncrystallizable oil was also produced from 
reactions with bromomorphide (2). 
 
 
Figure 1.4. Desomorphine yield after dehalogenation of chloromorphide isomers and 
bromomorphide in either methanol or dilute hydrochloric acid (HCl). 
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Further research found that desomorphine could be obtained as a hydriodide from 
demethylating dihydrodesoxycodeine-D with a 93% yield (45).    It was determined that 
this was the most practical pathway as dihydrodesoxycodeine-D could be prepared from 
α-chlorocodide, which was more easily accessible than the halogenomorphides (Figure 
1.5) (2).   
 
Figure 1.5. Synthesis of desomorphine using α-chlorocodide.  
 
 
In 1952 Perrine and Small published their attempts to improve the synthesis of 
desomorphine (47).  They first attempted to synthesize dihydrodesoxycodeine-D from 
dihydrocodeinone (hydrocodone) using hydrazine and ethyl mercaptan.  These first 
attempts produced dihydrodesoxycodeine-C and dihydrothebainone but not desomorphine.  
They then adapted a synthesis published by Rapoport and Bonner (48).  The original 
synthesis produced dihydrodesoxycodeine-D through detosylation of 6-
toluenesulfonylcodeine.  It had previously been shown that desomorphine could be 
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produced by demethylating dihydrodesoxycodeine-D (45) and Perrine and Small applied 
that to successfully derive desomorphine from 6-toluenesulfonylcodeine.  The complete 
pathway is shown in Figure 1.6. 
 
 
Figure 1.6. Synthesis of desomorphine using 6-toluenesulfonylcodeine. 
 
 
After reports of Krokodil use began to surface, Srimurugan published a high yield 
synthesis for desomorphine and its deuterated analog (49).  The reaction pathway is 
summarized in Figure 1.7.  It proceeds in a similar fashion to that published by Perrine 
and Small (47) (Figure 1.6) however a mesyl group is added to codeine instead of a tosyl 
group due to a higher yield and shorter reaction time.  The final product had a purity of 





Figure 1.7. Synthesis of desomorphine using 6-methanesulfonylcodeine.  
 
From the available information in published literature, the favored synthesis for the 
clandestine production of desomorphine resembles the Nagai method commonly used to 
synthesize methamphetamine (6, 50).  A crude liquid-liquid extraction (LLE) with gasoline 
and alkali household cleaning products is used to extract codeine from over the counter 
(OTC) preparations.  The isolated codeine is then mixed with iodine, hydrochloric acid and 
phosphorous.  The mixture is heated and allowed to react for approximately forty-five 
minutes (50).  The proposed reaction pathway is similar to that suggested by Small (2) but 
with α-chlorocodide replaced with α-iodocodide due to the presence of iodine (51) (Figure 
1.8).  Given that the reagents used for clandestine synthesis are not pure and that OTC 
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preparations of codeine can contain other drugs in addition to binders, it is unsurprising 
that recent studies have shown Krokodil to contain numerous side products in addition to 
desomorphine (51, 52).  There is also evidence that variations in the source of reagents, for 
example different formulations between cleaning products, may also effect the 
composition of Krokodil (5). 
 
 
Figure 1.8. Clandestine synthesis of desomorphine. 
  
Pharmacology 
Pharmacodynamics   
Desomorphine is a semi-synthetic opioid and as such its pharmacological effects 
are due to interactions with opioid-receptors which are present at several sites in the CNS.  
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A large cluster of opioid-receptors is located within the limbic system of the brain, which 
is involved with emotional response.  Opioids, as narcotic analgesics, block pain responses 
by interacting with terminal nerve endings and blocking the release of neurotransmitters.  
This prevents the recognition of nociceptive signals which in turn inhibits a negative 
emotional response due to pain.  In some instances, this interaction can also produce 
euphoria. 
The three major receptor types involved with the pharmacological effects of opioids 
are the µ, κ and δ receptors.  The µ receptors produce the largest number opioid effects 
including analgesia (supraspinal and spinal), euphoria, reduction of gastrointestinal 
motility, respiratory depression, hypothermia, bradycardia, tolerance and physical 
dependence.  The κ receptors produce spinal analgesia, miosis, sedation, mild respiratory 
depression and diuresis.  The analgesia produced by κ receptors can also be accompanied 
by psychomimetic effects.  Spinal analgesia, respiratory stimulation, dysphoria, delusions, 
hallucinations and vasomotor stimulation are mediated via δ receptors.  Opioids may also 
occasionally bind to σ receptors, which produce CNS excitation and can cause 
hypertension, tachycardia, tachypnea, mydriasis and hallucinations.  Drug-receptor 
interactions can be agonistic or antagonistic in nature.  Some opioids have agonistic effects 
at one receptor while having antagonistic effects at another.  Opioids that are full 
antagonists tend to produce reduced analgesic effects and are often used to treat opioid 
intoxication, with naloxone and naltrexone being the most common examples.  Opioids 
that are strong µ receptor agonists typically have the highest potential for abuse due to the 
production of euphoria and physical dependence. 
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The pharmacological response of an individual opioid is determined by its chemical 
structure.  Structure-activity relationships of the opioids have been widely studied.  
Common structural alterations involve the C3 and C6 functional groups as well as the 
nitrogen ring (Figure 1.9).  In general, changes to C3 decrease analgesic potency while 
changes to C6 increase it.  A noted exception to this trend is diacetylmorphine (heroin) 
(43).  Modifications to the nitrogen ring as a whole tend to significantly decrease potency, 
indicating that the tertiary amine plays a vital role. 
 
 
Figure 1.9. Morphine structure with carbon numbers labeled.  
 
All in vivo animal and human studies involving desomorphine’s pharmacology 
were performed in the early and mid-1900s (53).  In study involving dogs, desomorphine 
produced a greater depressant effect compared to morphine.  Desomorphine doses varied 
from 2-5 mg and morphine doses were 10-50 mg, with the effect of desomorphine noted 
as being greater than the 10 mg dose of morphine but less than the 50 mg dose.  In cats, 
those dosed with desomorphine experienced less vomiting than those dosed with morphine 
and in a study using rhesus macaque monkeys, desomorphine showed ten times the 
depressant effects of morphine.  Additionally, rapid tolerance was observed in the subjects, 
though the degree of tolerance was less than morphine.  In rats, the LD50 of pure 
22 
 
desomorphine was found to be 27 mg/kg compared to 22 mg/kg for heroin, 300 mg/kg for 
codeine, and 226-318 mg/kg for morphine.   
In humans, desomorphine was found to have a duration of effect of up to three 
hours (54).  Increasing the dose of desomorphine did not noticeably extend the duration of 
effect but it was noted to be approximately ten times more potent than morphine.  The 
reduced onset of action is linked to the elimination of the C6 hydroxyl group, rendering 
desomorphine more lipophilic than morphine and facilitating diffusion across the blood 
brain barrier.  A decrease in respiration rate was noted with both desomorphine and 
morphine, but unlike morphine, the individuals who were treated with desomorphine did 
not develop tolerance with respect to respiratory depression with prolonged use.  The 
increased potency relative to morphine and the reduced tolerance to respiratory depression 
could have serious consequences to individuals who abuse this drug.  Patients who reported 
Krokodil at a drug treatment facility in the Republic of Georgia indicated that the short 
duration of action lead them to inject the drug anywhere from one to ten times daily (19). 
The withdrawal effects experienced after ceasing desomorphine use appeared to be 
the typical abstinence syndrome experienced by opioid users (40).  In 1943, Wright and 
Sabine published a study regarding the effects of morphine, hydromorphone, codeine and 
desomorphine on the activity of cholinesterase (55).  It is the inactivation of cholinesterase 
that causes the respiratory depression characteristic of the opioids.  Using multiple media, 
including human serum and brain, they found that desomorphine inactivated cholinesterase 
to a greater extent than morphine, hydromorphone and codeine.  In summary, 
desomorphine is both more potent and more toxic than morphine and, based on its observed 
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pharmacological effects, a potent µ agonist with diminished affinities for both κ and δ 
receptors. 
Due to the presence of multiple morphinans and traces of precursor reagents, the 
side effects of Krokodil are expected to exceed those of desomorphine but due to the 
limited number of published reports, the knowledge of those side effects is confined to 
anecdotal accounts from users and clinical observations from health care professionals.  
Reported side effects include abscesses, dermatological lesions and ulcers, thrombosis, 
necrotizing fasciitis, osteonecrosis, sepsis, damage to blood vessels, muscle, cartilage, and 
bone, multiple organ failure, endocarditis, hypotension, bradycardia, loss of cognitive 
functions, speech difficulty, changes in personality, loss of memory, hallucinations, and 
death (50, 56).  Many of the severe effects, such as necrotic ulcers (Figure 1.10), are likely 




Figure 1.10. Necrotic ulcers associated with Krokodil use. Images originally published in 
(31, 57). 
Pharmacokinetics 
Knowledge of a drug’s metabolism plays a key role in predicting drug-drug 
interactions and facilitating analytical detection.  The rate of metabolism directly affects a 
drug’s half-life and window of detection and known metabolites may serve as alternative 
biomarkers for analytical methods.  When multiple drugs are metabolized by the same 
enzymes the duration of effect of one or both may be altered.  Additionally, metabolites 
may also be pharmacologically active and may be more potent that the precursor, such as 
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morphine-6-glucuronide, which can create a secondary high (58).  There are two types of 
reactions that take place during metabolism: the transformation of functional groups and 
the conjugation of the drug with endogenous substances.  Phase I reactions, catalyzed by 
cytochrome P450 mono-oxygenases (CYPs), include demethylation, dealkylation, 
deamination, desulfuration, epoxide formation, hydrolysis, hydroxylation, N-oxide 
formation, sulfoxide formation and reduction. Phase II reactions may involve glucuronic 
acid (uridine diphosphate-glucuronosyltransferases, UGTs), sulfate (sulfotransferases) and 
glutathione (glutathione S-transferases).  Phase I and II reactions generally occur 
synchronously, with many hydroxylated and carboxylated phase I species undergoing 
conjugation. 
Opioids with free hydroxyl groups tend to be primarily conjugated during 
metabolism.  Up to 75% of a morphine dose is conjugated to form morphine-3-glucuronide 
while approximately 5% converted to normorphine (59).  Research into the enzyme 
isoforms (isozymes) involved with morphine metabolism has shown that the major phase 
II isozyme is UGT2B7 (60) which catalyzes the formation of both morphine-3-glucuronide 
as well as the minor metabolite morphine-6-glucuronide.  Six additional isozymes 
(UGT1A1, UGT1A3, UGT1A6, UGT1A8, UGT1A9 and UGT1A10) have also been 
shown to catalyze the formation of morphine-3-glucuronide but not morphine-6-
glucuronide (61).  These additional biotransformation pathways likely contribute to 
morphine-3-glucuronide being morphine’s major metabolite over morphine-6-
glucuronide, which is significant as morphine-6-glucuronide is pharmacologically active 
while morphine-3-glucuronide is not.  The CYP isozymes involved in morphine 
metabolism have also been explored.  Both CYP2C8 and CYP3A4 have been shown to 
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catalyze the formation of normorphine (62), with CYP3A4 being the major contributor.  
CYP2D6 has also been shown to catalyze the phase I metabolism of levorphanol (63), 
which is structurally identical to desomorphine with the exception of the epoxide bridge. 
Approximately 31% of a levorphanol dose is conjugated and 2.5% is converted to 
norlevorphanol (64). 
There is limited information regarding the pharmacokinetics of desomorphine.  The 
primary route of administration reported is intravenous injection which means that it will 
not be subjected to first-pass metabolism (50).  Its shorter duration of action likely 
corresponds to a shorter half-life but the only report of its window of detection, a few hours 
in blood and three days in urine, was not accompanied by any supporting data (11).  The 
first study to investigate desomorphine’s metabolism was published in 2016 (65).  Using 
multiple models, including supersomes™, human liver microsomes and an in vivo rat 
study, seven phase I metabolites were identified (nordesomorphine, desomorphine-N-oxide 
and five hydroxydesomorphine isomers).  Four phase II metabolites were also identified 
(desomorphine-glucuronide, desomorphine-sulfate, nordesomoprhine-glucuronide and 
desomorphine-N-oxide-glucuronide).  CYP3A4 was found to catalyze the formation of 
most of the phase I metabolites but notably did not account for the formation of two of the 
hydroxydesomorphine isomers.  Eight UGTs were found to catalyze the formation of 
desomorphine-glucuronide: UGT1A1, UGT1A8, UGT1A9, UGT1A10, UGT2B4, 
UGT2B7, UGT2B15 and UGT2B17.  These results are largely consistent with what has 
been observed for morphine and levorphanol but there are notable differences.  In this 
study, only CYP3A4 was shown to metabolize desomorphine in contrast to previous 
studies with morphine and levorphanol.  Morphine has been shown to be metabolized by 
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CYP2C8 and CYP3A4, and levorphanol has been shown to be metabolized by CYP2D6 
and CYP3A4.  UGT2B7 was the major UGT isozyme involved in desomorphine 
metabolism, which is consistent with morphine.  However, morphine is additionally 
metabolized by UGT1A3 and UGT1A6 which have not been shown to metabolize 
desomorphine. Conversely, morphine has not been observed to be metabolized by 
UGT2B4, UGT2B15 and UGT2B17, which were shown to metabolize desomorphine.  
These differences are likely due to the structural differences between morphine and 
desomorphine, which influences how each interacts with enzymatic binding sites. 
Experimental approaches to drug metabolism 
There are three categories of testing models that are used to study metabolism: in 
vivo, in vitro, and in silico (66).  In brief, in silico models are predictions of drug 
metabolism based on existing knowledge of structurally similar drugs and enzyme crystal 
structures.  In vivo models performed using living subjects (human or animal) provide 
information including but not limited to bioavailability, distribution, clearance rate, and 
duration of exposure.  In vitro models work on a smaller scale than in vivo, but dispite their 
limitations, they can provide very reliable infomation (67, 68).  In vitro models are widely 
used to investigate parameters including but not limited to metabolic stability, drug-drug 
interactions, and toxicity. 
The ideal approach to determining the metabolism of desomorphine in humans 
would be to conduct an in vivo study, in which willing participants would be administered 
controlled doses.  Urine and blood would be collected at set time intervals and analyzed 
for the parent drug and metabolites.  However, the rate and efficiency of metabolism is 
highly variable between individuals.  Age, disease, and genetic variation can all affect 
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metabolism and to draw any generalized conclusions from such a study would require a 
large population of subjects, which would be time consuming and costly (69-71).  The use 
of an in vitro model has many advantages.  In general terms hepatic in vitro models can be 
divided into the following categories: recombinant enzymes, subcellular fractions, whole 
cell cultures, and tissue cultures (72).   
Recombinant enzymes 
Recombinant enzymes are created by encoding the gene of an enzyme into a vector 
that can be expressed in a system other than its native environment.  The gene is obtained 
by isolating messenger ribonucleic acid (mRNA) for an enzyme from tissue and using that 
mRNA to produce the complementary deoxyriboneucleic acid (cDNA) that encodes the 
enzyme (73).  The cDNA can then be inserted into a vector for expression. Multiple 
enzymes have been expressed this way, the most common being CYPs, and more recently 
UGTs.  Whole cell expression systems are commonly used, which includes mammalian 
cells, yeast cells, bacterial cells, and insect cells.   
The species of mammalian cells used can vary based on availability and study 
needs.  A virus or a plasmid is used to introduce the cDNA, and most mammalian cells 
offer the advantage of having an endogenous endoplasmic reticulum which helps support 
the activity of the expressed enzyme but may also have endogenous CYP enzymes.  Using 
selection markers can amplify the cDNA copy number and increase the recombinant 
enzyme’s expression beyond that of the endogenous enzymes (73).   
The yeast species most commonly used for recombinant enzyme expression is 
baker’s yeast, Saccharomyces cerevisiae though many others can be used (74).  Insertion 
vectors are used, either replicating vectors or vectors that can be integrated with the host 
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genome, to insert the desired gene (73).  Yeast also has an endoplasmic reticulum, however 
unlike mammalian cells the efficient expression of the recombinant enzyme often requires 
modification of the gene.  This is accomplished by deleting a portion of the untranslated 5’ 
region of the cDNA (75). 
Escherichia coli is the most common bacterial species used for expressing 
recombinant enzymes.  It is easily manipulated with numerous vectors but also requires 
extensive modification to the gene sequence to produce high expression of enzymes.  
Modification techniques used for inserted genes include modifications to the N-terminal 
and mutating the cDNA sequence to code for common E. coli codons rather than 
mammalian ones (76).  Enzyme expression can also be enhanced by co-expressing 
cytochrome oxidoreductase and sometimes cytochrome b5 (77). 
Insect cell expression systems use baculoviruses as vectors (72), which are a group 
of viruses that exclusively infect insect cells (73).  As with mammalian and yeast cells, 
insect cells contain endogenous endoplasmic reticulum.  It is not necessary to modify 
cDNA for expression in insect cells but the co-expression of cytochrome oxidoreductase 
and sometimes cytochrome b5 for may still be necessary for efficient enzyme expression 
(78). 
Recombinant enzymes are excellent tools for investigating individual enzyme 
pathways and the effect of enzyme polymorphism.  Their high activity produces relatively 
large quantities of metabolites compared to other in vitro models, allowing for easier 
analysis of their structures.  Interpretation of the results must be done with care however, 
for these enzymes are not functioning in their native environment and the strategies used 
to maximize their expression and activity mean that the metabolic products and reaction 
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rates might be shifted from in vivo.  Studies comparing different expression systems also 
indicate varying levels of enzyme activity, with enzymes expressed in bactosomes being 
more active than those expresses in supersomes™ (79, 80), however bactosome expression 
requires more genetic modification, which could possibly account for the increase in 
activity but any additional modification can carry a risk of altering an enzymes function 
and potentially what metabolites are formed.   
Subcellular fractions 
Subcellular fractions are isolated from liver tissue.  These fractions contain much 
of the infrastructure found in the whole cells, but they are not entirely self-supporting.  It 
is necessary to add a source of elections, also referred to as a cofactor, for the reactions to 
proceed.  There are three forms of subcellular fractions: microsomes, cytosol fractions, and 
S9 fractions. 
Microsomes are vesicles of endoplasmic reticulum which contain CYPs and other 
membrane bound enzymes, such as UGTs (75).  Enzymatic activity can vary between 
individuals so to overcome this, microsomes are ‘pooled’, meaning the final product 
contains microsomes from multiple individual donors to mitigate individual variation and 
allow for generalized conclusions to be drawn.  Unpooled microsomes also have their uses 
as they can be used to investigate whether an enzyme’s polymorphisms will affect the 
affinity towards a drug or change the final product formed.  Additionally, pooled 
microsomes from donors of only one gender can be used to instigate the effect of gender 
on metabolism. 
Cytosol fractions are portions of the cellular cytosol, which contains enzymes that 
are not bound to a membrane.  This does not include CYPs but does include multiple phase 
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II enzymes, including glutathione S-transferase, sulfotransferase, and N-acetyl transferase 
(75).  Cytosol fractions are not used as often as other subcellular fractions because these 
metabolic pathways are not commonly involved with drug metabolism but can prove useful 
in instances where extensive phase II metabolism occurs, such as the case with many 
opioids. 
S9 fractions are a combination of microsomes and cytosol fractions.  Like 
microsomes and cytosol fractions, S9 fractions still require cofactors for reactions to 
proceed and can be pooled from multiple donors.  They give a more complete metabolic 
profile for a drug but overall have a lower enzyme activity compared to cytosol fractions 
and microsomes which can make detecting metabolites difficult (72). 
Subcellular fractions are versatile tools for metabolism studies.  They can be used 
to study drug interactions and individual enzyme pathways can be studied with the 
application of specific enzymatic inhibitors (66).  S9 fractions can also be used to study the 
both phase I and phase II metabolic processes simultaneously.  While more representative 
of in vivo than recombinant enzymes, subcellular fractions still lack extracellular factors 
and components that may influence metabolic pathways. 
Whole cell culture and tissue fractions 
As whole cell cultures consist of intact cells instead of enzymes or subcellular 
fractions, they are more representative of in vivo physiology, but must be cultured in 
specialized media to support their lifecycles.  There are three types of whole cell cultures: 
liver cell lines, transgenic cell lines, and hepatocytes.  Like subcellular fractions, cells from 
different donors can be pooled to reduce variation between individuals.  However, in 
contrast to subcellular fractions, whole cell cultures contain not only all of the enzymes 
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involved in hepatic metabolism, but also the additional cellular structures present in 
eukaryotic cells, which may influence metabolism pathways.  
Liver cell lines are isolated from primary tumors of liver parenchyma.  As these are 
typically harvested from livers suffering from cirrhosis or hepatitis, they typically do not 
express all of the families of metabolic enzymes (75).  There are multiple cell lines 
available, each of which expresses different families of enzymes.  Enzyme expression can 
be increased through induction but it is still difficult to investigate individual enzyme 
pathways with cell lines (72).  Their main advantage is that they are easier to cultivate than 
other cell cultures. 
Transgenic cell lines can be considered both whole cell cultures and recombinant 
enzymes.  They are liver cell lines that have been used to express recombinant enzymes in 
order to overexpress select enzymes (75).  Transgenic cell lines share the advantages of 
both cell lines and recombinant enzymes.  They are however limited in the number of 
enzymes that can be expressed at one time. 
Hepatocytes are isolated from liver tissue obtained from liver transections (81).  
They are a popular in vitro model due to a strong resemblance to in vivo liver (82).  
Hepatocytes exist in three forms: primary, cultured, or cryopreserved.  Primary hepatocytes 
refer to hepatocytes that are freshly isolated from tissue.  They are generally only viable 
for a few hours unless cultured.  Cultured hepatocytes are stable for up to four weeks but 
are subject to a decrease in CYP activity over time.  Cryopreservation allows for 
hepatocytes to be stored for longer periods of time without a loss of activity, making them 
the most popular whole cell model (72). 
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Tissue cultures are the closest representative of in vivo interactions as they not only 
preserve the integrity of the cell but the extracellular environment as well, however they 
are the most difficult to prepare and work with.  The two forms of liver tissue cultures are 
liver slices and isolated perfused liver.  Like cell cultures they require specialized media to 
keep the tissue functioning (72).  Slices of liver tissue can be powerful investigative tools, 
but their reproducibility is dependent on uniform thickness between slices (75).  Long-term 
preservation of liver slices has not yet been developed so this model is only viable for a 
short period of time (83).   
An isolated perfused liver is a whole liver that is maintained through specialized 
media.  Human liver has never been used for this purpose due to the requirement of an 
intact liver (72).  As animal liver is not always a good reflection of the human system this 
technique is rarely used in the realm of human drug discovery.  It is typically only used 
when bile secretion is suspected to be important.  Bile secretion is perhaps this model’s 
only advantage over other models as it has a very short window of viability, generally about 
3 hours (75). 
Forensic toxicology 
Forensic toxicology may include a variety of investigation types, including but not 
limited to fatalities (post mortem), impaired driving, and drug-facilitated sexual assault 
(ante mortem).  The type of sample matrix encountered depends on the case type, although 
blood and urine are the most frequently encountered specimens.  Postmortem toxicology 
may also involve tissues, stomach contents, bile, and vitreous humor.  Additional sample 
matrices include hair, oral fluid and sweat.   
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In general, the analytical process consists of presumptive testing followed by 
confirmatory analysis.  Presumptive testing, also called drug screening, is used to narrow 
down the class of drug that might be present and generally involves minimal sample 
preparation.  Once that information has been obtained, the analyte is isolated from the 
matrix via sample preparation techniques that are tailored to the chemical characteristics 
of the drug(s) in question.  After isolation the analyte, confirmatory testing takes place to 
specifically identify the analyte(s). 
Any analytical methodology developed for use in forensic toxicology laboratories 
must be carefully documented and systematically assessed to ensure it will produce reliable 
results.  The scope of validation is dependent on whether the method is intended to be 
presumptive, qualitative or quantitative.  The validation of presumptive methods can 
include the limit of detection, potential interferences, the precision at a decision point, 
dilution integrity and stability.  Validation of qualitative methods often includes the limit 
of detection, carryover, potential interferences, dilution integrity, stability, and matrix 
effects (if applicable).  The validation of quantitative methods is the most rigorous and in 
addition to the parameters assessed with qualitative methods, should also assess bias, 
precision, the limit of quantitation and calibration model.  Validation standards for forensic 
toxicology were published by the Scientific Working Group for Forensic Toxicology 
(SWGTOX) in 2013 (84).  Those recommendations are currently undergoing a process to 
become an American National Standard. 
Drug screening 
Drug screening is intended to presumptively identify drugs or classes of drug that 
may be present in a specimen.  Screening techniques used in forensic toxicology are 
35 
 
generally either immunoassay (IA) or mass spectrometry (MS) based.  While IA techniques 
are most commonly encountered in forensic toxicology laboratories, MS-based screening 
is growing in popularity, likely due to the proliferation of designer drugs and new 
psychoactive substances (85).  
IAs utilize antibody reagents, which are typically raised against an antigen in 
animal species.  Antibodies isolated from serum can be immobilized onto a surface for 
immunoassay testing purposes.  There are five immunoglobulin classes, IgG, IgM, IgA, 
IgE and IgD, with IgG being the most abundant.  Polyclonal antibodies can be subject to 
considerable variation due to the nature of biological systems.  Monoclonal antibodies are 
more reproducible, and are created by harvesting antibody cells, then fusing them to tumor 
cells to form hybridomas.  These can be screened for specific antibody production and the 
desired cells cloned to increase antibody production.   
Because most drugs are less than 2000 Da in mass, they are not naturally antigenic, 
necessitating linkage to a carrier protein to facilitate interaction.  These carrier proteins are 
linked to the drugs using functional groups (amines, hydroxyls, etc) to attach the 
crosslinked ‘bridge’ between the drug, or hapten, and the carrier protein.  For drugs with 
multiple functional groups, the site selected for covalent bonding may determine which 
part of the hapten can be recognized by the immune system.  The nature of the attachment 
can significantly influence assay performance (86).  Cross-reactivity arises in IAs when 
substances structurally related to the target drug bind to the antibody.  The covalent 
bonding between the very large carrier protein and the small drug may occlude certain 
portions of the molecule, making them “invisible” to the immune system during antibody 
production.  This can lead to decreased specificity at those sites, resulting in cross-
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reactivity.  However, this lack of specificity can also be exploited to create immunoassays 
capable of detecting multiple drugs within a class of structurally similar substances, such 
as the benzodiazepines or barbiturates.   
The most commonly used IAs in forensic toxicology are enzyme-linked 
immunosorbent assays (ELISAs) and enzyme multiplied immunoassay technique (EMIT®) 
(85).  All are competitive assays, meaning that any drug present in the sample will compete 
with labelled drug for antibody binding sites.  In homogeneous assays it is not necessary 
to separate bound and unbound drug prior to detection. In a heterogeneous ELISA, 
unbound drug is removed prior to the addition of the enzyme substrate.  In the case of 
ELISA, a colorimetric reaction is used to identify drug in the specimen.  An established 
cut off concentration, is used to differentiate a positive from a negative result.  While 
individual laboratories may establish cut off concentrations independently, 
recommendations for impaired driving casework have been published (87). In an ELISA, 
antibodies are frequently immobilized on the surface of microtiter wells.  Drug in the 
sample and enzyme-labelled drug are incubated in the well, after which unbound 
components are discarded. Horseradish peroxidase-labelled drug and tetramethylbenzidine 
(TMB) are frequently utilized for colorimetric detection.  Using this approach, there is an 
inverse relationship between color intensity (measured spectrophotometrically) and drug 
concentration. Heterogeneous ELISAs can be readily adapted to a wide variety of 
biological matrices. Other advantages include small sample volumes, high throughput, 
sensitivity, resistance to matrix effects, rapid analysis and potential for automation.  
Sodium azide, a common antimicrobial agent used to preserve urine, can interfere with 
horseradish peroxidase activity and should not be used.  
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Using EMIT, glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate to 
gluconolacetone-6-phosphate and reduces nicotinamide adenine dinucleotide (NAD) to 
NAD+.  The absorbance of NAD+ (340 nm) is measured as a function of time, with the 
amount of NAD+ produced being directly proportional to the amount of free drug present 
in the sample.  Advantages of EMIT include the wide concentration range and ease of 
automation.  However, due to it homogeneous nature, EMIT is more susceptible to non-
specific interferences and may require additional sample preparation for more complicated 
biological matrices (88).   
IAs typically require minimal sample preparation for aqueous matrices, however 
solid matrices, such as tissues may require protein precipitation, centrifugation and/or 
dilution.  The major limitation of all IAs is their reliance on structural similarity in order 
for a drug to be detected. Immunoassays for common opioids often utilize morphine as the 
target drug.  As such they are incapable of detecting fentanyl, methadone or newer designer 
opioids that do not resemble morphine in structure.  This may require the use of several 
IAs to detect a specific class of drug, which may be cost-prohibitive and inefficient. The 
development of a new commercial immunoassay is also a time-consuming process.  In 
contrast, MS based screening techniques can be readily adapted for novel drugs, negating 
the time delay between the first appearance of a drug and the development of a suitable 
immunoassay.  Due to the dynamic nature of the designer drug landscape, this adaptability 
is a significant advantage for forensic laboratories that already have MS instrumentation.    
The MS is used to ionize molecules and separate them according to their mass-to-
charge ratios. Accompanying mass spectral fragmentation of the molecule can provide 
valuable structural information.  MS combined with separation techniques such as gas 
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chromatography (GC) and liquid chromatography (LC), are widely used for confirmatory 
analyses in forensic toxicology (85).  While MS bases techniques may require more 
extensive sample preparation than ELISA, the existence of simultaneous extraction 
methods for acidic, basic and neutral drugs allows for broad spectrum drug screening (89, 
90). 
GC-MS has the advantage of being a well-established technique with large 
reference libraries available for comparison purposes (91).  However, GC-MS is 
incompatible with large, nonvolatile compounds, as well as highly polar compounds, 
including many endogenous substances present in biological specimens.  Derivatization is 
often needed for polar analytes (such as morphine), and conjugated metabolites must be 
hydrolyzed prior to extraction to facilitate their detection.   
LC-MS is compatible with polar compounds, including conjugated species. Sample 
preparation is sometimes less extensive compared to GC-MS, but this approach can 
compromise sensitivity and matrix effects.  High resolution mass spectrometry (HRMS) 
can be used to provide more detailed information in terms of structural elucidation.  This 
is a significant advantage for novel drugs, for which reference materials or analytical 
standards may not be commercially available.  One disadvantage of LC-MS based 
techniques include the potential for significant ionization suppression or enhancement. 
This can negatively impact analyte detection, particularly at low concentrations.  
Additionally, the fragmentation of molecules is not as reproducible as GC-MS, but careful 
control of ionization parameters allows for comparison of sample spectra with library 





The goal of sample preparation is to isolate an analyte (drug) from the biological 
matrix with high recovery and minimal interferences from endogenous compounds.  
Regardless of the extraction technique being used, the sample should be homogeneous to 
ensure an equal distribution of the drug throughout the specimen.  When necessary, this 
can be readily achieved for blood, urine and other body fluids using simple vortex mixing 
or sonication.  However, solid samples including tissues typically require mechanical 
homogenization.  Biological matrices rich in protein, such as blood and tissue, may require 
an additional step to precipitate the proteins and remove them from the matrix prior to 
extraction.  This can be achieved through the use of organic solvents such as acetonitrile, 
acidic solutions such as trichloroacetic acid, or inorganic materials.  After the proteins have 
been precipitated, the sample can be centrifuged or filtered to remove them from solution.  
Protein precipitation can be problematic with highly protein bound drugs as they may co-
precipitate with the proteins (93, 94).  In those instances, sample dilution, sonication, 
centrifugation or filtering may be preferable.  
Opioids tend to undergo extensive phase II metabolism, much like cannabinoids 
and benzodiazepines. As such they are present in biological samples in both free and bound 
(conjugated) form.  Often the ratio of free to bound drug in blood or tissue is calculated to 
provide insight regarding acute or chronic administration of the drug.  The highly polar 
nature of conjugated metabolites increases the difficulty associated with their extraction 
from biological specimens and may also render them incompatible with gas 
chromatography-mass spectrometry (GC-MS).  The hydrolysis of conjugated metabolites 
to yield free drug can make them more amenable to analysis, and as such samples are 
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typically analyzed twice, once to determine the amount of free drug present and again 
following hydrolysis to measure the total drug present.  These two measurements are then 
used to calculate the proportions of bound and free drug.  The two categories of hydrolysis 
reactions commonly used are chemical, using either strong acid or strong base, and 
enzymatic, using preparations of β-glucuronidase or sulfatase.   
Chemical hydrolysis, which is commonly performed using acid at elevated 
temperatures, is less costly and requires less time than enzymatic options but has been 
shown to cause degradation in opioids (95-97), which can complicate interpretation of the 
results.  As such, despite studies showing acid hydrolysis to be more efficient for 
hydrolyzing conjugated morphine metabolites, the more time-consuming enzymatic 
methods are often preferred to reduce loss of analyte and misinterpretation of the results.  
Enzymatic hydrolysis does not cause such degradation but some opioids, like morphine, 
are more resistant to enzymatic hydrolysis, resulting in extended incubation times to ensure 
complete hydrolysis (98-100).  β-glucuronidase has been isolated from multiple species 
and each isoform varies in activity for different drugs (97, 101), necessitating the individual 
optimization of hydrolysis reactions for each. 
Commonly used preparations of β-glucuronidase include Escherichia coli, Helix 
pomatia and Patella vulgata among others.  When optimizing hydrolysis, enzyme 
concentration, temperature and pH are evaluated to determine which conditions will 
provide complete reproducible results in the least amount of time.  It has been shown that 
the increasing the concentration of β-glucuronidase will not uniformly increase the extent 
of hydrolysis for all species (102).  Increasing the temperature of the reaction may reduce 
reaction time, however each species has different limitations. In particular, E. coli, whose 
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optimal reaction temperature is 37°C, can tolerate temperatures up to 50°C without an 
appreciable decrease in efficiency while other species will be more efficient at 60°C (101).  
Manufacturers will recommend an optimal pH or pH range based on test substrates, and 
while in most cases that pH will be efficient for drug hydrolysis, a greater shift in pH may 
occasionally be necessary, as is the case for hydrolysis of morphine-glucuronides by P. 
vulgata (102).  While assessing hydrolysis conditions, the stability of a glucuronide must 
also be considered as some glucuronides, particularly acyl- and N-glucuronides can be 
labile in neutral and alkaline solutions and may require hydrolysis with a β-glucuronidase 
that can tolerate more acidic conditions (103).  The affinity for individual glucuronides 
may also vary between species.  Comparison studies have shown P. vulgata to be more 
efficient for hydrolyzing morphine-glucuronides than E. coli and H. pomatia (98, 102), 
while the opposite is true for buprenorphine-glucuronides (97, 104).   
Recently, recombinant β-glucuronidase preparations have become commercially 
available, which are genetically modified to increase both their activity and their affinity 
for analytes like the opioids.  Two recent studies have been published evaluating one 
recombinant option, IMCSzyme™, with opioids.  The first study compared hydrolysis with 
IMCSzyme™ with acid hydrolysis, showing that no degradation occurred when using the 
recombinant enzyme (95).  The second study compared the recombinant enzyme with 
traditional preparations and found it to be either more efficient or comparable to the well-
established enzymes for most of the substrates tested (105).  Recombinant enzymes are 
purified preparations that do not contain additional endogenous proteins and compounds 
encountered in traditional β-glucronidase preparations. This may reduce the amount of 
42 
 
sample cleanup needed to remove impurities from the sample and reduce detector fouling 
and routine instrument maintenance. 
Liquid-liquid extraction (LLE) is a commonly employed extraction technique for 
toxicological specimens.  In brief, the aqueous sample matrix, after adjustment of the pH 
with buffer, is mixed with an immiscible organic solvent.  After the drug partitions into the 
solvent it can be concentrated before analysis.  Solvent polarity and hydrogen bonding are 
important considerations for LLE as most drugs that will be encountered have some degree 
of polarity.  For example, a strongly polar drug will require a solvent with a high degree of 
polarity for extraction and a drug that is capable of accepting hydrogen bonds but not 
donating them will be more efficiently extracted with a solvent that can donate hydrogen 
bonds.  The pKa of the drug is also an important point of consideration.  Most drugs will 
more readily partition into the organic solvent when they are uncharged.  While specific 
pH requirements can be calculated with the Henderson-Hasselbalch equation, acidic drugs 
are predominantly uncharged below their pKa, while basic drugs are uncharged above their 
pKa.  Opioids require special consideration in this regard as many of them form 
zwitterions, therefore the pH of the sample is typically adjusted to their isoelectric point 
prior to LLE.  For drugs with multiple pKa values that are similar in magnitude, relatively 
small variations in the sample pH may dramatically shift the ionization status of the drug. 
This may impact reproducibility of the assay and overall robustness.  
One of the major disadvantages of LLE is the large quantity of solvent required for 
extraction.  If the initial partition into the organic solvent has a poor yield, successive 
extractions or large solvent to sample ratios (e.g. 5:1 or more) may be needed to achieve 
sufficient analyte recovery (106).   After the initial extraction, back-extraction techniques 
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are often required to remove additional impurities.  This is readily achieved for basic 
compounds via the addition of an acidified buffer or reagent.  For analysis with instruments 
incompatible with aqueous samples, a subsequent extraction with organic solvent is 
required.  LLE is a relatively simple extraction with minimal steps, but while each 
additional step further purifies the sample, there is also a corresponding loss of drug, 
lowering the overall extraction efficiency.  In addition to significant solvent volumes and 
the challenge of extracting zwitterions, the formation of an emulsion during the mixing of 
aqueous and organic phases is another potential complication. 
Solid phase extraction (SPE) is an extraction technique that avoids some of the 
pitfalls of LLE.  Silica or polymer-based sorbent in an SPE cartridge can facilitate the 
selective binding of drugs in an aqueous matrix, while allowing impurities to pass through 
unhindered.  After washing with appropriate aqueous and organic solvents, the drug can be 
eluted with a minimal amount of solvent, resulting in a highly concentrated extract and 
creating minimal solvent waste.  Functional groups bound to the stationary phase determine 
the chemical properties of the sorbent material and may consist of hydrocarbon chains, 
phenyl groups, polar groups, cation and anion exchange groups.  Copolymeric sorbent 
phases, which contain multiple types of functional groups with different chemical 
properties, can be used to extract a wide range of drugs.  Amphoteric bases, like the opioids, 
can be efficiently extracted using copolymeric or mixed-mode SPE.  Using this approach, 
opioids can be readily extracted using SPE by adjusting the pH of the sample to ionize the 
basic nitrogen, introducing the sample to the SPE column, washing the column with 
aqueous, acidic and polar solvents to removed contaminants, drying the column and eluting 
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drugs with an alkaline organic solvent.  While SPE requires more steps than LLE, it is 
typically faster, produces less solvent waste, and can be automated if necessary. 
A final step that may be necessary is derivatization, particularly for analysis using 
GC-MS.  Polar functional groups can result in poor chromatographic properties.  Hydroxyl, 
carboxylic acid and amine functional groups are often derivatized, which reduces both their 
polarity and volatility, leading to improved chromatographic separation, peak shape and 
quantitative assay performance (107).  As many opioids contain tertiary amines and 
hydroxyl groups, they can be readily derivatized using silylation and acylation. Silylation 
is often used to replace an active proton with an alkylsilyl group. A large number of 
silylating reagents are available for this purpose, including N,O-
bis(trimethylsilyl)trifluoroacetamide and N-methyltrimethylsilyltrifluoroacetamide.  
Acylation usually involves the addition of a haloalkylacyl due to the associated increase in 
electron affinity. Although acylation is commonly used for drugs containing alcohols, 
amines, thiols and phenols, it is not effective for carboxylic acids (108).  Examples of 
acetylation reagents include N-methyl-bis(trifluoroacetamide) and trifluoroacetic 
anhydride.  Separation using LC instead of GC typically eliminates the need for 
derivatization because it is compatible with both aqueous samples and highly polar 
analytes. 
Confirmatory analysis 
Confirmatory testing is a vital step in forensic toxicology testing.  Qualitative 
testing is used to specifically identify the drug(s) present, while quantitative testing is used 
to identify the quantity of the substance in the matrix.  Instrumentation used for 
confirmatory testing requires a high degree of selectivity to provide sufficient confidence 
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in the results.  Mass spectrometric (MS) techniques satisfy this requirement but cannot 
typically analyze multiple analytes simultaneously, necessitating some form of separation 
technique be applied. 
Partition chromatography, invented by Martin and Synge in 1941 (109), is widely 
used in forensic toxicology laboratories for analytical separation.  A sample is introduced 
to a chromatographic column and as it travels the length of the column, each component of 
the sample (drug or otherwise) will partition between a stationary phase and mobile phase.  
A component’s affinity for the stationary phase will affect its rate of migration through the 
column and differences in migration rate result in separation.   
The degree of separation is dependent on the chemical properties of the stationary 
phase.  The main forms of interactions in partition chromatography are hydrogen bonding, 
dipole-dipole interactions and dispersion.  A nonpolar stationary phase is limited to 
dispersion interactions with analytes, but a polar stationary phase is capable of hydrogen 
bonding and dipole-dipole interactions with polar analytes.   
Chromatography columns may be either open tubular (capillary), with the 
stationary phase coating the wall of a capillary, or packed, with the stationary phase coating 
the packing material (typically silica particles).  Capillary columns are commonly used 
with GC which uses an inert gas as the mobile phase.  As such, samples analyzed using 
GC must be suitably volatile (boiling points typically <400°C). The order in which analytes 
elute from the column is affected by their boiling points. To vaporize samples, the inlet is 
maintained at an elevated temperature.  Columns are housed in a thermostatically-
controlled oven and the temperature can be increased over time to reduce the analysis time 
required for high boiling point compounds.  Column efficiency is measured by the height 
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equivalent of a theoretical plate (HETP) and is in part a function of the choice of carrier 
gas for the mobile phase.  It is desirable to produce the smallest HETP possible, while 
maintaining acceptable analysis time and reproducibility. 
Hydrogen, helium and nitrogen are common choices for carrier gases as they are 
inert and will not react with the analyte.  Nitrogen produces the highest efficiency in 
separations but small variations in flow rate can cause significant differences which may 
affect the chromatography.  Hydrogen can provide the shortest analysis time and is less 
susceptible to differences from variations in flow rate, but its use at high temperatures is 
not favorable from a safety standpoint.  Helium falls has intermediate properties, with a 
greater efficiency than hydrogen and a shorter analysis time than nitrogen.  GC is most 
suitable for nonpolar analytes <1000 Da in mass and commonly utilizes a nonpolar column.  
Polar compounds such as desomorphine and other opioids may require derivatization prior 
to analysis to improve chromatographic behavior. 
Packed chromatography columns are used with LC, which uses a liquid mobile 
phase.  It is amenable to nonpolar, polar and high molecular weight compounds.  Stationary 
phases can be polar (normal phase) or nonpolar (reverse phase).  Nonpolar mobile phases 
are used with normal phase LC (NPLC) and polar mobile phases are used with reverse 
phase LC (RPLC).  Analyte elution order will change depending the polarity of the 
stationary phase.  With NPLC, nonpolar analytes will elute from the column first and with 
RPLC, polar analytes will elute first.  As most drugs have some degree of polarity, RPLC 
is commonly used in forensic toxicology.  In addition to polarity, elution order is also 
affected by analyte mass as the column packing material is generally composed of porous 
or superficially porous silica particles.  Smaller analytes will migrate into small pores on 
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the particles while larger molecules will not, therefore drugs with larger mass will elute 
before smaller ones of similar polarity. The mobile phase consists one or more solvents, 
which may be aqueous or organic in nature, or a combination thereof.  Isocratic elution is 
achieved by using the same composition of mobile phase throughout the separation.  
However, varying the ratio of aqueous and organic mobile phase solvents (gradient elution) 
adjusts the polarity of the mobile over time and can decrease the retention time of analytes 
that interact strongly with the stationary phase.  While pure solvents can be used as mobile 
phase components, it is generally advisable to control the pH of the mobile phase during 
RPLC separation to achieve uniform movement and charge state of the analyte. 
For forensic purposes, GCs and LCs are commonly coupled directly to an MS.  
Regardless of which separation technique is used, the ionized compounds must be in the 
gas phase to be detected by the MS.  As such, MS instruments typically operate under high 
vacuum to facilitate the vaporization of high molecular weight compounds.  There are 
multiple mass analyzers available, but the most common configurations encountered in 
forensic toxicology include quadrupole, ion trap and time-of-flight (TOF) mass analyzers. 
Most mass analyzers are compatible with multiple ionization techniques, however 
not all ionization techniques are compatible with all separation techniques.  The best 
example of this is electron impact (EI) ionization, which is widely used with GC-MS but 
is not capable of ionizing molecules in the liquid phase and is not used with LC-MS.  
During EI ionization molecules pass through a stream of electrons generated from a 
tungsten filament.  The electrons have higher energy than the chemical bonds within the 
molecule, so as the molecule passes through the stream they not only ionize but fragment 
as well.   The characteristic pattern associated with the fragmentation process are detected, 
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producing a mass spectrum that can be compared to reference libraries  EI ionization is 
considered a “hard” ionization technique due to the high energy of the electrons and the 
significant fragmentation that ensues.  In combination with GC, chemical ionization (CI) 
is a “softer” ionization technique, whereby high energy electrons are replaced with 
energized or charged gas molecules, such as methane or ammonia.  Softer ionization 
techniques are also compatible with LC interfaces. These include electrospray ionization 
(ESI) and atmospheric pressure chemical ionization (APCI).  Although these softer 
ionization techniques do not produce as many fragments as EI ionization, they can be used 
in tandem MS configurations to facilitate subsequent fragmentations of both precursor and 
product ions. 
ESI ionizes analytes in the liquid phase, making it compatible with LC. Generally, 
ESI functions in either positive or negative ion mode, although some configurations can 
switch between the two during data acquisition, referred to as fast polarity switching.  With 
positive mode ESI the column effluent is sprayed into the source through a nebulizer needle 
that is held at a high electric potential. This draws negative ions away, both isolating 
positive ions and repealing them out, breaking the surface tension and forming aerosol 
droplets.  This process is often assisted by a flow of heated nitrogen.  Once droplets are 
formed the internal coulombic repulsion caused by the excess charge causes the droplets 
to continue to separate which increases their charge.  As this process continues, coulombic 
fission occurs, leaving only ions which pass into the mass analyzer.   
APCI is a versatile ionization technique compatible with GC and LC as it is capable 
of ionizing analytes in both gas and liquid phases.  The nebulizer needle used with APCI 
is a short tube maintained at a high temperature to vaporize the aerosol components as they 
49 
 
leave the needle.  A corona discharge electrode near the end of the vaporization tube 
produces a cloud of electrons which initiates a cascade of reactions producing ions.  APCI 
is a chemical ionization technique as the sample components are not directly ionized by 
the electron cloud, but by a series of reactions with reagent ions.  APCI is particularly 
efficient at ionizing neutral compounds, such as steroids, that are not efficiently ionized 
with ESI, while ESI is often preferred for more polar compounds (110).  However, because 
APCI uses high temperatures to vaporize eluent, it can thermally degrade labile analytes.   
Both ESI and APCI are subject to matrix effects, which arise from reactions 
between an analyte and additional compounds that are present in the biological sample. 
These substances can either suppress or enhance ionization of the analyte. Although ion 
suppression is more prevalent, these matrix effects can greatly influence precision, bias 
and sensitivity of the assay. They are highly dependent on the matrix, analyte and sample 
preparation technique.  Sources of ion suppression include both endogenous compounds, 
including ionic species, polar compounds, and organic molecules (carbohydrates, amines, 
urea, lipids, etc), and exogenous compound that may be introduced during sample 
preparation or analysis (polymer residues, phthalates, detergents, buffers, stationary phase 
particles, etc).   
Mechanisms that have been proposed to explain ion suppression include: 
competition between the analyte and co-eluting compounds for available charge, matrix 
compounds binding to the analyte and causing co-precipitation, and analyte ions being 
neutralized through acid/base reactions in the gas phase (111).  Choice of ionization 
technique can also have an effect, with ESI being more susceptible to matrix effects than 
APCI (112).  Several strategies exist for reducing matrix effects.  As only co-eluting 
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compounds can affect analyte ionization, the method can be optimized to achieve baseline 
separation between the analyte and all other sample components.  Simplified sample 
preparations that do not separate analytes from sample components carry an increased risk 
of ion suppression.  Extraction techniques like LLE and SPE remove more endogenous 
compounds but usually involve a pre-concentration step which may exaggerate ion 
suppression, in which case reducing the sample volume may be beneficial.  Matrix matched 
calibrators and the use of internal standards (IS) mitigate the effect of ion suppression on 
quantitation.  An isotopically labelled internal standard that coelutes with the analyte is 
ideally suited for this purpose because any decrease in ionization efficiency will influence 
the IS proportionally. 
Quadrupole mass analyzers are frequently utilized with GC-MS and gain their name 
from four linear electrode rods arranged into two pairs, forming a diamond-like shape.  
Each pair generates an electrostatic field, one direct current and the other radiofrequency, 
which bisect each other perpendicularly.  Manipulation of these fields create a resonate 
frequency for individual mass-to-charge ratios, allowing ions with specific m/z to fully pass 
through the quadrupole to the detector.  Quadrupole analyzers are capable of varying the 
resonate frequency emitted to either scan the full mass range (scan mode) or allow only 
specific ions to pass through (selective ion monitoring, SIM).   
Ion trap mass analyzers are variations of quadrupole analyzers whereupon the 
electrodes have been reconfigured to form a cylindrical shape with the electrodes at either 
end creating a direct current field and the electrode ring in between them creating a 
radiofrequency field.  After ions enter the trap their energy is quenched using helium and 
they can then be selectively ejected from the trap by varying the potentials of the end 
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electrodes.  Alternatively, the ions can be held within the trap and excited by varying the 
radiofrequency field, creating further fragmentation.  As ion traps are compatible with 
multiple ionization techniques, they can provide a low-cost alternative to expensive tandem 
MS instrumentation. 
Unlike quadrupole and ion trap analyzers, TOF mass analyzers are not capable of 
selecting specific masses.  Instead, ions are pulsed from the source and accelerated through 
an electric field where they then pass through a flight tube to the detector (either a time-to-
digital converter or an analog-to-digital converter).   The detector is off-set from the ion 
source and a reflectron is used to focus the kinetic energies of the ions and repel them 
towards the detector once they reach the end of the flight tube.  The principle of TOF mass 
analyzers is that larger ions take more time to reach the detector than smaller ones.  Modern 
TOF instruments have high resolution, making them capable of accurate mass 
measurements which provide greater specificity than can be achieved with other mass 
analyzers. 
Mass analyzers can be combined to create tandem MS (MS/MS), of which one of 
the most common configurations consists of three coupled quadrupoles.  This is a powerful 
and sensitive analytical technique.  Targeted acquisition can be achieved by either single 
reaction monitoring or multiple reaction monitoring, where specific precursor ions are 
selected for fragmentation in the second quadrupole (referred to as collision induced 
dissociation) and the third quadrupole operates in SIM mode monitoring specific product 
ions.  Additional acquisition modes include product ion scans, where entire product spectra 
of selected precursors are recorded, precursor ion scans, where precursors ions of various 
masses are fragmented but only selected product fragments recorded, and neutral loss 
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scans, where precursor ions of various masses are fragments and all fragmentations leading 
to the loss of a specific neutral fragment are recorded.  Coupled quadrupole/time-of-flight 
mass analyzers (Q/TOF-MS) take advantage of both the scanning capability of the 
quadrupole and the accurate mass capability of the TOF to create a highly specific 
instrument which can be particularly valuable for structural elucidation.  Instruments can 
function in either full scan mode or in targeted mode, where specific precursors are selected 
for fragmentation and the entire spectrum is recorded. 
Most types of mass analyzers detect charged species via an electron multiplier or 
photomultiplier and record the mass to charge ratio (m/z) of detected ions.  No matter how 
efficient the ionization technique used, only a proportion of the total number of molecules 
that enter the MS are ionized and detected.  Electron multipliers and photomultipliers 
amplify that signal to generate quantifiable data.  For most drugs, only a single charge is 
produced during ionization such that the recorded m/z is analogous with the mass of the 
molecule, however complex molecules such as proteins can produce multiple charges 
during ionization.  Despite the relatively low efficiency of ionization the proportion of 
molecule ionized to the whole remains sufficiently constant to allow for quantification 
based on the responses of known quantities of a drug.  As the intensity of the signal 
produced is a function of the quantity of molecules present in the detector at any one time, 
it is vitally important for the calibrators used for quantitation to be analyzed under the same 
conditions as the unknown sample to ensure accurate and consistent results.  
Analytical methodology for desomorphine 
Desomorphine was reported to be detectable using one enzyme-linked 
immunosorbent assay, with a cross-reactivity of approximately 50% (113).  However, there 
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has not been a thorough study of its cross-reactivity across multiple commercial ELISA 
platforms.  Every commercially available ELISA has its own proprietary formulation and 
antibody reagent. As a result, the cross-reactivity of antibody reagents towards 
desomorphine could be highly variable, which could impact drug detection.    
Richter applied metabolite-based screening approaches utilizing GC-MS and LC-
HRMS, using an Orbitrap™ detector. Desomorphine and its metabolites were identified in 
urine using codeine-D6 as the IS (65).  For GC-MS, samples were hydrolyzed using acid 
hydrolysis, extracted with LLE and derivatized via acetylation before analysis. Using this 
approach, desomorphine and nordesomorphine were successfully identified. 
Desomorphine, nordesomorphine and desomorphine-glucuronide were successfully 
identified using LC-HRMS following protein precipitation and LLE.  While originally 
described as screening approaches these methods could be adapted for confirmatory 
analysis. 
There are very few published methods that describe the confirmatory analysis of 
desomorphine in biological matrices or even seized drug samples, and most are not 
validated for quantitative use.  Savchuk was the first to describe analytical methodology to 
detect desomorphine using both GC-MS and LC coupled with an ultraviolet detector (LC-
UV) to analyze urine and seized drug samples (5).  Acid hydrolysis was used to hydrolyze 
conjugated metabolites and samples were extracted utilizing LLE.  For GC-MS analysis 
both silylation and acetylation were successfully applied.  While concentrations were 
reported, they were determined by comparison of absolute rather than relative peak area.  
The absence of an internal standard in this published study is problematic and it would not 
be considered appropriate for quantitative use in forensic toxicology.  
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Su was the first to describe a quantitative method, utilizing GC-MS to identify 
desomorphine in urine.  However, the limit of quantitation was 250 ng/g which is not 
sufficiently sensitive for forensic purposes (114).  Samples were extracted utilizing solid 
phase dynamic extraction and solid phase microextraction without derivatization.  Su was 
the first to describe the use of desomorphine-D3 as an IS however.  
Alves  used LC with diode array detection (LC-DAD) and GC-MS to analyze seized 
drugs with a limit of quantitation of 490 ng/mL (51) and later used GC-MS to analyze 
desomorphine in blood samples with a limit of quantitation of 103 ng/mL (115). 
Phenacetin, which bears no structural resemblance to desomorphine, was used as the IS.  
Drug samples were extracted using LLE, and silylated derivatives were analyzed using 
GC-MS.  Blood samples were extracted using a QuEChERS (Quick, Easy, Cheap, 
Effective, Rugged and Safe) method before derivatization.  This was the first method to 
describe the analysis of desomorphine in whole blood, however, given the lack of 
pharmacokinetic data for desomorphine, the reported LOQ of 103 ng/mL may not be 
sufficiently sensitive for forensic use. 
Soares described a qualitative assay for Krokodil drug samples using both LC-DAD 
and LC-HRMS (Orbitrap™) (52).  LLE was used to extract desomorphine but no IS was 
reported.  The purpose of the study was to characterize Krokodil samples and in addition 
to desomorphine, a total of fifty-four morphinans were identified. 
Using LC-MS/MS Eckart described a quantitative assay to identify desomorphine 
in serum, plasma and tissue (116).  Samples were extracted utilizing SPE and codeine-D6 
was used as the IS.  The reported limit of quantitation was 0.1 ng/mL, which provides 
sufficient sensitivity for forensic use.  Urine, which is one of the most common biological 
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matrices encountered, was not evaluated in the study.  The method was then applied to over 
two hundred authentic specimens, spanning clinical and forensic cases, though 
desomorphine was not identified in any of them.  A summary of published analytical 












Separation  Detector 
Sample 
Volume 




LLE GC  MS 3 mL  
acylation; 
silylation 













LLE GC  MS 100 µL  Silylation phenacetin Rtx-5 490 ng/mL (51) 
blood QuEChERS GC  MS 300 µL  Silylation phenacetin Rtx-5 103 ng/mL (115) 








SPE LC  MS/MS 
200 µL;  
2 g  
 N/A codeine-D6 phenyl-hexyl 0.1 ng/mL (116) 
drug 
samples 







urine LLE LC  Orbitrap™ 2 mL  N/A codeine-D6 phenyl-hexyl NR (65) 
drug 
samples 
none LC  
DAD; 
Orbitrap™ 
10 µL  N/A NR C18 NR (52) 
DAD, diode array detector; GC, gas chromatography; LC, liquid chromatrography; MS, mass spectrometry; N/A, not applicable; NR, not reported; 
QuEChERS, Quick, Easy, Cheap, Effective, Rugged and Safe; UV, ultraviolet detector
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In addition to the described GC and LC methods, two recent reports described the 
qualitative analysis of desomorphine at trace levels utilizing a portable MS and direct 
sample analysis TOF-MS.  The portable MS technique was developed for use in 
clandestine laboratory investigations (117).  Items that may be encountered in clandestine 
laboratories (glassware, enameled cookware, Teflon-coated cookware, prescription 
bottles, etc) were swabbed and the swabs were directly introduced into the MS inlet.  In 
the second method, samples were deposited directly on a mesh target screen for analysis 
(118).  Sixty-four authentic seized drug casework samples were analyzed using this 
method but desomorphine was not detected in any.  The method was also applied to urine 
samples however the complexity of the matrix produced inconsistent results. 
Statement of the problem 
Few case reports of Krokodil use have been published in scientific literature and to 
date only one case has been analytically confirmed.  The lack of analytically confirmed 
cases makes estimating the true prevalence of Krokodil use difficult.  Despite published 
clinical case reports, media reports and surveys of self-reported use, desomorphine abuse 
is not well understood.   
While one study investigated its metabolism, the enzymes responsible for its 
biotransformation have not yet been investigated.  Pharmacokinetic studies in humans are 
lacking and the only report of its window of detection was unsubstantiated by actual data.  
Despite this, it is reasonable to expect forensic analytical methods to have comparable 
sensitivity to that of morphine (i.e. low ng/mL). Existing analytical methodology may not 
be sufficiently sensitive for forensic use, particularly in light of reported delays between 
Krokodil use and specimen collection.  Existing GC-MS methodologies do not have the 
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sensitivity that is required for forensic use and the only quantitative LC-MS/MS method 
was not developed for use with urine, which is one of the most common sample matrices 
in forensic toxicology.   
To facilitate identification in forensic toxicology investigations, a comprehensive 
study of desomorphine metabolism and analysis is required.  Recombinant CYPs and 
UGTs were used to more thoroughly investigate the biotransformation pathways 
responsible for desomorphine’s metabolism.  Commercially available ELISAs were 
evaluated for cross-reactivity with desomorphine, and hydrolysis of the glucuronidated 
metabolite investigated.  As instrumentation is variable between laboratories, analytical 
methodologies to identify and quantitate desomorphine in biological matrices were 
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Desomorphine (Krokodil) is a semi-synthetic opioid that has drawn attention as a 
recreational drug, particularly in Russia, neighboring former Soviet Republics, Eastern and 
Central Europe.  It has no accepted medicinal uses and is currently a schedule I drug in the 
United States.  In clandestine environments, desomorphine is synthesized from codeine 
using red phosphorous, hydroiodic acid and gasoline.  Residual starting materials in illicit 
preparations have been associated with severe dermatological effects and extensive tissue 
necrosis.  Desomorphine is not well studied, and there are limited reports concerning its 
pharmacology or detection in biological matrices. Immunoassays are widely relied upon 
for both antemortem and postmortem toxicology screening. Although desomorphine is an 
opioid of the phenanthrene-type, its ability to bind to conventional opioid antibodies has 
not been described. In this report we describe the cross-reactivity of desomorphine using 
six commercially available enzyme-linked immunosorbent assays (Immunalysis Opiates 
Direct ELISA, Immunalysis Oxycodone/Oxymorphone Direct ELISA, Randox Opiate 
ELISA, OraSure Technologies OTI Opiate Micro-plate EIA, Neogen Opiate Group ELISA 
and Neogen Oxycodone/Oxymorphone ELISA). Cross-reactivites were highly variable 
between assays, ranging from 77% to <2.5%. In general, assays directed towards morphine 
produced greater cross-reactivity with desomorphine than those directed towards 
oxycodone. The Immunalysis Opiates Direct ELISA produced the greatest cross-reactivity, 
although several of the assays evaluated produced cross-reactivity of a sufficient magnitude 
to be effective for desomorphine screening. 




Desomorphine Screening Using Commercial Enzyme-Linked Immunosorbent 
Assays 
Introduction 
Desomorphine (dihydrodesoxymorphine) is a synthetic opioid that was briefly 
commercialized by Roche in the 1940s under the tradename Permonid. Structurally it 
differs from morphine in the absence of a hydroxyl group on C6 and the reduction of the 
C7-C8 double bond.  The chemical structures of desomorphine, morphine and related 
opioids are shown in Figure 2.1.  Desomorphine was first synthesized in the early 1900s 
as an alternative to morphine (3).  Like other narcotic analgesics, it binds to the µ-opioid 
receptor and has been shown to have ten-times the analgesic potency of morphine (3, 4). 
Users experience euphoria and sedation as well as enhanced respiratory depression.  Its 
shorter duration of action, no more than two hours, and greater toxicity compared to 
morphine caused it to be abandoned therapeutically (1).  In the early 2000s it reappeared 
as an inexpensive alternative to heroin, most notably in parts of Eastern Europe and the 
Soviet Republic, where the cost of heroin is particularly high (2). The first published case 
study in the US was in the Midwest in 2014 (5) and although not widespread, an additional 




Figure 2.1. Structure of desomorphine and other structurally related opioids.  
 
 
Desomorphine is readily synthesized via the reduction of codeine using hydroiodic acid 
and red phosphorus, which are commonly used during clandestine methamphetamine 
production. Household items, such as Drano® and gasoline, are often used for 
alkalinization and primitive solvent extraction. Following illicit manufacture, residual 
starting materials and impurities may remain posing significant harm (2, 7).  The final 
product is typically a light brown liquid that is commonly administered via intravenous or 
subcutaneous injection.  The reported adverse effects of desomorphine abuse include skin, 
tissue and vein lesions that may culminate in infection, gangrene or limb amputation (8). 
The tendency of the skin to appear rough and scaly around the site of injection is 
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responsible for desomorphine’s street name of Krokodil (crocodile in Russian). In the 
United States the drug attracted sensational media attention in 2013 as a “flesh-eating drug” 
due to the severe dermatological sequale associated with its use. Nevertheless, domestic 
case reports have been somewhat limited, largely attributed to the widespread availability 
of other opioids, which hold much greater appeal to the US drug-abusing population. 
In the United States desomorphine is a schedule I drug under the federal Controlled 
Substance Act (1).  Codeine, the starting material for desomorphine, is controlled more 
strictly in the United States compared with many other parts of the world, where it is often 
available over-the-counter.  Although there have been numerous reports of desomorphine 
use world-wide, there have been limited published reports involving analytical 
confirmation (9-12). In the absence of confirmed toxicological results, physicians rely 
heavily on patient history and admissions of Krokodil use (13). The absence of analytically 
confirmed cases is undoubtedly hampered by the scope of toxicological testing that is 
commonly employed. As a result, the true prevalence of desomorphine use in the United 
States is relatively unknown. 
Immunoassay techniques are widely used for toxicological screening. However, the 
degree to which desomorphine cross-reacts with commercial opiate-based assays has not 
been systematically evaluated. Gas chromatography-mass spectrometry (GC-MS) and 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques are widely 
used to identify opiates in biological evidence. However, these confirmatory procedures 
typically target specific opioids, such as morphine, codeine, 6-monoacetylmorphine or 
keto-opioids (notably hydrocodone, hydromorphone, oxycodone and oxymorphone). As 
such, this targeted approach to identification (typically using selected ion monitoring or 
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multiple reaction monitoring) is unlikely to identify desomorphine. Although mass 
spectrometric screening techniques are readily adapted to emerging drugs of interest, 
immunoassays are commonly used. For this reason, cross-reactivity of desomorphine using 
commercial opiate assays could be highly beneficial and increase the likelihood of 
detection.  
Enzyme-linked immunosorbent assays (ELISAs) are among the most widely used 
screening techniques in forensic toxicology laboratories.  These heterogeneous 
immunoassays are amenable to blood, urine and tissue samples that are encountered in 
antemortem and postmortem toxicology investigations. Some assays are designed to be 
highly specific towards the target analyte, having little or no cross-reactivity towards other 
compounds in order to limit false positives. Conversely, there is often a need to develop 
assays with broad cross-reactivity in order to capture multiple drugs or metabolites within 
a specific class of drugs (e.g. benzodiazepines, barbiturates). The cross-reactivity of 
polyclonal antibodies that are used in commercial immunoassays is largely dependent on 
immunogen design and the site at which coupling of the hapten (drug) to the carrier protein 
takes place. Not surprisingly, crosslinkers that are commonly used to “bridge” the drug to 
the carrier protein make use of common functional groups such as amines, hydroxyls and 
others, to facilitate the coupling chemistry. The nature of the carrier protein and the length 
of the crosslinker also play an important role. The site at which coupling takes place on the 
drug molecule may be effectively hidden from view, resulting in antibodies that lack 
specificity for that site or region of the molecule (14). As such, bioconjugation techniques 
can play an important role in cross-reactivity, and ultimately assay utility and performance.  
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Structurally the opioids can be broadly classified a phenanthrenes (e.g. morphine, 
codeine, dihydrocodeine, 6-monoacetylmorphine, hydrocodone, hydromorphone, 
oxycodone, oxymorphone), phenylheptylamines (e.g., methadone, propoxyphene), 
phenylpiperidines (e.g., fentanyl, meperidine), morphinans (e.g., levorphanol, 
butorphanol), benzomorphans (e.g., pentazocine) and cyclohexanols (e.g., tramadol). The 
phenanthrenes (including desomorphine) are characterized by the morphine-like aromatic 
core. Although morphine is an effective target drug for many of the phenathrene-type 
opioids, characteristics of the antibody reagents varies considerably and can often elicit 
poor cross-reactivity towards some of the keto-opioids. For this reason, manufacturers may 
offer immunoassays specifically directed towards these popular opioids (namely, 
oxycodone and/or oxymorphone).  
Despite the structural alterations at C6 and C7-8, desomorphine retains the 
morphine-like structure typical of the phenanthrenes, suggesting that it might lend itself to 
some degree of cross-reactivity with commercial opioid assays. In this study we evaluated 
a total of six commercial ELISAs directed towards morphine and 
oxycodone/oxymorphone. The latter were selected as possible candidates for 
desomorphine cross-reactivity because unlike morphine, these keto opioids are also 
saturated in the C7-C8 position (Figure 2.1). 
Materials and methods 
Morphine, desomorphine and oxycodone were obtained from Cerilliant (Round 
Rock, TX). Pooled human urine was collected from drug-free volunteers and preserved 
with 1% (w/v) sodium fluoride.  Deionized water was generated from a Direct-Q 3 (UV) 
system (Millipore, Billerica, MA).  Six immunoassay kits were obtained from four 
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commercial sources: Immunalysis Opiates Direct ELISA (catalog no. 207-0192) (IA-OPI) 
and Oxycodone/Oxymorphone Direct ELISA (catalog no. 221B-0096) (IA-OXY), 
(Pomona, CA); Randox Opiates ELISA (catalog no. OPI10014) (RX-OPI),(Kearneysville, 
WV); OraSure Technologies OTI Opiates Micro-plate EIA (catalog no.1150ET) (OS-OPI), 
(Bethlehem, PA); and Neogen Opiate Group ELISA (catalog no. 130419) (NG-OPI) and 
Oxycodone/Oxymorphone ELISA (catalog no. 130719) (NG-OXY) (Lexington, KY).  
Morphine and oxycodone were the target drugs in the opiate and oxycodone/oxymorphone 
assays, respectively.  
Desomorphine cross-reactivity was measured relative to the target drug in urine.  
Calibrators were prepared by fortifying drug-free urine with drugs over a range of 
concentrations. Each assay was performed in accordance with the manufacturer’s 
specifications, summarized in Table 2.1. Assays were performed manually using a 
multichannel pipette, a Biotek ELx50/8 Microplate Strip Washer (Winooski, TX) and a 








Summary of experimental conditions. 
 















Immunalysis Opiates Direct 
(IA-OPI) 
urine, whole blood, 
serum, plasma, oral 
fluid 




whole blood, serum, 
plasma 
1:10 10 µL 100 µL/60 min 100 µL/30 min 100 µL 
Neogen Opiate Group 
(NG-OPI) 
urine, whole blood, oral 
fluid 




urine, whole blood, oral 
fluid 
1:50 10 µL 100 µL/45 min 100 µL/30 min 100 µL 
Orasure OTI Opiates 
(OS-OPI) 
serum 1:10 25 µL 100 µL/30 min 100 µL/30 min 100 µL 
Randox Toxicology Opiates 
(RX-OPI) 
urine, whole blood 1:50 50 µL 75 µL/60 min 125 µL/20 min 100 µL 
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Briefly, drug-fortified urine at the appropriate dilution (in deionized water or 
supplied buffer) was added to microtiter wells, together with the appropriate volume of 
drug-enzyme conjugate. Manufacturer-recommended dilutions (provided in the assay 
specification sheet) were used unless none were specified. Following incubation for the 
specified time, excess (unbound) reagent and drug was removed using six washes with 
deionized water. The appropriate volume of tetramethylbenzidine substrate solution was 
added. Following incubation for the recommended time in the dark, the appropriate volume 
of acidic stop reagent was added, and the absorbance was measured (A 450nm – 630 nm).  
Dose-response curves were generated for each assay using replicate analyses (n=3) for both 
the target drug (morphine or oxycodone and desomorphine).  Percent binding was 
calculated using Equation 1 where A0 was absorbance of the blank (drug-free urine).  
Unlike federally regulated workplace drug testing programs, the majority of laboratories 
that perform forensic toxicology investigations establish their own cutoffs, depending on 
the type of work they perform. For the purpose of this study a morphine cutoff of 200 
ng/mL and an oxycodone cutoff of 100 ng/mL was selected to reflect recommended cutoffs 
for impaired driving casework (15). Although we recognize that cutoff concentrations 
throughout laboratories are not consistent, for the purposes of this study it was necessary 
to calculate cross-reactivities consistently between each assay. The cross-reactivity of 
desomorphine among the opiate assays was calculated using Equation 2 where C200 was 
the concentration of desomorphine required to give an absorbance reading equivalent to 
200 ng/mL of morphine in urine.  The cross-reactivity of desomorphine among the 
oxycodone/oxymorphone assays was calculated using Equation 3 where C100 was the 
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concentration of desomorphine required to produce an absorbance reading equivalent to 
100 ng/mL of oxycodone. 
                                                       
% Binding =  
A
A0
 X 100     Equation 1 
% Cross − Reactivity =  
200
C200
 X 100    Equation 2 
% Cross − Reactivity =  
200
C100
 X 100    Equation 3 
Results and discussion 
The cross-reactivity towards desomorphine and binding characteristics for each of 
the assays are summarized in Table 2.2 and dose-response curves are depicted in Figure 
2.1. Data represents the mean of triplicate measurements at each concentration in urine. 
Cross-reactivity towards desomorphine was widely variable between assays, ranging from 
77% (Figure 2.2) to <2.5% (Figure 2.4). Error bars are omitted from the composite figure 
for clarity. Generally, the opiate immunoassays (directed towards morphine) produced 
greater cross-reactivity than those directed towards oxycodone. Although desomorphine 
and the keto opioids are saturated at C7 and C8 (unlike morphine), structural alterations at 




Figure 2.2. Dose-response curves for each assay using target drug (morphine or 
oxycodone) and desomorphine using Immunalysis Opiates Direct (IA-OPI) and 
Oxycodone/Oxymorphone Direct (IA-OXY), Neogen Opiates (NG-OPI) and 
Oxycodone/Oxymorphone (NG-OXY), OraSure Technologies OTI Opiates (OS-OPI) and 




Figure 2.3. Immunalysis Opiates Direct (IA-OPI). Data are shown as the mean ± SD (n=3) 




Figure 2.4. Immunalysis Oxycodone/Oxymorphone (IA-OXY). Data are shown as the 










Cross-reactivity and binding characteristics of commercial ELISAs towards desomorphine. 


















IA-OPI morphine 200 260 77% 65 80 81% 
OS-OPI morphine 200 280 71% 340 700 49% 
NG-OPI morphine 200 390 51% 490 950 52% 
NG-OXY oxycodone 100 230 43% 190 1000 19% 
RX-OPI morphine 200 800 25% 40 65 62% 





Table 2.2 also summarizes antibody binding characteristics and the effective 
concentration for 50% binding (EC50) for both desomorphine and the target drug. 
Estimation of cross-reactivity at the EC50 is also possible but was not selected for two 
reasons. Doing so would effectively estimate the cross-reactivity for each assay at a 
different concentration; and second, the purpose was to determine the likelihood of 
identifying a desomorphine-positive sample among routine casework. For this reason, 
cross-reactivity was estimated at a uniform cutoff concentration for each assay.  
Nevertheless, the ratio of EC50 (Target Drug/Desomorphine) was generally well-
correlated with the measured cross-reactivity. Numerical differences between these two 
approaches are expected and are caused by non-parallelism or binding cooperativity, which 
is inherent to antibody-antigen interactions. 
The Immunalysis Opiate Direct assay produced the highest cross-reactivity towards 
desomorphine, with comparable binding to that of morphine (Figure 2.2). However, the 
Orasure Opiate (71%) and Neogen Opiate (51%) assays also proved effective for the 
purposes of desomorphine screening. Very little is understood concerning the metabolism 
of desomorphine and until recently there were no published pharmacokinetic studies. 
Preliminary data suggest that Cytochrome P450 (CYP) and uridine diphosphoglucuronosyl 
transferase (UGT)-mediated transformations take place, similar to other phenathrene-type 
opioids (16). Nevertheless, potential metabolites are not yet commercially available.  
Cross-reactivity is greatly influenced by immunogen design and ultimately 
coupling chemistry between the drug and the carrier protein. The coupling has a tendency 
to obscure the site of action from “view”, resulting in immunoglobulins with reduced 
specificity for that region. Although antibody specificity is highly desirable in many 
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instances to reduce false positives, immunoassay screening for broad classes of drugs (e.g. 
benzodiazepines, barbiturates and opiates) can exploit this feature. Immunoassays 
exhibiting high cross-reactivity towards desomorphine (Immunalysis Opiates Direct) likely 
use an antibody reagent raised against an antigen or immunogen in which morphine was 
coupled in the C6 position (hydroxyl). The morphine-targeted assay with the lowest cross-
reactivity towards desomorphine (Randox Toxicology Opiates) is more likely to have used 
an antigen or immunogen that obscured the C3 position (phenol) and/or nitrogen ring while 
leaving the C6 position free to interact with the antibody reagent.  A similar immunogen 
design was likely used with the oxycodone-targeted assay that exhibited the lowest cross-
reactivity overall, while the second oxycodone-targeted assay investigated more likely 
obscured the C3 hydroxy to some degree.   
A limitation of the study was the use of different conditions for each of the assays 
(Table 2.1). Specimen dilutions, reagent volumes and incubation times varied between the 
assays. Recommended conditions are designed to optimize assay performance in the 
concentration range of interest. Use of uniform dilutions, reagent volumes or incubation 
times in all assays could have compromised the performance of some of the assays. For 
this reason, manufacturers’ recommendations were followed. 
Conclusions 
Desomorphine (Krokodil) is a fast-acting and potent injectable opioid whose 
clandestine synthesis has drawn widespread attention due to extensive tissue necrosis. 
Despite reports of recreational use, analytically confirmed cases are rare. In the absence of 
commercially available metabolites or reference materials, identification of desomorphine 
in forensic toxicology casework relies upon the identification of the parent drug in 
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biological samples. Since targeted chromatographic-based assays may fail to identify 
desomorphine during routine confirmations, immunoassays can play an important role in 
terms of identifying its use. Although desomorphine cross-reactivity was highly variable, 
several existing commercial ELISAs produced sufficient cross-reactivity to be highly 
effective for this purpose. 
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Desomorphine is reported to be the principal pharmacologically active opioid in 
Krokodil, a homemade injectable drug that is perceived to be a cheaper alternative to 
heroin.  There have been limited studies regarding its pharmacology or detection in 
biological matrices.  The goal of this study was to contribute further knowledge regarding 
its metabolism.  Recombinant human cytochrome P450 enzymes (rCYPs) and recombinant 
uridine 5'-diphospho-glucuronosyltransferases (rUGTs) were used to investigate the 
biotransformational pathways involved. Samples were analyzed by liquid 
chromatography/quadrupole-time of flight-mass spectrometry (LC-Q/TOF-MS).  Seven 
rCYP (rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C18, rCYP2C19, rCYP2D6 and rCYP3A4) 
enzymes were found to contribute to desomorphine metabolism and eight phase I 
metabolites were identified, including nordesomorphine, desomorphine-N-oxide, 
norhydroxydesomorphine, and five hydroxylated species.  Inhibition assays were used to 
confirm individual rCYP isoenzyme activity.  Nine rUGTs (rUGT1A1, rUGT1A3, 
rUGT1A8, rUGT1A9, rUGT1A10, rUGT2B4, rUGT2B7, rUGT2B15, and rUGT2B17) 
were found to contribute to the formation of desomorphine-glucuronide. 





In Vitro Metabolism of Desomorphine 
Introduction 
Desomorphine (dihydrodesoxymorphine, (5α)-17-methyl-4,5-epoxymorphinan-3-
ol) is a synthetic opioid that is commonly derived from codeine.  Its phenanthrene-type 
core is characterized by one aromatic and two saturated rings, in addition to a six-
membered nitrogen-containing ring (morphinan).  It is structurally similar to morphine but 
is reportedly more potent, and has a shorter onset and duration of action (1, 2).  The absence 
of the 6-hydroxyl and saturation of the C7-8 bond differentiate the drug from morphine 
(Figure 3.1). Synthesis of illicit desomorphine is similar to the Nagai method for 
methamphetamine, involving red phosphorus and hydroiodic acid (1).  When produced 
illicitly, Krokodil contains desomorphine and a significant number of other morphinans 
(3).  Following intravenous use of the drug, severe dermatological effects have been 
reported, including abscesses, skin lesions, and necrosis (1, 4-6).  This has been attributed 
to residual acid, reducing agent or solvent that may remain in Krokodil following its 
clandestine synthesis.  
 




Krokodil emerged as a drug of abuse in the 2000s in Russia and neighboring states 
(7-9).  Reports of its use in European countries (including Romania, Germany, Poland, 
Czech Republic, France, Belgium, Spain and Italy) have been attributed to the migration 
of Krokodil users. To date there have been very few cases reported in the United States, 
although none have been analytically confirmed (5, 6, 10).  Although the drug received 
widespread attention in the media as a “flesh eating drug”, the U.S. Drug Enforcement 
Administration has reported a very limited number of drug seizures (11). However, 
detection of desomorphine in biological samples is a challenge because it is not within the 
normal scope of testing. Although some opioid immunoassays may have sufficient cross-
reactivity to produce a positive screening result (12), mass spectral confirmation 
procedures may not target desomorphine. Additionally, published case reports involving 
desomorphine suggest that there is typically an extensive delay between use of the drug 
and seeking medical treatment for the severe dermatological side effects (5, 6, 13). By the 
time medical attention is sought, drug users have typically ceased using Krokodil due to 
the severity of the symptoms. As a consequence, the drug is no longer present and 
analytical confirmation is typically not possible.  To date there has been only one published 
case report in the literature. This involved a fatal case of endomyocarditis where the 
presence of desomorphine was confirmed in the urine (13). 
Ultra high pressure liquid chromatography (UPLC) coupled with high resolution 
time of flight (TOF) or quadrupole/time of flight-mass spectrometry (Q/TOF-MS) is a 
powerful tool for metabolite identification due to its mass resolving power, mass accuracy 
and sensitivity (14). Although Q/TOF-MS has lower resolution than other mass analyzers 
(e.g. Orbitrap™), it is compatible with the high data acquisition needs of UPLC and can 
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produce MS2 spectra of diagnostic value. Furthermore, the use of superficially porous 
particles can improve chromatographic resolution and assist in the separation of 
challenging isobaric metabolites. 
To date there has been only one published study describing desomorphine 
metabolism. In 2016, Richter investigated its biotransformation using pooled human liver 
microsomes (HLMs) and cytosol (15). Seven phase I metabolites were identified: 
nordesomorphine, desomorphine-N-oxide, and five hydroxydesomorphine isomers.  Phase 
II metabolites included glucuronides of desomorphine, nordesomorphine and 
desomorphine-N-oxide, in addition to desomorphine sulfate.  Cytochrome P450 (CYP) 
activity was investigated in vitro using recombinant isoenzymes (rCYP). Of the rCYPs 
investigated, only the CYP3A4 isoenzyme produced metabolic activity, but two of the 
hydroxydesomorphine isomers identified using HLMs were not identified using the rCYP 
microsomal incubations.  Uridine 5'-diphospho-glucuronosyltransferase (UGT) activity 
was also assessed using recombinant enzymes (rUGTs).  Metabolic activity was identified 
using UGT1A1, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and 
UGT2B17. 
Metabolite identification is important because it can help identify potential 
biomarkers, or compounds with pharmacological activity or unexpected toxicity. 
Identification of the enzymes responsible for metabolism can help predict the impact of 
genetic polymorphisms and the potential risk of drug-drug interactions. Recombinant 
isoforms are ideal for this task and can help identify the potential for induction or inhibition, 
whereby the pharmacokinetic profile of the drug can be significantly altered. 
Notwithstanding the limitations associated with in vitro techniques, this approach can 
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provide valuable information regarding potential metabolites and the involvement of CYP 
and UGT isoforms.  
Previous in vitro studies have been reported for other structurally related opioids.  
In 2003 Projean found morphine metabolism to be catalyzed by numerous CYPs, including 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (16).  Metabolism of the keto 
opioid hydromorphone was found to involve CYP2C9, CYP2D6, CYP3A4, and CYP3A5 
(17).  Levorphanol (which is structurally identical to desomorphine with the exception of 
the epoxy group) is reportedly mediated by CYP2D6 and CYP3A4 (16).  In 1997, Coffman 
found UGT2B7 to be the major isoform involved in the formation of morphine-3-
glucuronide and morphine-6-glucuronide (19).  A subsequent study in 2003 by Stone 
suggested that numerous UGTs were also involved (UGT1A1, UGT1A3, UGT1A6, 
UGT1A8, UGT1A9 and UGT1A10) in the formation of morphine-3-glucuronide (20).  In 
the study reported here, the CYP and UGT activity of desomorphine metabolism is further 
explored using rCYP and rUGT techniques and LC-Q/TOF-MS analysis.   The terms rCYP 
and rUGT will be used when referring to the data collected during this study and the terms 
CYP and UGT used for broader discussion. 
Materials and methods 
Chemicals and reagents 
Desomorphine, desomorphine-D3, ketoconazole and fluvoxamine were obtained 
from Cerilliant (Round Rock, Texas).  Formic acid and ticlopidine were obtained from 
Sigma Aldrich (St. Louis, Missouri).  Montelukast was obtained from Cayman Chemical 
(Ann Arbor, Michigan).  Acetonitrile (LC/MS grade) was obtained from Thermo Fisher 
Scientific (Waltham, Massachusetts).  Recombinant human cytochrome P450 (rCYP) 
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isoenzymes expressed in E. coli (bactosomes) were obtained from Xenotech, LLC (Kansas 
City, Kansas).  Recombinant human uridine 5'-diphospho-glucuronosyltransferase (rUGT) 
isoenzymes expressed in baculovirus infected insect cells (supersomes™) were obtained 
from Corning (Glendale, Arizona).  Reduced nicotinamide adenosine di-phosphate 
(NADPH) regenerating system solution A (40 U/mL glucose-6-phosphate dehydrogenase 
in 5 mM sodium citrate), solution B (26 mM NADP+, 66 mM glucose-6-phosphate and 66 
mM magnesium chloride in aqueous solution), UGT reaction mix solution A (25 mM UDP-
glucuronic acid), and UGT reaction mix solution B (250 mM 
Tris(hydroxymethyl)aminomethane-HCl (Tris-HCl), 40 mM magnesium chloride, and 
0.125 mg/mL alamethicin) were obtained from Corning (Glendale, Arizona).  All other 
chemicals and reagents (analytical grade) were obtained from VWR (Radnor, 
Pennsylvania). Deionized (DI) water was generated from a Direct-Q 3 (UV) system 
(Millipore, Billerica, Massachusetts).   
LC-Q/TOF-MS analysis 
Samples were analyzed using an Agilent Technologies (Santa Clara, California) 
1290 Infinity LC system equipped with a 6530 Accurate Mass Q/TOF-MS.  Gradient 
elution was performed using a Poroshell 120 EC-C18 column (2.1 x 100 mm, 2.7 µm) with 
a Poroshell 120 EC-C18 guard column (2.1 x 5 mm, 2.7 µm).  LC separation of metabolites 
was achieved at 35°C in a thermostatically controlled column compartment. Mobile phase 
A consisted of 0.1% formic acid in DI water and mobile phase B consisted of 0.1% formic 
acid in acetonitrile.  Optimal separation of metabolites was achieved using a flow rate of 
0.3 mL/min with the following gradient: 10% B 0-2 mins, increasing to 37% B by 6 mins 
and 90% B by 10 mins.  Metabolites were identified using electrospray ionization (ESI) in 
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the positive mode. MS conditions for rCYP incubations were as follows: gas temperature 
150°C, gas flow 13 L/min, nebulizer 45 psi, sheath gas temperature 200°C, sheath gas flow 
12 L/min, VCap voltage 4000 V, nozzle voltage 1000 V, fragmentor 150 V.  MS conditions 
for rUGT incubations were as follows: gas temperature 350°C, gas flow 10 L/min, 
nebulizer 20 psi, sheath gas temperature 400°C, sheath gas flow 12 L/min, VCap voltage 
2500 V, nozzle voltage 0 V, fragmentor 150 V.  MS2 spectra were generated using collision 
induced dissociation (CID) energies of 30, 40 and 50 eV.  Scan speeds were 8 spectra/sec 
for MS and 3 spectra/sec for MS2.  The mass range was 100 - 1000 m/z.  Data was acquired 
in full scan mode using a preferred list of suspected metabolites. Data files were processed 
using MassHunter software (Agilent Technologies). 
rCYP incubations 
Each rCYP isoenzyme (rCYP1A2, rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C18, 
rCYP2C19, rCYP2D6 and rCYP3A4) was incubated separately to evaluate individual 
metabolic activity for desomorphine. Once microsomal conditions had been fully 
optimized, incubations were performed using replicate measurements (n=4).  Incubations 
were carried out at 37°C in the presence of 200 µM desomorphine and 50 pmol/mL rCYP 
isoenzyme.  The incubation mixture also contained 100 mM potassium phosphate buffer 
(pH 7.4), 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM magnesium citrate, and 
0.4 U/mL glucose-6-phosphate dehydrogenase.  Incubation mixtures were assayed at t = 0, 
30, 60, 120, 180 and 240 minutes. Each 25 µL aliquot was quenched using an equal volume 
of ice-cold acetonitrile containing 0.1% formic acid and 5 µM internal standard 
(desomorphine-D3).  The solution was centrifuged at 10,000 x g at 4°C for 3 minutes.  The 
supernatant was mixed with an equal volume of a 50/50 mixture of mobile phase A/B and 
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2 µL was injected onto the LC-Q/TOF-MS. Control and blank samples were included in 
each assay. In controls, rCYP isoenzymes were replaced with Xenotech control bactosomes 
and in the blank samples, desomorphine was replaced with phosphate buffer (no drug). 
Inhibition studies 
For the inhibition study, each rCYP isoenzyme was incubated side by side, in the 
presence and absence of inhibitor (n=3).  Conditions were identical to those described 
earlier, with the exception of the inhibitor. Ketoconazole (20 µM) was used for CYP2C9, 
CYP2C18, CYP2C19 and CYP3A4; fluvoxamine (20 µM) was used for CYP1A2 and 
CYP2D6; ticlopidine (10 µM) was used for CYP2C8 and montelukast (10 µM) was used 
for CYP2B6.  For the inhibition studies, aliquots were removed at t = 0 and 240 minutes 
and samples were analyzed using LC-Q/TOF-MS as described above.  
rUGT incubations 
Each rUGT isoenzyme (rUGT1A1, rUGT1A3, rUGT1A6, rUGT1A7, rUGT1A8, 
rUGT1A9, rUGT1A10, rUGT2B4, rUGT2B7, rUGT2B15, and rUGT2B17) was incubated 
separately to evaluate individual metabolic activity for desomorphine. Once microsomal 
conditions had been fully optimized, incubations were performed using replicate 
measurements (n=3).  Incubations were carried out at 37°C in the presence of 200 µM 
desomorphine and 0.25 mg/mL rUGT isoenzyme.  The incubation mixture also contained 
90 mM Tris-HCl (pH 7.5), 8 mM magnesium chloride, 25 µg/mL alamethicin, and 2 mM 
uridine 5’-diphospho-glucuronic acid (UDPGA).  Incubation mixtures were assayed at t = 
0, 30 and 120 minutes. Each 25 µL aliquot was quenched using an equal volume of ice 
cold acetonitrile containing 0.1% formic acid and 5 µM internal standard (desomorphine-
D3).  The solution was centrifuged at 10,000 x g at 4°C for 3 minutes.  The supernatant 
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was mixed with an equal volume of a 50/50 mixture of mobile phase A/B and 2 µL was 
injected onto the LC-Q/TOF-MS. Control and blank samples were included in each assay. 
In controls, rUGT isoenzymes were replaced with Corning control supersomes™ and in 
the blank samples, desomorphine was replaced with Tris-HCl buffer (no drug).  
Metabolite identification 
Potential metabolites were first identified by observing changes in each rCYP and 
rUGT incubation mixtures over time.  Using the optimized LC separation, the abundance 
of each potential metabolite was normalized to the internal standard (desomorphine-D3). 
Measurement of the relative peak area (RPA) minimized random errors associated with 
volumetric steps, injection volume and ionization efficiency.  The exact masses of 
predicted metabolites were monitored using a preferred list and MS2 spectra of compounds 
that appeared to increase over time were further investigated over a range of CID voltages. 
Results and discussion 
Identification of phase I metabolites 
A total of eight potential metabolites were identified including nordesomorphine 
(m/z 285, 3.04 mins), desomorphine-N-oxide (m/z 288, 4.11 mins), five hydroxylated 
species (m/z 288, 0.99, 1.35, 1.79, 2.41 and 3.66 mins) and norhydroxydesomorphine (m/z 
274, 2.50 mins). The chromatographic separation of desomorphine and its metabolites is 
shown in Figure 3.2 and MS2 spectra are shown in Figure 3.3.  Each metabolite’s chemical 
formula, exact mass, accurate mass, mass error, and product ions are detailed in Table 3.1. 
Mass errors for all assignments were within 5 ppm for all metabolites except 





Retention time, chemical formula, exact mass, accurate mass and mass error for 
















desomorphine 3.22 C17H21NO2 272.1645 272.1643 0.91 
nordesomorphine 3.04 C16H19NO2 258.1489 258.1482 2.54 
desomorphine-N-oxide 4.11 C17H21NO3 288.1594 288.1597 1.11 
hydroxydesomorphine 
isomer 1 
0.99 C17H21NO3 288.1594 288.1593 0.25 
hydroxydesomorphine 
isomer 2 
1.35 C17H21NO3 288.1594 288.1591 1.07 
hydroxydesomorphine 
isomer 3 
1.79 C17H21NO3 288.1594 288.1595 0.38 
hydroxydesomorphine 
isomer 4 
2.41 C17H21NO3 288.1594 288.1591 1.20 
hydroxydesomorphine 
isomer 5 
3.75 C17H21NO3 288.1594 288.1594 0.03 





Figure 3.2. Extracted ion chromatograms for desomorphine, 3.22 min (m/z 272); 
nordesomorphine, 3.04 min (m/z 258); desomorphine-N-oxide, 4.11 min and 
hydroxydesomorphine, 0.99, 1.35, 1.79, 2.41 and 3.75 min (m/z 288) and 




Figure 3.3. MS2 spectra of desomorphine (A), nordesomorphine (B), desomorphine-N-
oxide (C), hydroxydesomorphine (D-H), and norhydroxydesomorphine (I). 
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The fragmentation of desomorphine (m/z 272, M+1) is dominated by the loss of the 
nitrogen ring (m/z 215, M-57), which is characteristic for phenanthrene-type opioids (21). 
Subsequent loss of hydrogen, water and CO produce ions at m/z 213, 195 and 167 (Figure 
3.3).  In combination, HRMS and these characteristic losses were used to identify 
metabolites and their associated ions. Structural assignments and associated mass errors 
for desomorphine and its metabolites are presented in Table 3.2. Not surprisingly, the most 
significant mass shifts were observed with some of the least abundant ions, or metabolites 
produced at low intensity. All of the metabolites of desomorphine undergo fragmentation 
consistent with the loss of the nitrogen ring, resembling the parent drug.  Product ion 
spectra for the N-demethylated species (nordesomophine) and N-oxide bear the closest 
resemblance to the parent drug. Desomorphine-N-oxide shows an immediate oxygen loss, 
which is highly characteristic of N-oxides (22).  Five of the metabolites identified in this 
study have an additional oxygen, consistent with hydroxylation or isobaric internal 
heteroatom dealkylation products. In the absence of analytical standards, specific 
assignments were not attempted, although mass spectra did provide some distinguishable 
information.  
Product ion spectra (Figure 3.3) depict water losses (m/z 231/229 to 213/211 and 
m/z 213 to 195) in hydroxydesomorphine isomers 1, 2 and 3, which are absent in the 
product ion spectra of isomers 4 and 5. Protonated ions of aliphatic hydroxylated 
metabolites are reported to undergo more facile water loss than aromatic hydroxylation 
(18, 22). As a result, isomers 1-3 were tentatively identified as aliphatic hydroxylated 
species, in contrast to isomers 4 and 5. While isomers 1-3 showed significant dehydration 
consistent with stable aliphatic hydroxylation, isomers 4 and 5 did not. This might be 
112 
 
attributed to aromatic hydroxylation, or products of aliphatic hydroxylation adjacent to 
heteroatoms followed by spontaneous ring-opening to isobaric ketones. The mass spectrum 
for norhydroxydesomorphine also shows significant dehydration, suggestive of aliphatic 
hydroxylation.  This is also consistent with the equivalent norhydroxylated product 
observed by Bonn for oxidation of levorphanol, which is identical in structure to 





















Chemical formula, exact mass, accurate mass and mass error for product ions of 














+ 215.1067 215.1064 1.00 
C14H11O
+ 195.0804 195.0807 1.08 
C13H11
+ 167.0855 167.0856 0.53 
nordesomorphine C14H15O2
+ 215.1067 215.1065 0.74 
C14H11O
+ 195.0804 195.0806 1.04 
C13H11
+ 167.0855 167.0855 0.19 
desomorphine-N-oxide C17H21NO2
+ 271.1567 271.1566 0.27 
C16H18NO2
+ 256.1332 256.1330 0.77 
C14H15O2
+ 215.1067 215.1066 0.42 
C14H11O




+ 231.1016 231.1016 0.06 
C14H13O2
+ 213.0910 213.0907 1.40 
C14H11O




+ 231.1016 231.1010 2.33 
C14H13O2
+ 213.0910 213.0915 2.53 
C14H11O




+ 231.1016 231.1018 0.92 
C14H11O2
+ 211.0754 211.0748 2.67 
C13H11O




+ 260.1645 260.1637 2.92 
C16H22NO
+ 244.1696 244.1674 8.92  
C15H17O
+ 213.1274 213.1263 5.19 
 
C13H13O








+ 260.1645 260.1643 0.62 
C16H20NO
+ 242.1539 242.1535 1.95 
C13H13O
+ 185.0961 185.0979 9.85 
C12H13
+ 157.1012 157.1013 0.98 
norhydroxydesomorphine C16H18NO2
+ 256.1332 256.1323 3.45 
C15H20NO
+ 230.1539 230.1524 6.83 
C14H13O2
+ 213.0910 213.0876 15.82 
 
rCYP activity 
Of the eight rCYP isoenzymes tested, metabolic activity was observed using 
rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C18, rCYP2C19, rCYP2D6 and rCYP3A4.  No 
detectable metabolism was observed with rCYP1A2.  Figure 3.4 shows metabolite 
formation (30-240 mins) for nordesomorphine and Figure 3.5 shows metabolite formation 
(30-240 mins) for hydroxydesomorphine isomers 1-5, desomorphine-N-oxide and 
norhydroxydesomorphine.  As these metabolites cannot be quantified without an analytical 
standard, their abundance was compared relative to the internal standard.  Comparing the 
relative peak areas (RPAs) of all of the metabolites, nordesomorphine was the major 
metabolite using all rCYPs, except for rCYP2B6 where hydroxydesomorphine isomer 3 




Figure 3.4. Production of nordesomorphine over time using rCYP2C8, rCYP2C18, and 
rCYP3A4 (top) and rCYP2B6, rCYP2C9, rCYP2C19, and rCYP2D6 (bottom). The 
quantity of nordesomorphine is expressed using relative to the internal standard. Data is 





Figure 3.5. Metabolite production over time for hydroxydesomorphine isomer 1 (A), 
hydroxydesomorphine isomer 2 (B), hydroxydesomorphine isomer 3 (C), 
hydroxydesomorphine isomer 4 (D), hydroxydesomorphine isomer 5 (E), desomorphine-
N-oxide (F), and norhydroxydesomorphine (G). The quantity of each metabolite is 
expressed relative to the internal standard. Error bars represent mean ± 1 SD (n=4). 
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No detectable metabolism was observed in any of the controls or blanks.  The rate 
of metabolite formation was not estimated because in vitro rates of reaction using rCYPs 
may not be reflective of in vivo kinetics.  While the lack of analytical standards or certified 
reference materials means that the concentrations of metabolites in each rCYP reaction 
cannot be determined, a comparison of the relative abundance between rCYPs does provide 
useful information (Figure 3.6).  This demonstrates that although rCYP3A4 was the only 
isoform to produce desomorphine-N-oxide and norhydroxydesomorphine, other isoforms 
were involved for six of the eight metabolites. Moreover, rCYP2C18 was the major isoform 
responsible for the formation of nordesomorphine. While the results here confirm the 
activity of CYP3A4 first reported by Richter (15), our results provide supplemental 




Figure 3.6. Relative contribution of rCYPs during in vitro metabolism studies. 
Abbreviations:  NorDM, nordesomorphine; DM-OH, hydroxydesomorphine; DM-N-OX, 
desomorphine-N-oxide; NorDM-OH, norhydroxydesomorphine. 
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Inhibition studies were performed to verify observed isoenzyme activity. 
Uninhibited and inhibited reactions were in parallel, and the RPAs of the metabolites 
produced in each were compared and used to calculate the decrease in production that 
occurred (% inhibition).  The RPAs of uninhibited and inhibited reactions of rCYPs 
capable of metabolizing desomorphine to nordesomorphine are shown in Figure 3.7.  
Significant inhibition (>20%) was observed for all rCYPs for all phase I metabolites 
identified (Table 3.3).  Isoenzymes capable of phase I metabolism are summarized in 
Figure 3.8.  Although the formation of the N-oxide was solely attributed to CYP3A4, 
several other isoforms were capable of N-demethylation and hydroxylation. Although in 
vitro assays using recombinant enzymes can identify possible pathways, they do not always 
mimic in vivo biotransformations. These pathways, and the extent to which each isoform 
may contribute, are variable.  Despite the convenience of in vitro studies, this is an 














Percent inhibition for phase I metabolites (n=3). 
Metabolite % Inhibition ± Standard Deviation 
nordesomorphine 
rCYP2C18 (89% ± 2%), rCYP2C8 (93% ± 1%), 
rCYP3A4 (91% ± 1%), rCYP2C9 (64% ± 3%), 
rCYP2D6 (41% ± 12%), rCYP2C19 (48% ± 8%), 
rCYP2B6 (57% ± 11%) 
desomorphine-N-oxide rCYP3A4 (55% ± 7%) 
hydroxydesomorphine isomer 1 rCYP3A4 (91% ± 3%), rCYP2D6 (69% ± 10%) 
hydroxydesomorphine isomer 2 rCYP3A4 (90% ± 2%), rCYP2D6 (46% ± 11%)  
hydroxydesomorphine isomer 3 
rCYP2B6 (88% ± 5%), rCYP2D6 (58% ± 6%), 
rCYP2C9 (69% ± 5%), rCYP3A4 (86% ± 1%), 
rCYP2C18 (86% ± 3%) 
hydroxydesomorphine isomer 4 rCYP3A4 (97% ± 1%), rCYP2D6 (68% ± 2%) 
hydroxydesomorphine isomer 5 rCYP3A4 (90% ± 2%), rCYP2D6 (65% ± 7%) 








Figure 3.7. Inhibition of nordesomorphine production using rCYP2C8, rCYP2C18, 
rCYP3A4 (left) and rCYP2B6, rCYP2C9, rCYP2C19, rCYP2D6 (right) at 240 
minutes.The quantity of nordesomorphine is expressed relative to the internal standard.   














No detectable metabolism was observed in any of the controls or blanks.  Of the 
ten rUGTs evaluated, metabolic activity was observed in rUGT1A1, rUGT1A3, rUGT1A8, 
rUGT1A9, rUGT1A10, rUGT2B4, rUGT2B7, rUGT2B15, and rUGT2B17.  No detectable 
metabolism was observed in rUGT1A6.  The rate of metabolite formation was not 
estimated because in vitro rates of reaction using rUGTs may not be reflective of in vivo 
kinetics.  Desomorphine-glucuronide was identified. Its MS2 spectrum and mass 
assignments are summarized in Figure 3.9 and Table 3.4, respectively. 
 
 












Chemical formula, exact mass, accurate mass and mass error for precursor and product 











448 C23H29NO8+ 448.1966 448.1962 0.80 
272 C17H22NO2+ 272.1645 272.1643 0.66 
215 C14H15O2+ 215.1067 215.1063 1.67 
167 C13H11+ 167.0855 167.0847 4.92 
 
A shorter timeline was used for the rUGT incubations compared to the rCYP 
incubations due to the fact that production of desomorphine-glucuronide appeared to 
plateau at 120 minutes.  Because of this, the source parameters for analysis were further 
optimized in order to improve sensitivity.  Figure 3.10 depicts the relative abundance of 
desomorphine-glucuronide produced by each rUGT at 120 minutes. The greatest activity 







Figure 3.10. Desomorphine-glucuronide production by rUGT1A9, rUGT2B4, rUGT2B7 
(top) and rUGT1A1, rUGT1A3, rUGT1A8, rUGT1A10, rUGT2B15 and rUGT2B17 
(bottom) at 240 minutes. The amount of desomorphine-glucuronide is expressed using the 
relative peak area (RPA).  Error bars represent mean ± SD (n=3). 
 
Comparison with previous studies 
The results of this study regarding the individual CYPs involved in desomorphine 
metabolism complement previous work (15).  Richter’s study investigated rCYP1A2, 
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rCYP2A6, rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C19, rCYP2D6, rCYP2E1, rCYP3A4 
and rCYP3A5.  Metabolic activity was only observed with rCYP3A4 and 
norhydroxydesomorphine was not identified in any of the in vitro or in vivo experiments.  
These differences may be attributed to differences in microsomal incubation conditions 
and the use of rCYPs expressed in bactosomes, rather than supersomes™. There is 
evidence to suggest that bactosomes have greater activity and turnover compared to 
supersomes™ (23).  One of the unique metabolites identified in our study (the doubly 
oxidized norhydroxydesomorphine) was not present in sufficiently high yield until two 
hours, which may explain why is was not detected previously using a 30 minute incubation 
(15).  
The results of this study are in good agreement with previously published 
metabolism studies using phenanthrene-type opioids.  Metabolism of morphine involves 
CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoforms (16).  CYP3A4 is known 
to preferentially catalyze the oxidative N-demethylation of drugs within this class.  Like 
desomorphine, levorphanol is also saturated at the C7-8 bond and is fully reduced at carbon 
6.  Consistent with our results, Bonn observed that CYP3A4 was solely responsible for the 
formation of levorphanol-N-oxide, while N-demethylation involved both CYP3A4 and 
CYP2D6 (18). Accordingly, the role of other isoforms involved in hydroxylation was also 
identified in that same study. Hydroxylation of levorphanol was found to involve CYP3A4, 
and to a lesser extent CYP2D6, also consistent with our findings (Figure 17).  As in the 
levorphanol study, a product was identified that was both hydroxylated (appearing to be an 
aliphatic hydroxylation in both cases) and N-demethylated. 
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In this study, rCYP2C18, rCYP2C8 and rCYP3A4 were the major cytochrome 
P450 enzymes responsible for N-demethylation. Although hydroxylation was largely 
mediated by rCYP3A4 (and to a lesser extent rCYP2D6), hydroxydesomorphine isomer 3 
was produced predominantly by rCYP2B6. Although in vitro assays do not mimic in vivo 
transformations, the abundance of nordesomorphine in the microsomal incubations, 
relative to other metabolites, is consistent with this being the major metabolite in vivo.  As 
opioids are known to be preferentially metabolized by glucuronidation, it is highly probable 
that nordesomorphine is the most likely phase I metabolite to be identified in forensic 
toxicology investigations. 
The results for the UGTs in this study also complement previous work.  Richter 
previously reported that rUGT1A1, rUGT1A8, rUGT1A9, rUGT1A10, rUGT2B4, 
rUGT2B7, rUGT2B15, and rUGT2B17 metabolized desomorphine (13).  The study 
reported here was the first to investigate rUGT1A3 using desomorphine.  Previous studies 
have shown UGT1A1, UGT1A3, UGT1A6, UGT1A8, UGT1A9, UGT1A10, and 
UGT2B7 to have metabolic activity for morphine with UGT2B7 being the major 
contributor (19).  All are also involved in the metabolism of desomorphine. The main 
contributor is UGT2B7, with UGT1A9 and UGT2B4 being the next most active. Stone 
also tested UGT1A6 and UGT2B15 for morphine metabolism and UGT1A6 metabolized 
morphine, while UGT2B15 did not (20).  The opposite is true for desomorphine. 
Conclusions 
This study identified a new phase I metabolite, additional CYP450 isoenzyme 
activity, and an additional UGT isoenzyme that may be involved in the biotransformation 
of desomorphine. The results presented here complement existing work and are consistent 
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with metabolic pathways of other phenanthrene-type opioids.  The identification of 
potential metabolites is important in forensic toxicology so that appropriate compounds 
can be targeted in biological fluids.  Furthermore, a comprehensive understanding of 
isoenzymes involved in drug metabolism is also important in terms of drug-drug 
interactions and the potential for adverse drug reactions. 
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Desomorphine, the principal opioid in Krokodil, has an analgesic potency 
approximately ten-times that of morphine.  Similar to other opioids, during phase II 
metabolism it undergoes conjugation with glucuronic acid to form desomorphine-
glucuronide.  Although hydrolysis of conjugated species is sometimes required prior to 
analysis, desomorphine-glucuronide has not been fully investigated.  In this study, six 
hydrolysis procedures were optimized and evaluated. Deconjugation efficiencies using 
chemical and enzymatic hydrolysis were evaluated and stability in aqueous solution was 
assessed.  Acid hydrolysis was compared with five β-glucuronidase sources (BGTurbo™, 
IMCSzyme™, Escherichia coli, Helix pomatia and Patella vulgata).  At optimal 
conditions, each hydrolysis method produced complete hydrolysis (≥96%).  However, 
under simulated challenging conditions, P. vulgata was the most efficient β-glucuronidase 
for the hydrolysis of desomorphine-glucuronide.  Both BGTurbo™ and IMCSzyme™ 
offered fast hydrolysis with no need for sample cleanup prior to liquid chromatography-
quadrupole time of flight mass spectrometry (LC-Q/TOF MS) analysis.  Hydrolysates 
using E. coli, H. pomatia and P. vulgata underwent additional sample treatment using β-
Gone™ cartridges. Additionally, the stability of free and conjugated drug was evaluated at 
elevated temperature (60°C) in aqueous solutions between pH 4-10.  No degradation was 
observed for either desomorphine or desomorphine-glucuronide under any of the 
conditions tested.  





Stability and Hydrolysis of Desomorphine-Glucuronide 
Introduction 
Krokodil is a homemade heroin substitute that has been used in Russia and 
surrounding countries since the early 2000s (1).  In recent years, reports of its use have also 
emerged from the Republics of Armenia (2-4) and Georgia (5), Germany (6), Italy (7), 
Poland (8), Russia (9, 10), Spain (11), the United Kingdom (12) and the United States (13-
17).  To date, only one analytically confirmed case has been published, where 
desomorphine was identified in the post-mortem urine of a 39 year old male at 270 ng/mL 
(7).   Krokodil is clandestinely produced from codeine using hydroiodic acid and red 
phosphorus, producing a mixture of morphinans, of which desomorphine is a major 
component (18, 19).  Desomorphine is structurally similar to morphine, with differences at 
C6 (absence of the hydroxyl) and saturation of the C7-C8 double bond (Figure 4.1).  These 
structural differences make desomorphine approximately ten times more potent than 
morphine, with a faster onset of action but a shorter duration of effect (20).   Krokodil is 
predominately used intravenously, which bypasses many of the human body’s natural 
safeguards.  Residual precursor chemicals used during synthesis may remain in the final 
product, which may contribute to the severe dermatological sequela associated with its use, 








Recent studies indicate that desomorphine undergoes conjugation with glucuronic 
acid and sulfate during phase II metabolism, as well as N-demethylation, hydroxylation 
and N-oxide formation during phase I (21, 22).  Data from both studies indicate 
desomorphine-glucuronide to be the major phase II metabolite formed. This is consistent 
with morphine, of which approximately 75% of a dose is excreted as morphine-3-
glucuronide (23).  Polar glucuronidated species are not amenable to gas chromatographic 
analysis. If gas chromatography-mass spectrometry (GC-MS) based methods are used, 
glucuronides must be hydrolyzed prior to analysis.  Liquid chromatography (LC) based 
techniques are advantageous from this standpoint, because both free and conjugated drug 
can be identified simultaneously.  However, if both free and conjugated species are to be 
isolated from a biological matrix using either liquid-liquid extraction (LLE) or solid phase 
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extraction (SPE), careful selection of solvents and potential sorbent phase is necessary (24).  
Further limitations associated with the direct analysis of glucuronides may include their 
increased cost, availability, and for some conjugates, the absence of a stable isotope 
internal standard (IS).  
Conjugated metabolites are frequently hydrolyzed prior to extraction and 
instrumental analysis.  In doing so, the amount of free and bound drug is determined 
indirectly from the free (untreated) and total (hydrolyzed) fractions.  Although this 
approach requires the sample to be analyzed twice, the quantity of free and bound drug can 
provide valuable information from an interpretive standpoint.   
The hydrolysis of glucuronide species is typically achieved either chemically or 
enzymatically.   Strong acids or bases (sometimes at elevated temperatures) or β-
glucuronidase enzymes can be used, both of which have advantages and disadvantages.  
Chemical hydrolysis is often less costly, faster and sometimes more efficient that enzyme 
hydrolysis but can cause degradation, particularly with opioids (25, 26).  Conditions for 
enzyme hydrolysis are typically less harsh and do not cause degradation, but the efficiency 
of β-glucuronidase enzymes varies significantly between individual drugs and drug classes, 
typically requiring much longer incubation times (24, 27, 28).  Additionally, there are 
commercially available β-glucuronidases isolated from multiple species, each of which can 
have varying activities towards different substrates. As a result, optimum enzymatic 
systems and conditions must be explored during method development (29-31).   
Previous studies involving opioids have shown that acid hydrolysis is often the 
most efficient method for hydrolysis, particularly with morphine (27, 30). However, under 
some conditions degradation may occur with 6-acetylmorphine, buprenorphine and keto 
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opioids (25, 26, 29), complicating the interpretation of the results.  Comparisons of 
different sources of β-glucuronidases have shown Patella vulgata to have a greater affinity 
for morphine compared with Escherichia coli and Helix pomatia (27), but conversely it has 
the lowest affinity of the three for buprenorphine (29).  Although appropriate 
glucuronidated controls should always be used to monitor the efficiency of the hydrolysis 
step, incomplete hydrolysis may reduce the overall sensitivity of the analytical method.  
Longer enzymatic incubations may increase the extent of hydrolysis, but the increased 
overall analysis time may be undesirable for high throughput laboratories or those with 
large caseloads. 
To date, only two studies have described the hydrolysis of desomorphine 
metabolites.  Savchuk used chemical hydrolysis using hydrochloric acid on human urine 
samples prior to GC-MS analysis (32).  Richter used β-glucuronidase from Helix pomatia 
to facilitate the identification of phase I metabolites of desomorphine in rat urine, and later 
acid hydrolysis was used during the development of a screening assay to detect 
desomorphine (21).    However, no comparison between different hydrolysis methods has 
been performed for desomorphine-glucuronide to date.   
In order to gain additional insight into the efficiency of desomorphine-glucuronide 
hydrolysis, six deconjugation processes were evaluated. Chemical hydrolysis (acid) and 
five enzymatic methods (BGTurbo™, IMCSzyme™, Escherichia coli, Helix pomatia and 
Patella vulgata) were compared side-by-side using desomorphine-glucuronide generated 
in vitro using recombinant human uridine 5'-diphospho-glucuronosyltransferase (rUGT) 
isoenzyme. Given that some glucuronides are known to be labile (33), the stability of 
138 
 
desomorphine and desomorphine-glucuronide was briefly investigated over a range of pH 
values (4-10). 
Materials and methods 
Reagents 
Recombinant human uridine 5'-diphospho-glucuronosyltransferase isoenzyme 2B7 
(rUGT2B7) expressed in baculovirus infected insect cells (supersomes™), UGT reaction 
mix solution A (25 mM UDP-glucuronic acid), and UGT reaction mix solution B (250 mM 
Tris(hydroxymethyl)aminomethane-HCl (Tris-HCl), 40 mM magnesium chloride, and 
0.125 mg/mL alamethicin) were obtained from Corning (Glendale, Arizona, USA).  
Desomorphine, desomorphine-D3 (IS) and morphine-3-glucuronide were obtained from 
Cerilliant (Round Rock, Texas, USA).  Acetonitrile (LC/MS grade) was obtained from 
Thermo Fisher Scientific (Waltham, Massachusetts, USA) and acetic acid was obtained 
from Mallinckrodt Chemicals (St. Louis, Missouri, USA).  Concentrated ammonium 
hydroxide was purchased from Macron Fine Chemicals (Center Valley, Massachusetts, 
USA) and concentrated hydrochloric acid was from J.T. Baker (Center Valley, California, 
USA). Formic acid (>95%), potassium phosphate (monobasic and dibasic), ammonium 
bicarbonate, ammonium acetate, TRIS-base, TRIS-HCL, β-glucuronidase from 
Escherichia coli (Type IX-A, lyophilized powder, 1,000,000-5,000,000 units/g), β-
glucuronidase from Helix pomatia (Type H-1, partially purified powder, ≥300,000 units/g) 
and β-glucuronidase from Patella vulgata (Type L-II, lyophilized powder, 1,000,000-
3,000,000 units/g) were obtained from Sigma Aldrich (St. Louis, Missouri, USA).  
IMCSzyme™ (genetically modified β-glucuronidase, purified solution, >50,000 units/mL) 
and its proprietary Rapid Hydrolysis Buffer were obtained from Integrated Micro-
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Chromatography Systems, LLC (Irma, South Carolina, USA).  BGTurbo™ (genetically 
enhanced β-glucuronidase solution for 10 min flash-hydrolysis, ~1 mg/mL, >90% purity, 
>200,000 units/mL) was obtained from Kura Biotec® (La Piedra Biotecnología, Puerto-
Varas, Chile).  β-Gone™ hydrolysis sample clean-up tubes were from Phenomenex 
(Torrance, California, USA) and deionized (DI) water was generated from a Direct-Q 3 
(UV) system (Millipore, Billerica, Massachusetts, USA).  Unless otherwise stated, all 
inorganic salts, acids and bases were ACS grade.    
LC-Q/TOF-MS  
An Agilent Technologies (Santa Clara, California) 1290 Infinity LC system 
equipped with a 6530 Accurate Mass Q/TOF-MS was used for analysis.  An Agilent 
Poroshell 120 EC-C18 column (2.1 x 100 mm, 2.7 µm) with a Poroshell 120 EC-C18 guard 
column (2.1 x 5 mm, 2.7 µm particle size) was used to separate compounds in a 
thermostatically controlled column compartment (35°C). Mobile phase A and B consisted 
of 0.1% formic acid in DI water and 0.1% formic acid in acetonitrile, respectively.  The 
flow rate was 0.3 mL/min with the following gradient: 10% B 0-2 mins, increasing to 37% 
B by 6 mins and 90% B by 10 mins.  Ionization was achieved using electrospray ionization 
(ESI) in the positive mode. MS conditions were as follows: gas temperature 350°C (10 
L/min), nebulizer 20 psi, sheath gas temperature 400°C (12 L/min), fragmentor 150 V, 
VCap voltage 2500 V, nozzle voltage 0 V.  Data was acquired in full scan mode using a 
preferred list of analytes (desomorphine, internal standard and desomorphine-glucuronide).  
Collision induced dissociation (CID) energies of 30, 40 and 50 eV were used to generate 
product MS2 spectra.  Scan speeds for MS and MS2 were 8 spectra/sec and 3 spectra/sec, 
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respectively and the mass range was 100 - 1000 m/z.  Data files were processed using 
MassHunter software (Agilent Technologies). 
Glucuronide production 
In the absence of a commercially available standard or authentic urine specimens 
from Krokodil users, desomorphine-glucuronide was generated in vitro using rUGTs as 
previously described (22). Although as many as nine UGTs may be involved in the 
glucuronidation of desomorphine, rUGT2B7 was selected for the in situ production of the 
conjugate, due to its increased activity relative to the other isoforms (22).  Incubations were 
carried out at 37°C in the presence of 25 µM desomorphine and 0.25 mg/mL rUGT2B7 
isoenzyme.  The incubation mixture also contained 90 mM Tris-HCl (pH 7.5), 8 mM 
magnesium chloride, 25 µg/mL alamethicin, and 2 mM uridine 5’-diphospho-glucuronic 
acid (UDPGA).  The reaction was stopped by heat shocking the mixture at 80°C for 15 
minutes.  The solution was centrifuged at 14,000 x g at 4°C for 10 minutes to remove 
proteins.  An aliquot of supernatant was diluted 1:1 with 90:10 A:B mobile phase 
containing IS (5 µM) and 2 µL was injected onto the LC-Q/TOF-MS for analysis.  The 
remaining supernatant containing desomorphine-glucuronide was hydrolyzed as described 
below prior to analysis.  
 Acid hydrolysis 
An equal volume of supernatant containing desomorphine-glucuronide (500 µL) 
and concentrated hydrochloric acid (500 µL) was combined and incubated at 95°C for 60 
minutes (n=2).  The sample was allowed to come to room temperature then neutralized (pH 
7) with ammonium hydroxide solution.  The sample was diluted 1:1 with 90:10 A:B mobile 
phase containing the internal standard (2.5 µM) and 2 µL was injected onto the LC-Q/TOF-
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MS for analysis.  The concentration of the IS was adjusted to give the same drug:IS ratio 
in all samples to facilitate comparison between methods. 
Enzyme hydrolysis 
A 50 µL aliquot of supernatant containing desomorphine-glucuronide was used for 
each enzymatic hydrolysis reaction described below.  Each reaction was performed in 
duplicate, and where possible the recommendations of the manufacturer were followed.  
For IMCSzyme™, the reaction mixture contained sample, 30 µL of IMCSzyme™, 90 µL of 
proprietary buffer, 30 µL of IS (prepared at 9.96 µM in 50:50 water:methanol) and 
sufficient DI water to bring the reaction volume to 300 µL.  The reaction mixture was 
incubated at 55°C for 30 minutes.  Following dilution (1:1) with 90:10 A:B mobile phase, 
2 µL was injected onto the LC-Q/TOF-MS for analysis.  For BGTurbo™, the reaction 
mixture contained sample, 15 µL of BGTurbo™, 15 µL of IS (prepared at 16.7 µM in 50:50 
water:methanol) and sufficient 50 mM phosphate buffer (pH 6.8) to achieve a final reaction 
volume of 150 µL.  The reaction mix was incubated at 55°C for 30 minutes.  The sample 
was then diluted 1:1 with 90:10 A:B mobile phase and 2 µL was injected onto the 
instrument for analysis.   
For hydrolysis with E. coli β-glucuronidase, the reaction mixture contained sample, 
150 µL of enzyme (prepared at 10,000 units/mL in 100 µM phosphate buffer pH 6.8), 15 
µL of IS (prepared at 9.96 µM in DI water) and sufficient 100 mM phosphate buffer (pH 
6.8) to achieve a final volume of 300 µL.  The reaction mixture was incubated at 37°C for 
180 minutes before being subjected to sample cleanup prior to analysis.  For hydrolysis 
with H. pomatia β-glucuronidase, the reaction contained sample, 150 µL of enzyme 
(prepared at 10,000 units/mL in 100 µM acetate buffer pH 5.0), 15 µL of IS (prepared at 
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9.96 µM in DI water) and sufficient 100 mM acetate buffer (pH 5.0) to reach a final volume 
of 300 µL.  The reaction mixture was incubated at 65°C for 180 minutes prior to sample 
cleanup.  For hydrolysis with P. vulgata β-glucuronidase, the reaction mixture contained 
sample, 150 µL of enzyme (prepared at 10,000 units/mL in 100 µM acetate buffer pH 5.0), 
15 µL of IS (prepared at 9.96 µM in DI water) and sufficient 100 mM acetate buffer (pH 
5.0) to achieve a final volume of 300 µL.  The reaction mixture was incubated at 65°C for 
180 minutes, then subjected to sample cleanup prior analysis.  In accordance with 
manufacturer recommendations, sample cleanup was achieved by adding 200 µL of the 
reaction mixture to 133 µL of 0.1% formic acid in methanol before allowing the sample to 
flow through a β-gone™ column under gravity.  The eluent was diluted 1:1 with 90:10 A:B 
mobile phase and 2 µL injected onto the LC-Q/TOF-MS for analysis. 
Short-term stability 
Acetate (pH 4-6), Tris-HCl (pH 7) and bicarbonate buffers (pH 8-10) (50 mM) were 
prepared at pHs ranging from 4 to 10.  Desomorphine-glucuronide generated in situ (100 
µL) was diluted 1:3 with each buffer.  An aliquot was immediately removed for t=0 and 
diluted 1:1 in 90:10 A:B mobile phase.  The buffered solutions were then incubated at 
60°C.  Aliquots were removed at 5, 10, 15, 30, 60, 120 and 180 minutes and diluted 1:1 in 
90:10 A:B mobile phase.  Samples were refrigerated prior to analysis using LC-Q/TOF-
MS.  
Results and discussion 
In Situ production of desomorphine-glucuronide 
Due to the absence of reference material or authentic specimens, deconjugation 
efficiencies were determined using desomorphine-glucuronide generated in situ using 
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rUGT enzyme. As a result, the total concentration of conjugated drug may be lower than 
expected in an actual biological specimen.  As a consequence, the efficiency of each 
deconjugation procedure was evaluated by varying the amount of enzyme, rather than 
increasing the quantity of drug. This approach was necessary to provide challenging 
conditions that would allow the deconjugation efficiency of each approach to be compared.   
During initial method development the quantity of desomorphine-glucuronide 
generated in situ was optimized. The activity of the rUGT supersomes™ diminished 
beyond a two-hour incubation (22), so a large excess of desomorphine (25 µM) was 
utilized. In the absence of a reference standard for desomorphine-glucuronide it was not 
possible to determine the exact concentration of metabolite produced in situ. However, 
using the optimized conditions, the absolute peak area of desomorphine-glucuronide 
produced a signal equivalent to 1,000 ng/mL of morphine-3-glucuronide.  The extracted 
ion chromatogram (EIC) and MS2 spectrum of desomorphine-glucuronide (M+H, m/z 448) 
in the diluted supernatant are depicted in Figure 4.2.  Not surprisingly, the MS2 spectrum 
indicates the major loss of the glucuronide moiety (M-176) with the fragmentation of the 
parent (m/z 448) to m/z 272. 
 
Figure 4.2. Extracted ion chromatogram of desomorphine-glucuronide (RT, 1.21 min) and 




Chemical hydrolysis of desomorphine-glucuronide produced complete hydrolysis, 
which is consistent with what has been observed with other opioids (27, 30).  No 
degradation of desomorphine was observed using the conditions tested, despite reports 
otherwise for other opioids (25).  As such, the stability of desomorphine-glucuronide was 
further investigated in the form of a short-term stability study conducted at 60°C and 
different pH values ranging from 4-10.  The temperature was selected based on the 
incubation temperatures of the enzymes used for hydrolysis.  The time was limited to 3 
hours as that was the longest incubation period used for hydrolysis.  The pH range was 
expanded to further explore pH-dependent effects (pH 4, 5, 6, 7, 8, 9 and 10).  The pH of 
each sample was adjusted and a t=0 aliquot was taken prior to placing samples into the 
heating block.  To account for changes in signal that might occur between samples, the 
relative peak area (RPA) of desomorphine-glucuronide/IS (desomorphine-D3) was used for 
comparison, and the coefficient of variation (%CV) between time stops was calculated for 
each pH.  Degradation was present if the RPA decreased by 20% or more.  Additionally, 
the appearance of potential degradation products was monitored.  For desomorphine-
glucuronide the %CV was less than 20% for each pH evaluated and changes in RPAs over 
time were not significant, indicating that the conjugate was stable.  The RPAs of 
desomorphine were also compared to assess potential degradation.  For desomorphine the 
%CV was less than 5% for each pH and no potential degradation products were found.  
These results are summarized in Tables 4.1 and 4.2.  Although no degradation was 
observed for either desomorphine or desomorphine-glucuronide, the stability was 
evaluated in aqueous buffer rather than biological matrix. Additionally, because the main 
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purpose was to evaluate the potential for pH dependent instability during deconjugation, 
only short-term stability was evaluated (over hours). Therefore, inferences regarding the 
stability of these compounds in authentic biological matrices, which may be stored for 
extended periods, should not be made.   
Table 4.1 
Results of short-term stability of desomorphine in aqueous solution.  Mean relative peak 
area (RPA) ± SD (n=8) for all time stops. 
 
pH Average RPA %CV 
4 4.28 ± 0.05 1% 
5 4.42 ± 0.05 1% 
6 4.39 ± 0.06 1% 
7 4.43 ± 0.06 1% 
8 4.44 ± 0.02 1% 
9 4.43 ± 0.16 4% 
10 4.49 ± 0.01 2% 
 
Table 4.2 
Results of short-term stability of desomorphine-glucuronide in aqueous solution.  Mean 
relative peak area (RPA) ± SD (n=8) for all time stops. 
 
pH Average RPA %CV 
4 0.10 ± 0.02 15% 
5 0.11 ± 0.02 17% 
6 0.11 ± 0.01 8% 
7 0.10 ± 0.01 9% 
8 0.11 ± 0.01 10% 
9 0.12 ± 0.02 16% 





H. pomatia and E. coli are widely used to hydrolyze opioids, although studies have 
shown P. vulgata to have a comparatively higher affinity for morphine, though less so for 
other opioids (29, 31).  IMCSzyme™ is a genetically modified β-glucuronidase that is 
purported to be more efficient that traditional preparations.  BGTurbo™ is another 
recombinant β-glucuronidase that has been modified to increase the reaction efficiency.  
Both recombinant enzymes have been purified to reduce the need for post-hydrolysis 
cleanup.   
First, the conditions for each hydrolysis reaction were optimized to maximize 
deconjugation of the drug.  The concentration of the IS used for each reaction was adjusted 
based on the total dilution factor for each protocol so that the RPAs for each reaction 
mixture could be directly compared.  Each enzyme evaluated produced complete, or near 
complete hydrolysis (≥96%) of desomorphine-glucuronide using optimized conditions. 
Table 4.3 summarizes the optimum conditions for each system in terms of reaction time 
and percent hydrolysis.  Lacking commercially available reference material for 
desomorphine-glucuronide, the ratio of drug to enzyme was increased by diluting the 
enzyme in appropriate buffer, in order to test the limits of the enzymatic systems. 
Hydrolysis reactions were repeated (n=2) for each enzyme under more challenging 
conditions using successive 1:5 dilutions. Differences in hydrolysis efficiency were first 
discernable at dilutions of 1:25 and above. Under these conditions, P. vulgata was the 
optimum deconjugation enzyme for desomorphine-glucuronide, hydrolyzing 92% of the 
drug.  This trend is consistent with what has been observed for morphine (27, 31), though 
it should be noted that newer recombinant β-glucuronidase enzymes have not been 
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investigated until recently. Only two published studies to date have evaluated IMCSzyme™ 
(25, 34), only one of which compared it to other enzymes, and no published studies have 
evaluated BGTurbo™.  The extent of hydrolysis observed for all enzymes at all dilutions 
tested is shown in Figure 4.3. One-way Analysis of Variance (ANOVA) was used for 
statistical comparisons.  At undiluted and 1:5 dilutions, no significant differences were 
observed. Under the most challenging conditions tested (1:125 dilution of enzyme), results 
were highly significant (F(4,9)=18.5, p=0.003). 
Table 4.3 
Incubation time and extent of hydrolysis at optimized conditions for each β-glucuronidase 
evaluated (n=2). 
 
Enzyme Incubation Time (Minutes) 
% Hydrolysis 
(Mean ± SD) 
BGTurbo™ 15 100 ± 0 
IMCSzyme™ 30 96 ± 1 
E. coli 180 100 ± 0 
H. pomatia 180 97 ± 1 







Figure 4.3. Extent of hydrolysis for IMCSzyme™ (IM), BGTurbo™ (BG), E. coli (EC), H. 
pomatia (HP) and P. vulgata (PV) at undiluted, 1:5 diluted, 1:25 diluted and 1:125 diluted 
enzyme levels.  Error bars represent the standard deviation (n=2). 
 
While more prone to loss of activity with dilution, in terms of reaction time and 
sample cleanup both recombinant systems offer key advantages over traditional enzymes.  
Optimum reaction times for both IMCSzyme™ and BGTurbo™ (Table 4.3) were much 
shorter than traditional enzymes.  Additionally, the increased purity of both meant that no 
sample cleanup was necessary.  This was also evident from the total ion chromatograms 
(TICs) of each preparation, which are shown in Figure 4.4.  Samples hydrolyzed with 
IMCSzyme™ and BGTurbo™ were analyzed without sample cleanup while samples 
hydrolyzed with E. coli, H. pomatia and P. vulgata were further purified using β-gone™ 
columns prior to analysis.  These proprietary columns remove excess enzyme which can 
cause detector fouling. Prior to use, β-gone™ columns were evaluated to ensure that 
analyte (desomorphine and desomorphine-glucuronide) was not lost during the cleanup 
step. No analyte loss was observed. Examination of the TICs showed that even after 
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sample cleanup there were many extraneous compounds in the sample which could 
potentially cause interference as well shorten the life of the column. 
 
 
Figure 4.4. Total ion chromatograms (TICs) of samples hydrolyzed with IMCSzyme™, 
BGTurbo™, E. coli, H. pomatia and P. vulgata.  No sample cleanup was used with 
IMCSzyme™ and BGTurbo™.  Sample cleanup was used with E. coli, H. pomatia and P. 




The short-term degradation of desomorphine and desomorphine-glucuronide at 
elevated temperature and various pH values was investigated and no degradation of either 
desomorphine or desomorphine-glucuronide was observed.  Using optimum conditions for 
chemical and enzymatic hydrolysis, deconjugation rates of 96-100% were achieved for all 
systems tested. Although all five enzymes were as effective as chemical hydrolysis under 
optimum conditions, P. vulgata was the most efficient enzyme under challenging 
conditions.   In terms of incubation time and sample cleanliness, the recombinant enzymes 
IMCSzyme™ and BGTurbo™ were superior compared to the traditional β-glucuronidase 
enzymes.  However, all of the enzymatic approaches are considerably more expensive than 
chemical hydrolysis.  
In this first report to evaluate the stability and deconjugation efficiency of 
desomorphine-glucuronide, the following limitations should be considered.  
Desomorphine-glucuronide was generated in situ due to the absence of commercial 
reference material or authentic urine specimens from Krokodil users. As such, the 
concentration of desomorphine-glucuronide used might be considerably less than the 
concentration found in authentic blood or urine specimens from desomorphine users.  In 
an effort to differentiate deconjugation efficiencies between the different enzymatic 
systems, sub-optimal conditions were employed. Deconjugation efficiencies were 
evaluated in aqueous solution rather than biological matrix which may influence overall 
performance (24).  Finally, although both desomorphine and desomorphine-glucuronide 
were stable for up to three hours at incubation temperatures up to 60oC over a range of pHs 
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Desomorphine, a semi-synthetic opioid, is a component of the street drug Krokodil.  
Despite continued reports of Krokodil use, confirmation via toxicological testing remains 
scarce.  The lack of confirmed desomorphine reports may be in part due to the limited 
published analytical methodology capable of detecting desomorphine at forensically 
relevant concentrations.  In an effort to assist with identification efforts, a robust analytical 
method was developed and validated.  Solid phase extraction (SPE) and gas 
chromatography-mass spectrometry (GC-MS) were used to determine desomorphine in 
blood and urine using a deuterated analog as the internal standard.  Data was acquired using 
selected ion monitoring (SIM) mode.  Extraction efficiencies in blood and urine were 69% 
and 90%, respectively.  The limits of quantitation in blood and urine were 5 ng/mL and 8 
ng/mL, ten-fold lower than previously published methods. Intra- and inter-assay CVs were 
2-4% (n=3) and 3-7% (n=15), respectively. The method was fully validated in accordance 
with published guidelines for forensic use. Furthermore, it provides a means by which 
desomorphine can be identified in toxicology specimens at forensically relevant 
concentrations, without the need for derivatization. 









Quantitative Analysis of Desomorphine in Blood and Urine Using Solid Phase 
Extraction and Gas Chromatography-Mass Spectrometry 
Introduction 
Desomorphine ((5α)-17-methyl-4,5-epoxymorphinan-3-ol) is a semi-synthetic 
opioid that gained notoriety in the early 2000s when reports of its abuse began to surface. 
Although the drug originated in Siberia, its popularity in Russia and the former Soviet 
Republics (as a less expensive alternative to heroin) increased significantly (1). By the mid-
2010s, its use had spread to central European countries. Desomorphine is currently listed 
as a Schedule I drug in the United States, where reports of use have been somewhat limited 
(2). It is reported to have approximately ten-times the analgesic potency of morphine, with 
a faster onset but shorter duration of action (3).  As its name suggests, 
dihydrodesoxymorphine is structurally differentiated from morphine by the absence of the 
C6 hydroxyl group and saturation of the C7-C8 double bond (Figure 5.1).  
 
Figure 5.1. Chemical structures of morphine and desomorphine.  
 
Krokodil is synthesized from codeine using harsh reagents such as hydroiodic acid 
and red phosphorous, also used in the clandestine manufacture of methamphetamine (4).  
Although Krokodil contains a number of morphinans, desomorphine is the principal 
component (5,6).  The clandestine synthesis often leaves behind byproducts and traces of 
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the precursor chemicals, contributing to the severe dermatological side effects. The name 
of the street drug comes from the crocodile-like appearance of the skin following 
intravenous or subcutaneous injection.  The sequela of abuse, including necrotic ulcers, 
gangrene and even osteonecrosis, may necessitate the amputation of limbs (7).  At least 
one fatality involving lethal endomyocarditis has been reported following chronic use of 
the drug (8). Most published case reports originate from emergency departments and 
clinical settings, with cases originating from the Republics of Armenia (9-11) and Georgia 
(12), Germany (13), Italy (8), Poland (14), Russia (15. 16), Spain (17), the United Kingdom 
(18) and the United States (19-23).  However, to date only one published case report 
included positive toxicology findings for desomorphine (8). This might be attributed to the 
time difference between actual drug use, and the manifestation of severe dermatological 
effects. However, analytical factors must also be considered. 
Immunoassays are widely used for both clinical and forensic screening purposes. 
Enzyme linked immunosorbent assays are commonly used in forensic toxicology settings 
because these assays are amenable to a variety of biological matrices including blood, 
urine, tissue, hair, etc). Non-specific binding of compounds structurally similar to the target 
drug can be exploited to create immunoassays capable of detecting multiple drugs within 
a particular class of drug (e.g. benzodiazepines). A recent evaluation of commercially 
available ELISAs indicated highly variable cross-reactivity towards desomorphine (24). 
Cross-reactivities using commercial opiate assays ranged from <2.5% to 77%. Reliance on 
immunoassay-based screening alone may not be sufficient to detect the drug if the cross-
reactivity is not sufficiently high. For forensic purposes, immunoassay-based screening 
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results also require analytical confirmation. GC-MS is widely used for this purpose and has 
long been considered the gold standard for confirmatory drug testing (25).   
Krokodil is typically administered intravenously. Although pharmacokinetic 
studies in humans have not been reported, desomorphine is more lipophilic than morphine, 
hence its faster onset of action. While desomorphine’s half-life is unknown, it is reported 
to have a duration of action approximately half that of morphine (3). Although one 
published case report suggested detection windows of a few hours in blood and three days 
in urine, no supporting data was provided (13). Recent studies identified several 
desomorphine metabolites using human liver microsomes and recombinant cytochrome 
P450 isoforms (rCYPs) (26, 27).  Phase I metabolism includes N-demethylation, 
hydroxylation and N-oxidation. However, reference standards for these metabolites are not 
commercially available, precluding them from analysis. Therefore, forensic laboratories 
must rely upon analytical methods with sufficient sensitivity to detect the parent drug in 
both blood and urine.  
There have been very few published methods for desomorphine analysis. Five 
reports describe the identification of the drug in either water, blood, urine or seized drug 
material using GC-MS. These are summarized in Table 5.1. Of these, only one was fully 
validated for quantitative analysis in a biological matrix (28).  In this method, Alves 
utilized a QuEChERS (quick, easy, cheap, effective, rugged and safe) extraction to identify 
desomorphine in silylated blood extracts with a limit of quantitation of 103 ng/mL.  
Phenacetin, which bears no structural similarity to desomorphine was used as the internal 
standard. Although liquid-liquid extraction was reported most frequently, it is known to 
have lower extraction efficiencies for zwitterionic drugs like desomorphine.  Su used solid 
162 
 
phase dynamic extraction (SPDE) and solid phase microextraction (SPME) to isolate 
desomorphine from water and urine (29). Although a deuterated internal standard was 
employed, the method also lacked requisite sensitivity for forensic purposes, with limits of 
quantitation ranging from 250-500 ng/g.  In addition to GC-MS methodology, a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) published by Eckart, was 
capable of identifying desomorphine in plasma, serum and tissue at concentrations as low 
as 0.1 ng/mL [30].  While this method is significantly more sensitive than available GC-










GC-MS analysis of desomorphine. 
Matrix Extraction Method Derivatization Limit of Quantitation Internal Standard Reference 
urine; drug samples LLE acylation; silylation NR NR (34) 
water; urine SPME; SPDE none 
250 ng/g (SPDE);  
500 ng/g (SPME)1 
desomorphine-D3 (30) 
drug samples LLE silylation 490 ng/mL2 phenacetin (6) 
blood QuEChERS silylation 103 ng/mL2 phenacetin (28) 
urine LLE acylation NR codeine-D6 (26) 
1LOQ criteria: signal to noise ratio >10:1. 
2LOQ criteria: bias/precision ±20% and signal 5x that of a blank sample. 
LLE, liquid-liquid extraction; NR, not reported; QuEChERS, quick, easy, cheap, effective, rugged and safe; SPDE, solid phase 
dynamic extraction; SPME, solid phase microextraction. 
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Derivatization of polar compounds is sometimes necessary to improve their gas 
chromatographic properties and detectability. Desomorphine is a zwitterion like morphine, 
bearing both amine (pKa 9.69) and phenol (pKa 10.62) functional groups (27, 28). It is 
therefore no surprise that the majority of the GC-MS methods described (Table 5.1) 
utilized derivatizaton (silylation and acylation). Although derivatization reduces polarity, 
imparts volatility and can improve detectability, it can result in detector fouling and 
introduces an additional step into the analytical scheme.    
Forensically relevant concentrations in blood and urine are dose-dependent and 
greatly influenced by the tolerance of the user. In the absence of human pharmacokinetic 
studies, an assay range comparable to that of morphine is desirable. Ideally, methods 
should be capable of identifying low ng/mL concentrations of desomorphine. The purpose 
of this study was to develop a highly sensitive GC-MS method for desomorphine in blood 
and urine for forensic use, and to fully validate the method in accordance with published 
recommendations (33). 
Materials and methods 
Chemicals and reagents 
Desomorphine, and desomorphine-D3 were obtained from Cerilliant (Round Rock, 
TX, USA).  Pooled drug free urine obtained from Utak Laboratories (Valencia, CA, USA) 
was preserved with 1% sodium fluoride prior to use.  Bovine blood preserved with 1% 
sodium fluoride and 0.2% potassium oxalate was obtained from Quad Five (Ryegate, MT, 
USA).  Methanol (LCMS grade) and concentrated hydrochloric acid were obtained from 
J.T. Baker (Center Valley, MA, USA).  Ethyl acetate (HPLC grade) was obtained from 
Fisher Scientific (Fair Lawn, NJ, USA) and concentrated ammonium hydroxide was 
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obtained from Macron Fine Chemicals (Center Valley, MA, USA).  Dichloromethane and 
isopropyl alcohol were obtained from Mallinckrodt Chemicals (St. Louis, MO, USA).  
Acetonitrile (LCMS grade) was obtained from Thermo Fisher Scientific (Radenor, PA, 
USA).  N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was obtained from Sigma 
Aldrich (St. Louis, MO, USA).  Deionized (DI) water was generated from a Direct-Q 3 
(UV) system (Millipore, Billerica, MA, USA).  PolyChrom Clin II 3cc (35 mg) solid phase 
extraction (SPE) columns were obtained from SPEware (Baldwin, CA, USA). 
Working standards of desomorphine were prepared in acetonitrile at 50, 5 and 0.5 
µg/mL for fortification in urine, and 25, 2.5 and 0.25 µg/mL for fortification in blood.  The 
internal standard solution was prepared in acetonitrile at 0.5 µg/mL for urine and 0.25 
µg/mL for blood.  Elution solvents containing concentrated ammonium hydroxide were 
prepared daily.  
Instrumentation 
SPE was performed using a Supelco Visiprep vacuum manifold (Supelco, 
Bellefonte, PA, USA) and extracts were evaporated to dryness under nitrogen using a 
Turbovap LV concentration workstation (Biotage, Charlotte, NC, USA).  An Agilent 
5975B VL MSD was coupled to an Agilent 6890N GC oven equipped with an Agilent 
7683B autosampler (Agilent Technologies, Santa Clara, CA, USA).  Separation was 
achieved using an Agilent DB-5 capillary column (30 m x 0.25 mm, 0.5 µm film thickness).  
The optimized GC-MS conditions were as follows: injection mode: split (2:1); injector port 
temperature: 250 °C; carrier gas: helium with flow rate 1.3 mL/min; oven program: 160 °C 
with initial hold time 0.5 min, 30 °C/min to 290 °C with a final hold time of 7.67 min; ion 
source temperature: 230 °C.  Preliminary mass spectral data were obtained in full scan 
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mode from m/z 50 to 600 amu.  Selective ion monitoring (SIM) mode was used for 
quantitation. The monitored ions for desomorphine were 271.1, 256.1, and 228.1 and for 
desomorphine-D3 were 274.1, 259.1, and 231.1.  Quantitation ions are shown in bold.  The 
dwell time for each ion was 25 ms and the total run time was 12.5 minutes.  All data was 
analyzed using Agilent ChemStation software. 
Urine extraction 
Internal standard solution (20 µL) was added to 1 mL of urine to achieve a final 
concentration of 10 ng/mL.  Urine was diluted with 1 mL of 0.1 M hydrochloric acid and 
transferred to PolyChrom Clin II SPE columns (3 cc, 35 mg).  Samples were allowed to 
flow through under gravity or sufficient vacuum to maintain constant flow (approximately 
1 mL/min).  Columns were successively rinsed with 1 mL of deionized water, 0.1 M 
hydrochloric acid, methanol and ethyl acetate.  After drying columns for five minutes at 
full vacuum, desomorphine was eluted using two 0.5 mL aliquots of elution solvent (4% 
ammonium hydroxide in ethyl acetate).  Extracts were evaporated to dryness under 
nitrogen at 50 °C then reconstituted in 30 µL of ethyl acetate.  An aliquot of 1 µL was 
injected onto the GC-MS for analysis. 
Blood extraction 
Internal standard solution (20 µg/mL) was added to 0.5 mL of whole blood to 
achieve a final concentration of 10 ng/mL.  A protein precipitation was performed with the 
addition of 2 mL of ice-cold acetonitrile while vortex mixing, followed by centrifugation 
at 4000 rpm for 10 minutes.  The supernatant was decanted and diluted with 1 mL of 0.1 
M hydrochloric acid.  Samples were transferred to SPE columns (3 cc, 35 mg) and extracted 
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as described for urine.  Extracts were reconstituted in 30 µL of ethyl acetate and 1 µL was 
injected onto the GC-MS. 
Method development 
To evaluate the need for derivatization, desomorphine was silylated with MSTFA.  
On-column derivatization was achieved by adding 10 µL of 0.1 mg/mL desomorphine 
standard to 10 µL of MSTFA. Data was acquired in full scan using a modified oven 
temperature programming: 80 °C (0.5 min), 30 °C/min to 290 °C. All other conditions were 
as described earlier. Ions were selected for SIM acquisition based on abundance and 
specificity for desomorphine.   
To optimize the extraction efficiency, samples of urine (1mL) were fortified with 
250 ng/mL of desomorphine and extracted as described earlier.  The solvents evaluated 
were 2% ammonium hydroxide in 80:20 dichloromethane/isopropanol, 4% ammonium 
hydroxide in 80:20 dichloromethane/isopropanol, 2% ammonium hydroxide in ethyl 
acetate and 4% ammonium hydroxide in ethyl acetate.  Additionally, samples of whole 
blood (0.5 and 1 mL) were fortified with 250 ng/mL of desomorphine and extracted as 
described in section 2.4.  
Method validation 
The method was validated in accordance with the Scientific Working Group for 
Forensic Toxicology recommendations (33).  Performance was evaluated in terms of 
extraction efficiency, limit of detection (LOD), limit of quantification (LOQ), bias, 
precision, calibration model, interferences, and carryover. The extraction efficiency in 
blood and urine (250 ng/mL) was calculated by comparing extracted and non-extracted 
samples.  Matrix containing internal standard (10 ng/mL) was extracted with and without 
168 
 
desomorphine.  Samples extracted without desomorphine were fortified with an equivalent 
amount post-extraction, but prior to evaporation and reconstitution.  Recovery of the 
analyte was calculated by comparing the relative peak area (drug/IS) of samples extracted 
in the presence of desomorphine (n=3) with those fortified post-extraction (n=3). 
The limits of detection and quantitation were determined empirically using drug-
free matrix fortified with desomorphine.  Three sources of drug-free matrix were analyzed 
in duplicate over three independent runs.  The LOD was defined as the lowest concentration 
of drug that produced a reportable result (relative retention time ± 2% of the standard, ion 
ratios ±5% and a signal-to-noise ratio of 3:1 or greater). The LOQ was defined as the lowest 
concentration to produce a reportable result (as described above) with a signal-to-noise 
ratio of 10:1 or more, and a quantitative result within 20% of the expected value. 
Calibration models were evaluated statistically using the coefficient of determination (R2), 
f-tests and standardized residual plots.  A total of nine non-zero calibrators were used in 
blood (5, 10, 25, 50, 100, 250, 500, 750 and 1000 ng/mL) and urine (8, 10, 25, 50, 100, 
250, 500, 750 and 1000 ng/mL). 
Bias and precision were evaluated at three concentrations (low, medium and high) 
in urine (30, 400 and 800 ng/mL) and blood (15, 400 and 800 ng/mL) in triplicate over five 
runs.  Within-run precision was calculated for each run at each concentration (n=3).  
Between-run precision was calculated over all five runs for all three concentrations (n=15).  
Bias was calculated from the following equation: 
𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛−𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 100.  The threshold for acceptable bias and 
precision was ± 20%. 
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Interferences from the matrix, isotopically labeled internal standard, common drugs 
and structurally related compounds were also evaluated.  Ion contributions from the stable 
isotope internal standard were evaluated by fortifying drug-free matrix with internal 
standard (10 ng/mL) and monitoring the signal of desomorphine.  Matrix interferences 
were examined using ten drug-free matrix samples from independent sources without 
internal standard (n=2).  Forty-two common drugs and twenty-four opioids were selected 
for drug interference, giving a total of sixty-six compounds.  These are summarized in 
Table 5.2.  Interferences were evaluated using negative and positive controls in blood and 
urine.  A 1:1 ratio, 10-fold excess and 100-fold excess of interferent (relative to 
desomorphine) was used for interference testing.  The negative control contained internal 
standard (10 ng/mL) and 1000 ng/mL of interferent.  Positive controls were prepared with 
internal standard (10 ng/mL), interferent (1000 ng/mL) and desomorphine at 1000, 100 and 
10 ng/mL, respectively. 
Carryover was assessed using by injecting a blank matrix (no drug or IS) or 
negative control (IS only) immediately following the high control (1000 ng/mL).  
Carryover was deemed to be present if the blank matrix or negative control produced a 










Summary of compounds included in interference study.  Compounds were separated into 
two groups: common drugs (n=42) and opioids (n=24). 
 
Common Drugs Opioids 
7-aminoclonazepam, 7-aminoflunitrazepam, 
acetaminophen, alprazolam, amitriptyline, 
amobarbital, amphetamine, butalbital, caffeine, 
carbamazepine, carisoprodol, clonazepam, cocaine, 
cotinine, cyclobenzaprine, dextromethorphan, 
diazepam, fluoxetine, flurazepam, gabapentin, 
ketamine, MDMA, meprobamate, methaqualone, 
11-nor-9-carboxy-Δ9-THC, nordiazepam, 
oxazepam, pentobarbital, phencyclidine, 
phenobarbital, phenytoin, pseudoephedrine, 
salicylic acid, secobarbital, sertraline, temazepam, 













propoxyphene, thebaine, tramadol 
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol. 
Results and discussion 
Method development 
Total ion chromatograms and mass spectra for desomorphine and its trimethylsilyl 
derivative are depicted in Figure 5.2. The mass spectrum of the underivatized drug is 
characterized by an intense molecular ion (m/z 271) with subsequent loss of a methyl group 
[M-15]+ (m/z 256), hydroxyl [M-17]+ (m/z 254), CH3N [M-29]
+ (m/z 242), C2H5N [M-43]
+ 
(m/z 228) and C3H7N [M-57]
+ (m/z 214) representing complete cleavage of the nitrogen 
ring. Since the phenanthrene-type opioids fragment in a predictable fashion, the silylated 
derivative also produced a mass spectrum with prominent M-15, 29, 43 and 57 losses, in 
addition to the loss of the trimethylsilyl (TMS) group [M-72]+. Full scan acquisition 
confirmed that the derivatization of desomorphine was complete (100% yield). Although 
the abundance of fragment ions improved with derivatization, chromatographic and mass 
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spectral properties were sufficient to proceed with method development without MSTFA. 
This approach decreases analysis time, detector fouling and routine maintenance. The 
quantification ion was the molecular ion, m/z 271 (also the base peak) and the two qualifier 
ions selected were m/z 228 and 256. Due to the ion ratios for m/z 228 and 256 being 20% 
and 18% respectively, a 5% absolute abundance threshold was established, instead of ± 
20% relative abundance, which is often used (33).  
 
Figure 5.2. Total ion chromatogram (TIC) and mass spectrum of desomorphine (A and B), 
and of silylated desomorphine (C and D). The retention time of desomorphine was 5.4 
minutes and of desomorphine-TMS was 7.9 minutes.  Fragmentation of qualifier ions are 
shown with arrows I (m/z 256) and II (m/z 228). 
 
Optimum extraction efficiencies in blood and urine were achieved using ethyl 
acetate containing 4% concentrated ammonium hydroxide. Figure 5.3 depicts a box plot 
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of desomorphine peak areas obtained using all four elution solvents (measured in triplicate) 
and Figure 5.4 shows representative extracted ion chromatograms (EICs) for each elution 
solvent and the average S/N ratios in urine.  The improved extraction efficiency using 
highly basified ethyl acetate is not surprising given the high pKa of the tertiary amine 
(9.69).  Ethyl acetate was a far superior elution solvent to dichloromethane/isopropyl 
alcohol (80/20), and increasing the ammonium hydroxide concentration from 2 to 4% more 
than doubled the desomorphine peak area. Although absolute recovery was improved using 
ethyl acetate, all elution solvents evaluated were free from coextractive interferences 
(Figure 5.4).  Sufficient sensitivity was achieved using a reduced volume of blood, so 
method validation was performed using 1 mL urine and 0.5 mL blood.  
 
Figure 5.3. Box plots comparing the desomorphine peak area from urine (250 ng/mL) 
extracted with different elution solvents (n=3). Elution solvents: 2% ammonium hydroxide 
in 80:20 dichloromethane/isopropanol (2% DCM/IPA), 4% ammonium hydroxide in 80:20 
dichloromethane/isopropanol (4% DCM/IPA), 2% ammonium hydroxide in ethyl acetate 




Figure 5.4. Representative EICs (m/z 271) of desomorphine from urine using different 
elution solvents. The average signal-to-noise (S/N) for each solvent (n=3) is shown in 
parentheses.  Elution solvents: 2% ammonium hydroxide in 80:20 
dichloromethane/isopropanol (2% DCM/IPA), 4% ammonium hydroxide in 80:20 
dichloromethane/isopropanol (4% DCM/IPA), 2% ammonium hydroxide in ethyl acetate 
(2% EA) and 4% ammonium hydroxide in ethyl acetate (4% EA). 
 
Method validation 
Extraction efficiencies were 90 ± 1% in urine (n=3) and 69 ± 2% in blood (n=3).  
The limits of detection and quantitation were 5 ng/mL in blood (n=18) and 8 ng/mL in 
urine (n=18).  Concentrations as low as 1 ng/mL were evaluated, and while the S/N ratios 
exceeded 3 at all concentrations, the secondary acceptance criteria (ion ratios ±5% 
absolute) was not met at any concentration less than 5 ng/mL for blood or 8 ng/mL for 
urine. Residual plot analysis identified a weighted (1/x) quadratic as the preferred 
calibration model.  However, using the f-test to determine the value of the addition of the 
quadratic term showed no significant difference from a linear model.  Additionally, in 
practice a weighted (1/x) linear calibration model gave the best quantitative performance 
at low concentration, while maintaining acceptable bias and precision at the high end of 
the calibration range.  The R2 values were above 0.99 for both matrices.  
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Bias, precision and S/N ratios are summarized in Table 5.3 and EICs at the LOQ 
are shown in Figure 5.5.  Bias and precision were evaluated at three concentrations (low, 
medium and high) in triplicate over five days.  Intra-assay CVs were 2-3% in blood and 2-
4% in urine.  Inter-assay CVs were 3-5% in blood and 3-7% in urine.  Bias and precision 
were within acceptable ranges (± 20%) at all concentrations tested and are summarized in 
Tables 5.4 and 5.5. 
Table 5.3 
Limits of detection and quantitation for desomorphine in blood and urine using GC-MS.  
The mean, standard deviation (SD), signal-to-noise ratio (S/N), bias and covariance (CV) 








Mean ± SD 
(ng/mL) 
n=18 
S/N Bias CV 
blood 5 5 4.42 ± 0.25 70:1 -12% 6% 









Precision and bias (n=15) for desomorphine in blood at low (15 ng/mL), medium (400 










15 2% 5% 1% 
400 3% 3% 5% 
800 3% 3% -3% 
 
Table 5.5 
Precision and bias (n=15) for desomorphine in urine at low (30 ng/mL), medium (400 










30 4% 7% 1% 
400 2% 3% 9% 
800 2% 3% 0% 
 
Interferences (matrix, isotopically labeled internal standard and other drugs) were 
systematically evaluated.  For both blood and urine, ten independent drug-free sources 
were analyzed. No quantitative or qualitative interferences were observed using either 
matrix, and no qualitative or quantitative inferences were observed from the deuterated 
analog.  Sixty-six drugs, including twenty-four opioids were evaluated for potential 
interferences (Table 4.2).  No quantitative inferences were observed for any of the 
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compounds.  However, when present at a 100-fold higher concentration than desomorphine 
in blood, levorphanol produced a qualitative interference (m/z 228 qualifier ion).  The same 
interference was observed for levorphanol at 10- and 100-fold concentrations in urine. 
Although bias and precision were still within acceptable ranges, this does highlight the 
potential for levorphanol to interfere qualitatively. Although levorphanol is not widely 
used, its d-isomer (dextrorphan) is a metabolite of dextromethorphan.  GC-MS cannot 
differentiate between these d and l isomers. Therefore, desomorphine might not be 
reportable in the presence of large excesses of either of these substances. Carryover was 
evaluated in both blank matrix and negative control samples.  No carryover was observed 
using methanol as a wash solvent with fifteen post-injection washes. 
Conclusions 
Opioid abuse in the United States and elsewhere has reached unprecedented levels. 
Forensic toxicology laboratories must have at their disposal analytical methods to detect a 
wide-range of substances. The prevalence of Krokodil use is difficult to estimate but it 
continues to be self-reported by drug users seeking medical treatment. The absence of 
sufficiently sensitive analytical methodology may in part explain why desomorphine is 
typically not reported in published case reports.  
In this report, a validated method for the quantitative analysis of desomorphine in 
blood and urine is described.  Using small sample volumes, solid phase extraction and GC-
MS was used to identify desomorphine at low ng/mL concentrations without the need for 
derivatization. Analytical performance greatly exceeded those of earlier studies and the 
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Desomorphine is a primary component of the drug Krokodil.  While reports of 
Krokodil use continue to appear in the literature, analytically confirmed cases remain quite 
scarce.  This might be attributed to trends in geographical use and limited published 
analytical methodology to detect its use.  A sensitive analytical method to detect 
desomorphine was developed and validated to assist with identification efforts.  Solid phase 
extraction (SPE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
were used to quantitatively identify desomorphine in urine.  An isotopically labelled analog 
was used as the internal standard.  Assay performance was evaluated in accordance with 
published guidelines. The extraction efficiency for desomorphine in urine was 90% and 
limits of detection and quantitation were 0.5 ng/mL. The calibration range of the assay was 
0.5 to 500 ng/mL.   Bias ranged from -1-2% (n=15) and the intra- and inter-assay CVs were 
2-3% (n=3) and 3-6% (n=15), respectively.  Ion suppression was -20% and -10% at low 
and high concentrations, respectively.  Interferences were assessed using common drugs, 
including twenty-four opioids and structurally related compounds. Using this approach, the 
quantitative analysis of desomorphine in urine is described at forensically relevant 
concentrations. 











Desomorphine ((5α,6α)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3-ol) is a 
semi-synthetic opioid that was first synthesized in the early 1930s (1).  As its name 
suggests, this 4,5-epoxymorphinan can be structurally differentiated from morphine by the 
absence of a hydroxyl group (C6) and a saturated bond (C7-C8) (Figure 6.1).   
Desomorphine has a faster onset of action compared to morphine due to its increased 
lipophilicity, but its duration of action is observed to be approximately half that of 
morphine (2).  From 1940 to 1951 desomorphine was used therapeutically in Switzerland 
under the trade name Permonid (3).  Notably, small scale production continued until 1981 
for use by a single patient.  At the 1961 United Nations Single Convention on Narcotic 
Drugs, attended by over seventy countries, desomorphine was placed into the most 
restrictive category (4).  At present, the drug is controlled in many countries including 
Australia, Brazil, the United Kingdom, Austria and Germany (5).  In the United States, 




Figure 6.1. Chemical structures of desomorphine (dihydrodesoxymorphine) and morphine.  
 
In 2003, desomorphine emerged as a drug of abuse in Siberia and Russia (3).  Using 
harsh chemicals, such as red phosphorous and hydroiodic acid, codeine is converted to 
desomorphine along with other morphinans to produce Krokodil (7-9).  The drug is 
typically administered intravenously as a substitute for heroin.  Precursor chemicals that 
remain following clandestine synthesis can cause severe dermatological side effects.  
Complications associated with Krokodil use include necrotic ulcers, gangrene and 
osteonecrosis, which may necessitate invasive surgeries or even amputation of limbs (10).   
In the years following its first appearance, reports of Krokodil use spread from 
Siberia and Russia through neighboring countries to central Europe and the United States.  
Despite anecdotal evidence suggesting that at one time there were approximately 100,000 
people using Krokodil in Russia alone (7), analytically confirmed cases were not being 
reported in the literature.  In contrast, numerous clinical case reports were described from 
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multiple countries, including Russia (11, 12), Republics of Georgia (13) and Armenia (14-
16), Germany (17), Italy (18), Spain (19), Poland (20) and the United States (21-25).  Most 
of these reports originate from drug users seeking medical attention for the complications 
of Krokodil use, although three involved fatalities (17, 18, 22).  To date only one case has 
been analytically confirmed, with desomorphine identified by gas chromatography-mass 
spectrometry (GC-MS) in the urine of a decedent at a concentration of 270 ng/mL (18). 
The lack of analytically confirmed cases makes it difficult to assess the true 
prevalence of Krokodil use.  There is no published half-life for desomorphine and the only 
report of its window of detection (a few hours in blood and three days in urine) was not 
accompanied by any supporting data (17).  Pharmacokinetic studies in humans are 
generally lacking.  Richter was the first to investigate desomorphine metabolism using 
human liver microsomes (26, 27).  Phase I metabolism pathways include N-demethylation, 
hydroxylation and N-oxidation, while Phase II metabolism includes conjugation with 
glucuronic acid and sulfates. Studies using recombinant cytochrome P450 isoenzymes 
(rCYPs) identified eight phase I metabolites (nordesomorphine, desomorphine-N-oxide, 
five hydroxydesomorphine isomers and norhydroxydesomorphine) that were produced by 
seven rCYPs (CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6 and 
CYP3A4) (27).  An investigation using recombinant uridine 5'-diphospho-
glucuronosyltransferase isoenzymes (rUGTs) suggested that desomorphine-glucuronide 
was formed by nine UGTs, including UGT1A1, UGT1A3, UGT1A8, UGT1A9, 
UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 (27). Unfortunately, reference 
materials for desomorphine metabolites are not commercially available, precluding 
quantitative identification in forensic investigations.  Despite the absence of 
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pharmacokinetic studies, it is reasonable to expect that analytical methods for forensic 
toxicology purposes should have comparable sensitivity to those of morphine. 
Enzyme-linked immunosorbent assays (ELISAs) are commonly used for 
toxicological screening purposes because they are compatible with multiple biological 
matrices.  However, immunoassay-based screening is typically directed towards one target 
analyte. Although antibody reagents with poor to moderate specificity can be exploited for 
the purposes of identifying a class of related compounds, the extent to which this is possible 
depends on the cross-reactivity.  An evaluation of commercially available opioid ELISAs 
showed that cross-reactivities towards desomorphine ranged from <2.5% to 77% (28).  
Should an immunoassay with low cross-reactivity be used, there is an elevated risk that the 
drug will go undetected. 
There are very few published methods that describe the quantitative analysis of 
desomorphine in biological matrices, and some lack the sensitivity necessary to be effective 
in toxicological investigations. Su (29) and Alves (30) utilized GC-MS to identify 
desomorphine in urine and blood with limits of quantitation of 250 ng/g and 103 ng/mL, 
respectively. We recently reported a more sensitive GC-MS assay, with limits of 
quantitation of 5 and 8 ng/mL in blood and urine (31). Liquid chromatography-mass 
spectrometry-based techniques are becoming increasingly widespread in toxicology 
laboratories for confirmatory testing.  Improved sensitivity and versatility with respect to 
polar compounds and metabolites is a distinct advantage over traditional GC-MS 
approaches.  Savchuck described LC with ultraviolet (UV) detection for the qualitative 
identification of desomorphine in urine and seized drug samples (32). Alves used LC with 
diode array detection (DAD) in seized drugs with a limit of quantitation of 490 ng/mL (8) 
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and Soares described a qualitative assay using both DAD and high-resolution mass 
spectrometry (HRMS) (9). Richter also used HRMS (Orbitrap™) to identify desomorphine 
and metabolites qualitatively in urine (26).  Using LC-MS/MS Eckart described a 
quantitative assay to identify desomorphine in serum, plasma and tissue (33).  These 
methods, including the internal standard (IS) and limits of quantitation (LOQ) are 
summarized in Table 6.1.  Validated methods capable of detecting desomorphine in urine 
at forensically relevant concentrations have not been described to date. The purpose of this 
study was to isolate desomorphine from urine with high extraction efficiency, quantify the 



















LOQ Detector Reference 
urine; drug 
samples 
3 mL LLE NR C18 NR UV (32) 
serum; plasma; 
tissue 








urine 2 mL LLE codeine-D6 phenyl-hexyl NR Orbitrap™ (26) 










Materials and methods 
Reagents and equipment 
Desomorphine and desomorphine-D3 (IS) were purchased from Cerilliant (Round 
Rock, TX, USA).  Pooled drug free urine from Utak Laboratories (Valencia, CA, USA) 
was preserved with 1% sodium fluoride before use.  Deionized (DI) water was generated 
using a Direct-Q 3 (UV) system (Millipore, Billerica, MA, USA) and PolyChrom Clin II 
3cc (35 mg) solid phase extraction (SPE) columns were purchased from SPEware 
(Baldwin, CA, USA).  Methanol (LCMS grade) and concentrated hydrochloric acid were 
from J.T. Baker (Center Valley, MA, USA).  Ethyl acetate (HPLC grade) was purchased 
from Fisher Scientific (Fair Lawn, NJ, USA), concentrated ammonium hydroxide was from 
Macron Fine Chemicals (Center Valley, MA, USA), acetonitrile (LCMS grade) was from 
Thermo Fisher Scientific (Waltham, MA, USA) and formic acid (>95%) was from Sigma 
Aldrich (St. Louis, MO, USA).   Desomorphine working standards were prepared in 
acetonitrile at 25, 2.5 and 0.25 µg/mL for fortification in urine and the internal standard 
solution was prepared at 0.25 µg/mL in acetonitrile.  The elution solvent (prepared daily) 
consisted of 4% concentrated ammonium hydroxide in ethyl acetate.  Samples were 
extracted using SPE using a Supelco Visiprep vacuum manifold (Supelco, Bellefonte, PA, 
USA) and extracts were evaporated under nitrogen using a Turbovap LV concentration 
workstation (Biotage, Charlotte, NC, USA).  
Solid phase extraction 
Urine (0.5 mL) was fortified with 50 µL of IS solution (0.25 µg/mL).  An aliquot 
of 1 mL of 0.1 M hydrochloric acid was added to the sample before transferring it to the 
SPE column.  Samples were allowed to flow under gravity, or when necessary, sufficient 
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vacuum to keep a constant flow of approximately 1 mL/min.  Columns were washed 
(successively) with 1 mL of DI water, 0.1 M hydrochloric acid, methanol and ethyl acetate.  
After drying under full vacuum for 5 minutes, desomorphine was eluted using two 0.5 mL 
aliquots of elution solvent.  Extracts were evaporated under nitrogen at 50°C before being 
reconstituted in 30 µL of 92:8 (A:B) mobile phase (described below).  An aliquot of 2 µL 
was injected onto the LC-MS/MS for analysis. 
LC-MS/MS analysis 
An Agilent Technologies 6470 triple quadrupole LC-MS/MS equipped with an 
Agilent 1290 Infinity II autosampler was used to analyze samples (Agilent Technologies, 
Santa Clara, CA, USA).  Agilent MassHunter software was used for acquisition and data 
analysis.  Nitrogen was generated using a Genius 3040 nitrogen generator (Peak Scientific, 
Billerica, MA, USA). Separation was achieved using an Agilent Poroshell 120 EC-C18 
column (2.1 x 100 mm, 2.7 µm particle size) with a matching guard column kept in a 
thermostatically controlled column compartment (35°C).  The mobile phase consisted of 
0.1% formic acid in deionized water (A) and 0.1% formic acid in acetonitrile (B).  The 
gradient elution profile was as follows: 8% B, flow rate 0.3 mL/min (0-2 min); 20% B, 0.3 
mL/min (2-6 min); 90% B, 0.4 mL/min (6-6.5 min); 8% B, 0.4 mL/min (6.5-7 min).  Data 
was acquired between 2 and 6 minutes.  The LC-MS/MS was equipped with an electrospray 
ionization (ESI) source that was operated in positive mode.  The optimized source 
conditions were as follows: drying gas temperature, 350°C; drying gas flow rate, 8 L/min; 
nebulizer, 20 psi; sheath gas temperature, 400°C; sheath gas flow rate, 10 L/min; capillary 
voltage, 4000 V.  Data was acquired using multiple reaction monitoring (MRM).  Precursor 
and product ions, collision energies, and fragmentor voltages for desomorphine and 
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desomorphine-D3 are detailed in Table 6.2.  The dwell time was 100 ms and the cell 
accelerator voltage was 7 V. 
Table 6.2 
Transition ions (m/z), fragmentor voltage and collision energies for desomorphine.  












195 (76%) 138 33 
167 (100%) 138 41 




195 (75%) 148 33 
167 (100%) 148 41 
152 (87%) 148 60 
 
Assay performance 
The method was validated in accordance with published guidelines from the 
Scientific Working Group on Toxicology (SWGTOX) (34).  Extraction efficiency in urine 
was determined by comparison of extracted and non-extracted samples at 250 ng/mL as 
described earlier (31).  The limits of detection and quantitation (LOD and LOQ) were 
established using drug-free urine fortified with desomorphine and IS. Three independent 
sources of drug-free matrix were analyzed in duplicate over three days.  The LOD was the 
lowest concentration of drug to produce a signal-to-noise ratio (S/N) of 3:1 or greater, 
retention time ± 2% of the control and relative ion ratios ± 20%.  The LOQ was defined as 
the lowest concentration of drug to produce a quantitative value within 20% of the expected 
value, a signal-to-noise (S/N) ratio of 10:1 or greater, retention time ± 2% of the control, 
ion ratios within ±20%, and precision and bias within 20%. 
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Bias and precision were evaluated in urine (2, 250 and 450 ng/mL) using three 
samples of pooled fortified matrix over five runs.  Intra- and inter- assay precision was 
determined for each concentration using the one-way analysis of variation (ANOVA) 
approach (34).  Bias was evaluated simultaneously with precision and tolerance for both 
was 20%.  The calibration model was established using five independent runs using ten 
non-zero calibrators (0.5, 1, 2, 5, 25, 75, 150, 250, 350 and 500 ng/mL).  The optimum 
calibration model was established using residual plot analysis. Significance testing and the 
coefficient of determination (R2) were also considered.    
Interferences from the isotopically labeled IS, the biological matrix and other drugs 
were also evaluated.  Ion contributions from the IS were evaluated by fortifying drug-free 
urine with internal standard (25 ng/mL) and matrix interferences were evaluated in 
duplicate using ten independently sourced drug-free urine samples extracted in the absence 
of IS.  Drug interferences were evaluated using a total of sixty-six analytes (Table 6.3).  
Both negative and positive controls were used.  The negative control consisted of urine 
fortified with internal standard (25 ng/mL) and interferent (500 ng/mL).  Positive controls 
contained internal standard (25 ng/mL) and desomorphine (5, 50 or 500 ng/mL) in the 














7-aminoclonazepam, 7-aminoflunitrazepam, acetaminophen, alprazolam, 
amitriptyline, amphetamine, amobarbital, butalbital, caffeine, carbamazepine, 
carisoprodol, clonazepam, cocaine, cotinine, cyclobenzaprine, 
dextromethorphan, diazepam, fluoxetine, flurazepam, gabapentin, ketamine, 
MDMA, meprobamate, methaqualone, 11-nor-9-carboxy-Δ9-THC, 
nordiazepam, oxazepam, pentobarbital, phencyclidine, phenobarbital, 
phenytoin, pseudoephedrine, salicylic acid, secobarbital, sertraline, 
temazepam, Δ9-THC, trazodone, valproic acid, zaleplon, zolpidem, zopiclone 
Opioids 
6-acetylcodeine, 6-acetylmorphine, buprenorphine, codeine, dihydrocodeine, 
fentanyl, heroin, hydrocodone, hydromorphone, levorphanol, meperidine, 
methadone, morphine, nalorphine, norcodeine, norhydrocodone, 
normeperidine, normorphine, noroxycodone, oxycodone, oxymorphone, 
propoxyphene, thebaine, tramadol 
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol. 
 
Matrix effects were examined at low and high concentrations (20 and 400 ng/mL).  
Ten drug-free urine samples from independent sources were extracted in the absence of 
desomorphine and were fortified with drug post-extraction.  Ion suppression or 
enhancement was calculated by comparing the mean peak areas of desomorphine in urine 
with the equivalent concentration in mobile phase.  Carryover was assessed using both 
blank matrix and negative controls analyzed immediately following the highest calibrator 
(500 ng/mL).  Carryover was present if a blank or negative control produced a detectable 
result (above the LOD).  Processed sample stability was evaluated at 24 hours after storage 
in the autosampler (4°C) at three concentrations (2, 250 and 400 ng/mL) in triplicate.  
Quantitative results and absolute response (peak areas) at 0 and 24 hours were compared.  
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Results and discussion 
The SPE was previously optimized to maximize the extraction efficiency (31).  An 
elevated concentration of ammonium hydroxide was necessary due to the high pKa of the 
basic nitrogen on desomorphine (pKa 9.69) (35). Using this approach, extraction 
efficiencies of 90 ± 1% (n=3) were achieved for this zwitterionic drug (31).  The limits of 
detection and quantitation were 0.5 ng/mL (n=18), the lowest concentration tested.  The 
associated bias, precision and S/N ratios are summarized in Table 6.4 and an extracted ion 
chromatogram at the LOQ is shown in Figure 6.2.  Ions for MRM were selected based 
upon abundance and specificity.  The quantification ion for desomorphine was m/z 167 and 
qualifier ions were m/z 195 (79%) and m/z 152 (86%). Relative ion abundances are shown 
in parentheses. Bias and precision were calculated at three concentrations (2, 250 and 400 
ng/mL) extracted in triplicate over five days using one-way ANOVA.  Intra-assay CVs 
were 2-3% and inter-assay CVs were 3-6%.  The bias ranged from -1-2% (Table 6.5).   
Table 6.4 
















0.5 0.5 0.52 ± 0.06 
58-594:1 
(238:1) 





Figure 6.2. Extracted ion chromatograms of desomorphine in urine at the LOQ (0.5 
ng/mL). 
Table 6.5 
Precision and bias (n=15) for desomorphine in urine at low (2 ng/mL), medium (250 










2 2% 6% -1% 
250 3% 3% 1% 
400 2% 3% 2% 
 
A weighted (1/x) quadratic calibration model was selected as the calibration model 
for quantitative analyses (0.5 – 500 ng/mL).  Although R2 values were greater than 0.99 
for all calibration models evaluated, standardized residual plots were optimal using a 
quadratic model.  Although an F-test indicated there was a significant difference between 
unweighted and weighted (1/x) quadratic models, the weighted (1/x) quadratic calibration 
model produced the highest R2 values and minimized bias at both the low and high ends of 
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the calibration. Although the only published report involving desomorphine was within the 
calibration range of the assay, urinary drug concentrations in authentic case samples could 
exceed this range. In those circumstances dilution integrity would need to be established. 
Interferences from matrix, isotopically labeled IS and other drugs were examined.  
Ten independent drug-free urine samples were analyzed (n=2) and no inferences were 
observed.  The deuterated analog also caused no inference.  Sixty-six drugs, including 
twenty-four opioids were evaluated for potential interferences (Table 6.3).  Qualitative and 
quantitative interferences were evaluated in the presence of 1-, 10- and 100-fold excess of 
the interfering substance. No qualitative or quantitative inference were observed for any of 
the drugs tested.  Extracted ion chromatograms (EICs) of desomorphine and the closest 
eluting opioids are shown in Figure 6.3.  While baseline separation was not achieved 
between desomorphine (m/z 272, MH+) and norhydrocodone (m/z 286, MH+), mass 
selectivity and the use of isotopically labelled internal standard prevented any interference, 




Figure 6.3. Extracted ion chromatogram depicting desomorphine (m/z 272) and closely 
eluting opioids (noroxycodone, m/z 302; oxycodone, m/z 316; norhydrocodone, m/z 286; 
6-acetylmorphine, m/z 328; hydrocodone, m/z 300) at a 10-fold excess concentration 
(relative to desomorphine). Data was acquired in full scan in order to identify the elution 
order. 
 
The potential for ion suppression or enhancement was investigated using ten drug-
free sources of urine with desomorphine added post-extraction at low and high 
concentrations (20 and 400 ng/mL).  The average ion suppression was -20% at 20 ng/mL 
(n=10) and -10% at 400 ng/mL (n=10), with CVs of 16% and 7% respectively (Table 6.6).  
In addition to matrix intereferences, the use of an isotopically labelled internal standard 





























20 -20 ± 13% 16% 22.16 ± 0.54 11% 2% 
400 -10 ± 7% 7% 402.29 ± 3.97 1% 1% 
 
Carryover was evaluated using blank matrix and negative control samples after 
injection of the highest calibrator (500 ng/mL).  No carryover was observed.  Processed 
sample stability was evaluated following 24 hours storage in the autosampler tray (4°C).  
Three concentrations (2, 250 and 400 ng/mL) were analyzed in triplicate at 0 and 24 hours 
and the average response for each concentration compared.  At 24 hours, absolute peak 
areas for desomorphine and the IS were within 2-3% of the original response, and bias was 
within 0.5-1.2% for all concentrations tested.  
Conclusions 
Drug users seeking medical treatment continue to self-report Krokodil use, but its 
prevalence is difficult to estimate due to a lack of analytically confirmed cases.  No 
authentic specimens from Krokodil users were available for this study.  Although abuse of 
the drug appears to be highly geographical, its analgesic potency is approximately ten-fold 
greater than morphine and intravenous use has been associated with severe and life-
threatening consequences. We describe the use of solid phase extraction to isolate 
desomorphine from urine with high analytical recovery (90%). Using LC-MS/MS, 
201 
 
desomorphine was identified at sub-ng/mL concentrations, facilitating identification of the 
drug within the range of forensic interest.  
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The semi-synthetic opioid desomorphine is a primary component of Krokodil, the 
use of which has been associated with severe dermatological side effects.   Confirmatory 
toxicological test results for desomorphine are scarce despite reports associated with its 
use, which may in part be attributed to delays seeking medical treatment, geographical 
trends and limited published methodology to detect its presence in biological matrices.  To 
assist with identification efforts, a sensitive method to detect desomorphine in urine was 
developed using solid phase extraction (SPE) and liquid chromatography-quadrupole/time 
of flight-mass spectrometry (LC-Q/TOF-MS).   A deuterated analog was used as the 
internal standard and assay performance was assessed in accordance with published 
guidelines.  This is the first report to describe the use of LC-Q/TOF-MS for the analysis of 
desomorphine in a biological matrix.  SPE yielded an extraction efficiency of 90% for 
urine.  The limits of detection and quantitation were 0.5 ng/mL and the associated 
calibration range was 0.5-500 ng/mL.  Ion suppression averaged -1% at 20 ng/mL and -7% 
at 400 ng/mL, with associated CVs of 11% and 2%, respectively.  No qualitative or 
quantitative interferences were observed for common drugs, including twenty-four opioids 
and structurally related compounds.  Intra- and inter-assay CVs were 3-5% (n=3) and 4-
7% (n=15) respectively, and bias ranged from -4-0% (n=15) at 2, 200 and 400 ng/mL.  The 
metabolism of desomorphine has been reported but reference materials are not yet 
available, preventing the inclusion of metabolites in quantitative assays at this time.  In the 
absence of authentic samples from Krokodil users, recombinant enzymes were used to 
generate desomorphine metabolites for analysis.  Ten phase I and phase II metabolites were 
identified, including a second norhydroxydesomorphine isomer not previously reported.  
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The LC-Q/TOF-MS method is capable of detecting both desomorphine and its phase I and 
phase II metabolites which should improve identification efforts in forensic and clinical 
toxicology laboratories. 






















Quantitative Analysis of Desomorphine in Urine Using Solid Phase 
Extraction and Liquid Chromatography-Quadrupole/Time of Flight-Mass 
Spectrometry 
Introduction 
The semi-synthetic opioid desomorphine ((5α,6α)-17-Methyl-7,8-didehydro-4,5-
epoxymorphinan-3-ol) is a constituent of the drug Krokodil which has been abused, 
primarily in Russia and surrounding countries since the early 2000s (1).  First synthesized 
in the 1930s, desomorphine is an amphoteric base and zwitterionic species. Like morphine, 
it contains a basic nitrogen in addition to the phenol. The key structural differences between 
desomorphine and morphine are the absence of the C6 hydroxyl and the saturated bond 
between C7 and C8 (Figure 7.1).  Desomorphine was briefly sold under the trade name 
Permonid in Switzerland from 1940 to 1951 (1).  While desomorphine is up to ten times 
more potent than morphine with a faster onset of action, its duration of effect is shorter (2).  
This coupled with concerns regarding its abuse liability led to discontinuation of its 
therapeutic use.  In the United States, desomorphine is a Schedule I drug in the Federal 
Controlled Substances Act (3).  Internationally, desomorphine is restricted under the 1961 
United Nations Single Convention on Narcotics Drugs, which was attended by over 
seventy countries (4).  Several countries have legislation restricting desomorphine use, 





Figure 7.1. Chemical structures of morphine and desomorphine. 
 
Krokodil is commonly synthesized from pharmaceuticals containing codeine, using 
harsh chemicals such as hydroiodic acid and red phosphorous (8).  The final product is 
typically a liquid, of which desomorphine is a major component, with other morphinans 
also produced as side products (9, 10).  The first reports of Krokodil use appeared in 2003 
in Russia. Since then its use has been reported through neighboring countries into central 
Europe and the Unites States.  Some reports suggest that at one point as many as 100,000 
people were using Krokodil in Russia and 20,000 in Ukraine (8).  Its popularity was 
attributed to a reduction in heroin availability due to a disease among poppy crops (11).  
Similar to heroin, Krokodil is commonly injected intravenously.  As such, remnants of the 
harsh precursor chemicals can enter the blood stream, bypassing the body’s natural 
safeguards.  Necrotic ulcers, gangrene and osteonecrosis have all been associated with 
Krokodil use, which may necessitate amputations or other invasive surgeries (12). 
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Despite reports of Krokodil use in the media, published case reports are rare, with 
the first originating from Germany in 2013 (13).  The case involved a fatality of a Krokodil 
user, but post-mortem toxicological analysis for desomorphine was negative.  Clinical case 
reports have since emerged from the Republic of Armenia (14-16), the Republic of Georgia 
(17), Italy (18), Poland (19), Spain (20), Russia (21, 22), the United Kingdom (23) and the 
United States (24-28).  Three of these involve fatalities (13, 18, 27) but the vast majority 
describe clinical and emergency department related reports.  To date only one case has 
been analytically confirmed, involving a fatality of a 39 year old male with desomorphine 
detected in post-mortem urine (270 ng/mL) (18).  Published case reports suggest that there 
is often a delay between time of drug use and seeking medical treatment, which may in part 
explain the lack of analytically confirmed reports.  Limitations in methodology may also 
contribute to the lack of analytically confirmed forensic cases.   
Forensic toxicology screening is commonly accomplished using enzyme-linked 
immunosorbent assays (ELISAs) because they are compatible with multiple biological 
matrices.  Immunoassay-based screening techniques are often directed towards one target 
analyte but may be used to identify a class of compounds due to non-specific binding with 
structurally similar compounds.  A recent study evaluated commercially available opioid 
ELISAs for cross-reactivity with desomorphine, which ranged from <2.5% to 77% (29). 
As a consequence, some ELISAs are unlikely to identify desomorphine in forensic 
toxicology specimens.   
Pharmcokinetic studies of desomorphine in humans are limited to date.  The first 
study on desomorphine metabolism was published by Richter in 2016 (30).  Utilizing rat 
models, human liver microsomes, recombinant cytochrome P450 isoenzymes (rCYPs) and 
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recombinant uridine 5’-diphospho-glucuronosyltranferase isoenzymes (rUGTs), phase I 
biotransformations included N-demethylation, hydroxylation and N-oxidation, while phase 
II metabolism involved glucuronidation and sulfation.  A subsequent investigation utilizing 
recombinant CYPs found that seven isoenzymes (CYP2B6, CYP2C8, CYP2C9, 
CYP2C18, CYP2C19, CYP2D6 and CYP3A4) may contribute to the formation of phase I 
metabolites (nordesomorphine, desomorphine-N-oxide, five hydroxydesomorphine 
isomers and norhydroxydesomorphine) (31).  The same study also investigated 
recombinant UGTs and found that nine rUGTs (UGT1A1, UGT1A3, UGT1A8, UGT1A9, 
UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17) may contribute to the 
formation of desomorphine-glucuronide.  While metabolites can be valid markers for drug 
use, the lack of commercially available reference materials precludes quantitative analysis 
at this time. 
Published methods describing the analysis of desomorphine in biological matrices 
are limited, and some lack the requisite sensitivity to be effective in toxicological 
investigations.  While gas chromatography-mass spectrometry (GC-MS) has traditionally 
been the most widespread technique for confirmatory testing in toxicology laboratories, 
liquid chromatography (LC) based approaches are becoming increasingly widespread due 
to an improved sensitivity and versatility with respect to polar compounds and metabolites 
(32).  GC-MS was used by Su to identify desomorphine in urine with a limit of quantitation 
of 250 ng/g (33) and by Alves to identify desomorphine in blood with a limit of quantitation 
of 103 ng/mL (34).  More recently, the authors published a more sensitive GC-MS assay 
for blood and urine, with limits of quantitation of 5 and 8 ng/mL, respectively (35).   
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The qualitative identification of desomorphine in urine and seized drug samples 
utilizing LC with ultraviolet detection was described by Savchuk (7) and Richter 
described a qualitative assay utilizing high resolution mass spectrometry (HRMS) using 
an Orbitrap™ detector to identify desomorphine and its metabolites in urine (30).  
Desomorphine was qualitatively identified in drug samples by Soares, utilizing both LC 
coupled to a diode array detector (DAD) and LC-HRMS (10).  Quantitatively, 
desomorphine has been identified in drug samples with a limit of quantitation of 490 
ng/mL using LC-DAD (9).  Eckart described a quantitative LC method utilizing tandem 
mass spectrometry (MS/MS) to identify desomorphine in serum, plasma and tissue with a 
limit of quantitation of 0.1 ng/mL (36).  Previously published methods have used 
phenacetin and deuterated codeine as internal standards. We previously described a 
validated quantitative LC-MS/MS assay to detect desomorphine in urine with a limit of 
quantitation of 0.5 ng/mL, which was the first LC-MS method to utilize a deuterated 
desomorphine analogue as the internal standard.  (37).  LC-based methods for both seized 
drugs and biological matrices are summarized in Table 7.1. The purpose of this study 
was to develop a method to quantitate desomorphine in urine using LC-Q/TOF-MS, 
validate the method in accordance with published recommendations (38) and utilize that 























urine 0.5 ng/mL 500 µL SPE desomorphine-D3 MS/MS (37) 




200 µL  
or 2 g  
SPE codeine-D6 MS/MS (36) 
drug samples NR 10 µL None NR DAD; Orbitrap™ (10) 
urine NR 2 mL LLE codeine-D6 Orbitrap™ (30) 
urine; drug samples NR 3 mL LLE NR UV (7) 







Materials and methods 
Chemicals 
Desomorphine, desomorphine-D3 and compounds used to assess interferences 
(Table 7.2) were obtained from Cerilliant (Round Rock, TX, USA).  Ethyl acetate (HPLC 
grade), dibasic and monobasic potassium phosphate were obtained from Fisher Scientific 
(Fair Lawn, NJ, USA).  Acetonitrile (LCMS grade) was purchased from Thermo Fisher 
Scientific (Radenor, PA, USA) and formic acid (>95%) was from Sigma Aldrich (St. Louis, 
MO, USA).  Concentrated ammonium hydroxide was obtained from Macron Fine 
Chemicals (Center Valley, MA, USA).  Dichloromethane and isopropyl alcohol were 
procured from Mallinckrodt Chemicals (St. Louis, MO, USA).  Concentrated hydrochloric 
acid and methanol (LCMS grade) were from J.T. Baker (Center Valley, MA, USA).  Pooled 
drug free urine obtained from Utak Laboratories (Valencia, CA, USA) was preserved with 
1% sodium fluoride prior to use.  PolyChrom Clin II 3cc (35 mg) solid phase extraction 
(SPE) columns were obtained from SPEware (Baldwin, CA, USA).  Deionized (DI) water 
was generated from a Direct-Q 3 (UV) system (Millipore, Billerica, MA, USA).  
Recombinant human cytochrome P450 isoenzyme 3A4 (rCYP3A4) expressed in E. coli 
(bactosomes) were purchased from Xenotech, LLC (Kansas City, Kansas).  Recombinant 
human uridine 5'-diphospho-glucuronosyltransferase isoenzyme 2B7 (rUGT2B7) 
isoenzymes expressed in baculovirus infected insect cells (supersomes™) were purchased 
from Corning (Glendale, Arizona).  UGT reaction mix solution A (25 mM UDP-glucuronic 
acid), UGT reaction mix solution B (250 mM Tris(hydroxymethyl)aminomethane-HCl 
(Tris-HCl), 40 mM magnesium chloride, and 0.125 mg/mL alamethicin), reduced 
nicotinamide adenosine di-phosphate (NADPH) regenerating system solution A (40 U/mL 
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glucose-6-phosphate dehydrogenase in 5 mM sodium citrate), and NADPH regenerating 
system solution B (26 mM NADP+, 66 mM glucose-6-phosphate and 66 mM magnesium 
chloride in aqueous solution) were also obtained from Corning. 
Table 7.2 
Drugs used to assess interference, divided into opioids (n=24) and common drugs (n=42). 
Opioids Common Drugs 
6-acetylcodeine, 6-acetylmorphine, 
buprenorphine, codeine, dihydrocodeine, 
fentanyl, heroin, hydrocodone, 
hydromorphone, levorphanol, meperidine, 
methadone, morphine, nalorphine, 
norcodeine, norhydrocodone, 
normeperidine, normorphine, 
noroxycodone, oxycodone, oxymorphone, 
propoxyphene, thebaine, tramadol 
7-aminoclonazepam, 7-aminoflunitrazepam, 
acetaminophen, alprazolam, amitriptyline, 
amobarbital, amphetamine, butalbital, 
caffeine, carbamazepine, carisoprodol, 
clonazepam, cocaine, cotinine, 
cyclobenzaprine, dextromethorphan, 
diazepam, fluoxetine, flurazepam, gabapentin, 
ketamine, MDMA, meprobamate, 
methaqualone, 11-nor-9-carboxy-Δ9-THC, 
nordiazepam, oxazepam, pentobarbital, 
phencyclidine, phenobarbital, phenytoin, 
pseudoephedrine, salicylic acid, secobarbital, 
sertraline, temazepam, Δ9-THC , trazadone, 
valproic acid, zaleplon, zolpidem, zopiclone 
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol. 
 
Sample preparation 
Working standards of desomorphine were prepared at three concentrations (25, 2.5 
and 0.25 µg/mL) in acetonitrile and the internal standard was prepared at 0.5 µg/mL in 
acetonitrile.  The elution solvent was prepared daily and consisted of 4% ammonium 
hydroxide in ethyl acetate.  A Supelco Visiprep vacuum manifold (Supelco, Bellefonte, 
PA, USA) and a Turbovap LV concentration workstation (Biotage, Charlotte, NC, USA) 
were used for extraction and evaporation.   
Aliquots of urine (0.5 mL) were fortified with 50 µL of IS solution to achieve a 
final concentration of 25 ng/mL.  Samples were diluted with 1 mL of 0.1 M hydrochloric 
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acid then transferred to PolyChrom Clin II SPE columns (3 cc, 35 mg) and allowed to flow 
through under gravity (approximately 1 mL/min).  When necessary, vacuum was applied 
to maintain the flow rate.  Samples were successively washed with 1 mL of deionized 
water, 0.1 M hydrochloric acid, methanol, and ethyl acetate.  After the final wash, samples 
were dried for five minutes on full vacuum.  Desomorphine was eluted using two 0.5 mL 
volumes of elution solvent.  Extracts were evaporated to dryness under nitrogen (50°C) 
before being reconstituted in 30 µL of mobile phase (92:8 A:B).  Samples were injected (2 
µL) onto the LC-Q/TOF-MS for analysis. 
LC-Q/TOF-MS analysis 
An Agilent Technologies 6530 LC-Q/TOF-MS equipped with an Agilent 1290 
Infinity autosampler was used to analyze samples (Agilent Technologies, Santa Clara, CA, 
USA).  Data was acquired and analyzed using Agilent MassHunter software.  An Agilent 
Poroshell 120 EC-C18 column (2.1 x 100 mm, 2.7 µm particle size) equipped with a 
matching Poroshell 120 EC-C18 guard column was for separation.  The autosampler 
chamber and column compartment were maintained at 4°C and 35°C, respectively.  Mobile 
phase A consisted of 0.1% formic acid in deionized water and mobile phase B consisted of 
0.1% formic acid in acetonitrile. The following elution profile was utilized: 8% B, 0-2 min 
(0.3 mL/min); 8-20% B, 2-6 min (0.3 mL/min); 20-90% B, 6-6.5 min (0.4 mL/min); 90-
8% B, 6.5-7 min (0.4 mL/min), followed by a re-equilibration period of 2 min.  Nitrogen 
was generated using a Genius 3040 nitrogen generator (Peak Scientific, Billerica, MA, 
USA).  An electrospray ionization source with Jet Stream technology was used in positive 
mode and Q/TOF-MS conditions were as follows: drying gas temperature, 350°C (10 
L/min); sheath gas temperature, 400°C (10 L/min); nebulizer, 20 psi; capillary voltage, 
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2500 V; nozzle voltage, 0 V; fragmentor, 150 V; skimmer, 65 V.  Data was acquired using 
targeted MS/MS acquisition with a mass range of 100-1000 Da, with MS and MS/MS scan 
rates of 5 spectra/s.  Precursor and product ions, collision energies and retention time for 
desomorphine and desomorphine-D3 are summarized in Table 7.3. 
Table 7.3 
Transition ions, collision energy (CE) and retention time for desomorphine and 













  167.0855 (100%) 
195.0804 (35%) 
152.0621 (43%)  
45 4.4 
desomorphine-D3 275.1833 






Assay performance was evaluated in terms of extraction efficiency, calibration 
model, bias, precision, limit of detection (LOD), limit of quantification (LOQ), 
interferences, matrix effects, carryover and processed sample stability. 
The extraction efficiency in urine was determined previously by direct comparison 
of the relative peak area (drug/IS) for extracted samples (n=3) with the mean relative peak 
area for non-extracted samples (n=3) (35). Extracted samples contained IS (25 ng/mL) and 
desomorphine (250 ng/mL) and non-extracted samples contained IS only.  Non-extracted 
samples were fortified post-extraction with an equivalent amount of desomorphine.  The 
calibration model was determined with five independent runs using ten non-zero calibrators 
221 
 
(0.5, 1, 2, 5, 25, 75, 150, 250, 350 and 500 ng/mL).  Calibration models were evaluated 
based on performance, the coefficient of determination (R2) and standardized residual 
plots.  Carryover was evaluated using negative controls (IS only) and blank matrix (no IS) 
immediately following injection of the highest calibrator (500 ng/mL, n=3).  Carryover 
was present when a reportable result was produced: S/N ratio of 3:1 or greater, retention 
time ± 2% of the standard and ion ratios within ±20% of the established value).   
Bias and precision were determined simultaneously over five runs in triplicate using 
pooled fortified matrix at three concentrations (2, 250 and 450 ng/mL).  The tolerance was 
±20% for both bias and precision.  Within-run precision was calculated for each 
concentration (n=3) over each run and between-run precision was calculated for each 
concentration over all five runs (n=15).  Limits of detection and quantitation (LOD and 
LOQ) were determined using three sources of drug-free matrix, analyzed in duplicate over 
three days.  The LOD was the lowest concentration to produce a reportable result, with a 
signal-to-noise ratio(S/N) ≥3:1, ion ratios ± 20%, and retention time ± 2% of the standard.  
The LOQ was the lowest concentration to produce a reportable result with quantitative 
values within 20% of the expected concentration, a signal-to-noise (S/N) ≥10:1 and 
acceptable bias and precision. 
The biological matrix and isotopically labeled IS were evaluated for potential 
interferences.  Ten drug-free urine samples from independent sources were extracted, in 
duplicate, in the absence of IS to evaluate matrix interference.  Ion contribution from the 
stable isotope IS was evaluated by fortifying drug-free urine with IS (25 ng/mL) and 
monitoring the signal of desomorphine.  Drug interferences were evaluated for sixty-six 
drugs including twenty-four opioids (Table 7.2).  Interferences were assessed qualitatively 
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and quantitatively using negative and positive controls. The positive controls contained 
desomorphine at one of three concentrations (5, 50 or 500 ng/mL) and were fortified with 
IS (25 ng/mL) and interferent (500 ng/mL).  The negative control was fortified with internal 
standard (25 ng/mL) and interferent (500 ng/mL). 
Processed sample stability was evaluated at three concentrations (2, 250 and 400 
ng/mL) at 0 and 24 hours.  Samples were stored in the autosampler (4°C) and analyzed in 
triplicate.  The average quantitative response and average peak area of desomorphine at 0 
and 24 hours were compared for all three concentrations.  Matrix effects were 
quantitatively assessed using post-extraction addition at two concentrations (20 and 400 
ng/mL) using ten drug free matrixes.  Ion suppression or enhancement was calculated by 
comparing the mean peak areas of desomorphine in matrix with the equivalent 
concentration of the drug in mobile phase (no matrix).   
Analysis of desomorphine metabolites 
Due to the absence of metabolite standards or authentic urine samples, 
desomorphine metabolites were generated in vitro using recombinant enzymes (rCYP3A4 
and rUGT2B7) as described previously (31).  Reactions were performed in duplicate at 
37°C in the presence of 200 µM desomorphine. The rCYP3A4 reaction contained 50 
pmol/mL rCYP isoenzyme, 100 mM potassium phosphate buffer (pH 7.4), 1.3 mM 
NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM magnesium citrate, and 0.4 U/mL glucose-
6-phosphate dehydrogenase.  The rUGT2B7 reaction contained 0.25 mg/mL rUGT 
isoenzyme, 90 mM Tris-HCl (pH 7.5), 8 mM magnesium chloride, 25 µg/mL alamethicin, 
and 2 mM uridine 5’-diphospho-glucuronic acid (UDPGA).  Both reactions were 
terminated after 2 hours using an equal volume of ice cold acetonitrile containing 0.1% 
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formic acid and 5 µM internal standard.  The samples were diluted 1:1 in 92:8 (A:B) mobile 
phase and 2 µL was injected onto the LC-Q/TOF-MS and analyzed using the parameters 
and elution gradient described in section 2.3.   
Results and discussion 
Method validation 
The SPE extraction was previously optimized to minimize the loss of desomorphine 
during the extraction process (35).  Extraction efficiencies of 90% were achieved using 4% 
ammonium hydroxide in ethyl acetate.  The increased concentration of ammonium 
hydroxide may in part be due to the high pKa of the tertiary amine (9.69) (39).  Both LOD 
and LOQ were 0.5 ng/mL (n=18).  Table 7.4 summarizes the associated bias, precision 
and S/N ratios at the LOQ and Figure 7.2 depicts the extracted ion chromatogram (EIC) 
of desomorphine at 0.5 ng/mL in urine.  Precision at 2, 250 and 400 ng/mL produced intra- 
and inter-assay CVs of 3-5% (n=3) and 4-7% (n-15) respectively. Bias ranged from -4-0% 
(n=15) (Table 7.5).  Figure 7.3 shows the MS2 spectrum of desomorphine with the 
quantitative and qualifier ions identified.  Quantitate and qualitative ions were selected 
based upon abundance and specificity.  Optimum CID voltages produced qualifier ion 























0.5 0.5 0.53 ± 0.05 
10:1 - 21:1 
(16:1) 





Figure 7.2. Extracted ion chromatogram of desomorphine in urine at the LOQ (0.5 ng/mL).   
 
Table 7.5 
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Figure 7.3. MS2 spectrum with chemical formulas and accurate masses of the precursor 
(MH+), quantitation (Q) and qualifier ions (Q1 and Q2).   
 
No carryover was observed under the conditions tested and processed samples were 
stable for 24 hours, with absolute peak areas within 0-5% of the original result (t=0) and 
the bias of the quantitative results ranging from -3 to 2% (n=3).  The calibration model 
selected for quantitative analysis (0.5 – 500 ng/mL) was a weighted (1/x) quadratic 
calibration model, which produced the highest R2 values and minimized bias at the low and 
high ends of the calibration.  While an F-test indicated no significant difference between 
unweighted and weighted (1/x) models, nor between linear and quadratic models, a 
weighted (1/x) quadratic model was selected based upon the residual plot analysis (Figure 
7.4).  No interferences from either the matrix or isotopically labeled internal standard were 
present. No qualitative or quantitative interference were observed with any of the sixty-six 
drugs tested at 1-, 10- and 100-fold excess (relative to desomorphine) (Table 7.2).  Ion 
suppression and enhancement were assessed using ten drug-free sources of urine fortified 
with desomorphine post-extraction at two concentrations (20 and 400 ng/mL).  The mean 
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ion suppression was -1% and -7% at 20 and 400 ng/mL, with associated CVs of 11 and 
2%, respectively (Table 7.6).  
 
 
Figure 7.4. Standardized residual plot for linear and quadratic weighted (1/x) calibration 
models.  Calibrator concentrations: 0.5, 1, 2, 5, 25, 75, 150, 250, 350 and 500 ng/mL. 
 
Table 7.6 
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11% 18.51 ± 0.54 
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Analysis of desomorphine metabolites 
Although previous studies have identified potential desomorphine metabolites, 
reference materials are not yet commercially available (30, 31).  In the absence of authentic 
urine samples, desomorphine metabolites generated in vitro were also identified using the 
targeted LC-Q/TOF-MS method described here.  EICs of the metabolites are shown in 
Figure 7.5, where in addition to the nine metabolites identified in our previous study (31), 
a second norhydroxydesomorphine isomer (RT 2.49 min) was also identified.  The 
identification of the second norhydroxydesomorphine isomer may be attributed to the 
different mobile phase gradient utilized in the validated method, which was further 
optimized to provide baseline separation between desomorphine and closely eluting 
opioids (37).  The samples containing phase I metabolites were reanalyzed in full scan 
mode and MS2 spectra were generated.  Mass spectra for both norhydroxydesomorphine 
metabolites (CID voltage 35) are depicted in Figure 7.6.  Structural assignments and 













Figure 7.5. Extracted ion chromatograms for phase I metabolites (A):  nordesomorphine, 
4.12 min (m/z 258); desomorphine-N-oxide, 5.12 min, and hydroxydesomorphine, 1.49, 
2.33, 2.53, 3.07 and 4.56 min (m/z 288); norhydroxydesomorphine, 2.49 and 3.21 min (m/z 
274), and the phase II metabolite (B) desomorphine-glucuronide, 1.49 min (m/z 448). 





Figure 7.6. MS2 spectra of (A) norhydroxydesomorphine isomer 1 and (B) 














Retention time (RT), chemical formula, exact mass, accurate mass and mass error (PPM) 
for desomorphine and its metabolites. Data acquired in full scan.  Structural assignments 
for desomorphine-glucuronide, nordesomorphine, hydroxydesomorphine isomers 1-5, 












+ 448.1966 448.1962 0.80 
 C17H22NO2
+ 272.1645 272.1643 0.66 
 C14H15O2
+ 215.1067 215.1063 1.67 
nordesomorphine 4.12 C16H20NO2+ 258.1489 258.1482 1.75 
 C14H11O
+ 195.0804 195.0807 1.08 
 C13H11
+ 167.0855 167.0856 0.53 
hydroxydesomorphine  
isomer 1 (aliphatic) 
1.49 C17H22NO3+ 288.1594 288.1593 0.25 
 C14H13O2
+ 213.0910 213.0907 1.40 
 C14H11O
+ 195.0804 195.0796 4.33 
hydroxydesomorphine  
isomer 2 (aliphatic) 
2.33 C17H22NO3+ 288.1594 288.1595 0.38 
 C14H15O3
+ 231.1016 231.1018 0.92 
 C14H11O2
+ 211.0754 211.0748 2.67 
hydroxydesomorphine  
isomer 3 (aliphatic) 
2.53 C17H22NO3+ 288.1594 288.1591 1.07 
 C14H15O3
+ 231.1016 231.1010 2.33 
 C14H13O2
+ 213.0910 213.0915 2.53 
hydroxydesomorphine  
isomer 4 (aromatic) 
3.07 C17H22NO3+ 288.1594 288.1591 1.20 
 C16H22NO2
+ 260.1645 260.1638 2.64 
 C16H22NO
+ 244.1696 244.1681 6.18 
hydroxydesomorphine  
isomer 5 (aromatic) 
4.56 C17H22NO3+ 288.1594 288.1594 0.03 
 C16H22NO2
+ 260.1645 260.1643 0.62 
 C16H20NO
+ 242.1539 242.1535 1.95 
    (continued) 
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desomorphine-N-oxide 5.12 C17H22NO3+ 288.1594 288.1597 1.11 
 C17H21NO2
+ 271.1567 271.1566 0.27 
 C14H15O2
+ 215.1067 215.1066 0.42 
norhydroxydesomorphine  
isomer 1 (aliphatic) 
2.49 C16H20NO3
+ 274.1438 274.1443 2.09 
 C14H11O
+ 195.0804 195.0808 1.69 
 C13H11
+ 167.0855 167.0866 6.63 
norhydroxydesomorphine  
isomer 2 (aliphatic) 
3.21 C16H20NO3+ 274.1438 274.1423 5.21 
 C16H18NO2
+ 256.1332 256.1323 3.45 
 C15H20NO
+ 230.1539 230.1524 6.83 
 
Conclusions 
In the absence of widespread screening and testing, the prevalence of Krokodil use 
is difficult to estimate.  Despite numerous published case reports, only one analytically 
confirmed case has been reported to date.  We describe a procedure to identify 
desomorphine in urine at sub ng/mL concentrations using LC-Q/TOF-MS. This method 
was fully validated in accordance with published guidelines.   
In the absence of authentic urine samples from Krokodil users, recombinant 
enzymes were used to generate desomorphine metabolites in vitro.  Ten phase I and phase 
II metabolites were identified using this method, which in addition to previously published 
work (31), included a second norhydroxydesomorphine isomer. This new procedure to 
identify desomorphine in urine should assist with identification efforts in both clinical and 
forensic toxicology.  
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Desomorphine is a semi-synthetic opioid that is a major constituent of Krokodil, a 
clandestinely produced heroin substitute.  Although Krokodil abuse was first reported in 
Russia and its surrounding countries, its true prevalence is unknown.  Published case 
reports have originated from the Republics of Armenia and Georgia, Germany, Italy, 
Poland, Russia, Spain, the United Kingdom and the United States.  To date only one 
reported case has been analytically confirmed in a biological matrix.  Although not 
widespread, its use in the United States is supported by data from the National Forensic 
Laboratory Information System in the early 2000s.  The delay between Krokodil use and 
the development of severe dermatological symptoms that require medical intervention may 
explain why few clinical case reports are analytically confirmed.  
To facilitate the identification of desomorphine, a comprehensive study of its 
metabolism and analysis was conducted.  As a commonly used screening technique, 
commercially available ELISAs targeting morphine and oxycodone (Immunalysis Opiates 
Direct ELISA, Immunalysis Oxycodone/Oxymorphone Direct ELISA, Randox Opiate 
ELISA, OraSure Technologies OTI Opiate Micro-plate EIA, Neogen Opiate Group ELISA 
and Neogen Oxycodone/Oxymorphone ELISA) were evaluated for cross-reactivity with 
desomorphine, which was found to be highly variable (<2.5% to 77%).  Depending on the 
choice of ELISA, desomorphine may go undetected during immunoassay screening.  The 
Immunalysis Opiates Direct ELISA produced the greatest cross-reactivity and several other 




The metabolism of desomorphine was investigated using recombinant CYPs and 
UGTs.  Eight phase I metabolites were identified in the initial investigation: 
nordesomorphine, desomorphine-N-oxide, five hydroxydesomophine isomers and 
norhydroxydesomorphine.  Norhydroxydesomorphine was a novel metabolite that had not 
previously been reported in the literature.  Later analysis of desomorphine metabolites 
using a validated method for the quantitative analysis of desomorphine identified an 
additional norhydroxydesomorphine isomer that was not previously observed.  Seven 
CYPs were found to contribute to desomorphine’s metabolism (CYP2B6, CYP2C8, 
CYP2C9, CYP2C18, CYP2C19, CYP2D6 and CYP3A4), with CYP3A4 mediating the 
production of all eight metabolites but CYP2C18 being the major contributor to the 
production of the major phase I metabolite, nordesomorphine.  Desomorphine-glucuronide 
was identified during phase II metabolism, with nine UGTs contributing to its production 
(UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, 
and UGT2B17).  UGT2B7 showed the greatest activity and the involvement of UGT1A3 
was a novel pathway not previously reported in the literature. 
Hydrolysis of conjugated metabolites to determine the relative proportions of free 
to total drug is sometime required.  The hydrolysis of desomorphine-glucuronide was 
investigated using acid hydrolysis and enzymatic hydrolysis with β-glucuronidase from 
BGTurbo™, IMCSzyme™, E. coli, H. pomatia and P. vulgata.  Acid hydrolysis with 
hydrochloric acid produced complete hydrolysis, and at optimal conditions all five 
enzymes also produced near complete hydrolysis.  At simulated challenging conditions P. 
vulgata maintained the highest activity.  BGTurbo™ and IMCSzyme™ offered the shortest 
incubation time necessary to produce complete hydrolysis and their purified preparations 
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required minimal sample cleanup compared to E. coli, H. pomatia and P. vulgata.  A short-
term stability study of desomorphine and desomorphine-glucuronide at 60°C indicated that 
both species were stable for three hours over a range of pH values (4-10).  
SPE and GC-MS were used to quantify desomorphine in blood and urine using 
desomorphine-D3 as the IS, without the need for derivatization.  The extraction efficiencies 
were 69% for blood and 90% for urine and the LOQs were 5 ng/mL and 8 ng/mL, 
respectively, which was ten-fold lower than previously published methods.  The intra- and 
inter-assay CVs were 2-4% (n=3) and 3-7% (n=15), respectively.  A weighted (1/x) linear 
calibration model was used with a calibration range of 5-1000 ng/mL for blood and 8-1000 
ng/mL for urine.  No carry over was observed.  A qualitative interference was observed 
with levorphanol at 10- and 100-fold concentrations (relative to desomorphine).  As 
levorphanol is a stereoisomer of dextrorphan (a metabolite of dextromethorphan), an 
interference from this substance is also expected.  
LC-MS/MS and LC-Q/TOF-MS were used to quantitate desomorphine in urine 
after SPE extraction.  For LC-MS/MS the LOD and LOQ were 0.5 ng/mL, with a 
calibration range of 0.5-500 ng/mL using a weighted (1/x) quadratic calibration model.   
The bias ranged from -1-2% (n=15), and the intra- and inter-assay CVs were 2-3% (n=3) 
and 3-6% (n=15), respectively.  Ion suppression ranged from -44-0% at low concentrations 
and -23-4% at high concentrations.  LC-Q/TOF-MS also had a LOD and LOQ of 0.5 
ng/mL.  The bias ranged from -4-0% (n=15), with intra- and inter-assay precision CVs of 
3-5% (n=3) and 4-7% (n=15), respectively.  The calibration model used was a weighted 
(1/x) quadratic model with a range of 0.5-500 ng/mL.  The ion suppression was -22-11% 
at low concentrations and -22-2% at high concentrations. 
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All three analytical methods were capable of detecting desomorphine at 
forensically relative concentrations, although some differences in performance were 
observed.  The greatest calibration range was achieved using GC-MS, but this was 
accompanied by reduced sensitivity compared with LC-MS/MS and LC-Q/TOF-MS.  
Overall, improved S/N ratios were observed using LC-MS/MS compared to LC-Q/TOF-
MS; however less ion suppression was observed with LC-Q/TOF-MS. 
In the absence of authentic urine samples from Krokodil users, recombinant 
enzymes were used to generate desomorphine metabolites for analysis using the validated 
LC-Q/TOF-MS method.  Ten phase I and phase II metabolites were identified using 
retrospective data analysis, which included a second norhydroxydesomorphine isomer that 
was not previously identified in the initial investigation of desomorphine’s metabolism. 
As drug users continue to self-report Krokodil use, it is important for laboratories 
to have sensitive and robust analytical methodology to detect desomorphine in biological 
specimens.  This research provides the forensic toxicology community with comprehensive 
information regarding desomophine’s metabolism and its analysis utilizing multiple 
techniques, which will aid in its identification.  This study was the first to describe the 
analysis of desomorphine in urine using LC-MS/MS and the first to describe the use of LC-
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